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9Scope of the thesis
Adult	 tissue	 homeostasis	 and	 repair	 relies	 on	 a	 small	 population	 of	 stem	 cells	 residing	
among	the	differentiated	cells	of	the	respective	tissues.	Adult	stem	cells	are	defined	by	their	
capacity	to	renew	themselves	(self-renewal)	and	to	generate	all	the	differentiated	cell	types	
of	the	tissue	(multipotency).	These	two	abilities	render	adult	stem	cells	very	attractive	for	
therapeutic	purposes,	because	they	might	restore	lost,	damaged,	or	aging	cells	and	tissues	in	
the	human	body.	With	respect	to	this,	hematopoietic	stem	cell	transplantation	has	achieved	
significant	therapeutic	success	over	the	years.	Moreover,	the	recent	establishment	of	stem	
cell	 cultures	 from	 intestine,	 liver	 and	 other	 organs	 in	 organoids	 holds	 great	 promise	 for	
personalized	and	regenerative	medicine.		Nevertheless,	several	restrictions	of	the	stem	cell	
based	therapeutic	approaches	such	as	the	shortage	of	compatible	donors,	low	number	of	
stem	cells	and	undefined	culture	conditions	limit	their	widespread	use.	Therefore,	the	ability	
to	propagate	adult	stem	cells	in	defined	conditions	ex vivo	would	undoubtedly	accelerate	
the	 exploitation	 of	 these	 stem	 cells	 for	 clinical	 purposes.	 An	 understanding	 of	 the	 cues	
governing	 the	 decisions	 between	 self-renewal	 and	differentiation	 is	 therefore	 necessary.	
The	Wnt	signaling	pathway	is	a	key	signaling	cascade	implicated	in	control	of	stem	cell	self-
renewal	and	differentiation	from	a	variety	of	mammalian	tissues	including	blood,	intestines,	
hair	follicles,	and	liver.	Therefore,	purified	Wnt	proteins	serve	as	important	tools	to	regulate	
stem	cell	behavior	in vitro.	The	work	described	in	this	thesis	aims	to	investigate	the	effects	
and	probable	use	of	Wnt	signaling	proteins	in	propagation	of	adult	stem	cells	from	a	variety	
of	tissues,	including	intestines,	blood	and	liver,	for	improving	the	applicability	of	adult	stem	
cells	in	clinics.	
To	provide	 the	necessary	background	 information	 relevant	 to	 the	work	described	 in	 this	
thesis,	the	Chapter 1	 is	dedicated	to	a	general	 introduction.	The	first	part	of	this	chapter	
describes	the	adult	stem	cell	systems	from	blood,	intestine	and	liver.	This	will	be	followed	
by	the	part	dedicated	to	the	Wnt	signaling	pathway	and	its	roles	in	adult	stem	cell	systems.	
In	 the	 last	part,	 the	applicability	of	 liver	 stem	cells	 in	gene	 therapy	of	 lysosomal	 storage	
disorders	with	the	focus	of	Hurler	disease	will	be	explained.	
The	derivation	and	expansion	of	stem	cells	in	the	form	of	organoids	from	human	intestine	
and	 liver	 are	 dependent	 on	Wnt	 signals	 provided	 in	 the	 form	 of	 a	Wnt3a	 conditioned-
medium,	which	contains	serum	and	other	undefined	factors.	The	use	of	stem	cells	in	clinics,	
however,	 requires	 a	 robust	 and	 defined	 cell	 culture	 medium.	 Chapter 2	 describes	 how	
exploiting	 the	hydrophobic	nature	of	Wnt	proteins	 to	 stabilize	 them	using	 lipid-modified	
nanoparticles	instead	of	detergents	enables	the	establishment	of	human	intestine	and	liver	
organoids	in	serum-free	media.
The	 Wnt	 signaling	 pathway	 has	 been	 implicated	 to	 play	 a	 role	 in	 the	 regulation	 of	
hematopoietic	stem	cell	self-renewal	and	differentiation.	Chapter 3	and	4	address	the	effect	
of	Wnt3a	induced	signaling	 in	ex vivo	culture	of	hematopoietic	stem	and	progenitor	cells	
from	mouse	bone	marrow	and	human	umbilical	cord	blood,	respectively.	
Having	established	the	serum-free	culture	of	adult	liver	organoids,	we	describe	in	Chapter 
5 a	proof-of-principle	 study	 investigating	 the	use	of	 these	stem	cells	 for	gene	 therapy	of	
lysosomal	storage	disorders,	in	particular	Hurler	syndrome.	
Finally,	in	Chapter 6	the	significance	and	implications	of	the	studies	performed	in	this	thesis	
are	discussed,	and	directions	for	further	studies	are	provided.	

CHAPTER 1 
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Chapter 1
ADULT STEM CELLS
From the cell theory to the modern stem cell concept
The	invention	of	the	microscope	at	the	beginning	of	the	seventeenth	century	enabled	the	
observation	of	microscopic	life	for	the	first	time.	In	1665,	using	the	microscope	he	devised	
Robert	Hooke	analyzed	the	structural	units	of	a	slice	of	cork	and	coined	the	term	‘cells’	to	
refer	to	these	units.	Although	Hooke	used	this	term	differently,	the	word	‘cell’	that	we	use	
today	comes	directly	from	his	work.	A	few	years	later,	another	distinguished	microscopist	of	
the	time,	Antonie	van	Leeuwenhoek,	observed	and	described	unicellular	living	organisms,	
which	he	named	as	‘animalcules’	for	the	first	time.	Van	Leeuwenhoek	also	studied	human	
semen	 and	 discovered	 spermatozoa.	 After	 Leeuwenhoek,	 however,	 it	 took	 two	 hundred	
years	 to	 improve	microscopes	 as	 well	 as	 tissue	 preservation	 techniques	 for	 further	 key	
observations.	For	 instance,	 in	the	first	half	of	the	19th	century,	Karl	Ernst	von	Baer	finally	
proved	 the	 presence	 of	 the	 mammalian	 egg	 under	 the	 microscope.	 Around	 the	 same	
time,	Matthias	Jakob	Schleiden	and	Theodor	Schwann	proposed	that	all	plant	and	animal	
tissues	were	composed	of	cells.	Later	on,	Remak,	Virchow	and	Kölliker	showed	that	cells	
arise	from	pre-existing	cells.	All	together,	these	findings	led	to	one	of	the	most	important	
generalizations	of	biology,	the	‘cell	theory’,	stating	that	all	organisms	are	made	of	cells	which	
are	the	basic	units	of	life	and	which	arise	from	a	pre-existing	cell1.
With	 the	 advent	 of	 the	 cell	 theory,	 it	 was	 realized	 that	 egg	 and	 sperm	were	 also	 cells.	
Soon	after,	the	fertilization	in	sea	urchins	was	demonstrated	by	Oscar	Hertwig	and	the	big	
question	of	how	does	a	multicellular	embryo	develop	from	a	single	fertilized	egg	emerged2.	
At	the	time,	Hertwig	was	a	student	of	Ernst	Haeckel,	a	major	supporter	of	Darwin’s	theory	
of	evolution	who	was	particularly	interested	in	common	ancestors	(phylogeny)	along	with	
embryology	 (ontogeny).	 In	his	work,	Haeckel	coined	 the	 term	 ‘Stammzellen’	 (german	 for	
stem	cells)	and	used	it	in	two	senses:	as	the	common	unicellular	ancestor	to	multicellular	
organisms	as	well	as	the	fertilized	egg	giving	rise	to	all	cells	of	the	organism.	The	term	‘stem	
cell’	reappeared,	a	few	years	later	in	the	late	19th	century,	when	several	scientists	including	
Theodor	Boveri	and	Valentin	Häcker	used	it	to	describe	the	cells	giving	rise	to	the	primordial	
germ	cells	as	well	as	primordial	somatic	cells.	At	the	same	time,	several	histologists	such	as	
Alexander	Maximow,	Ernst	Neumann	and	Artur	Pappenheim	were	starting	to	use	this	term	
for	a	common	precursor	of	the	blood	system3.	However,	the	phrase	‘stem	cells’	remained	
an	abstract	definition	until	the	demonstration	of	the	existence	of	hematopoietic	stem	cells	
(HSCs)	with	a	series	of	seminal	experiments	by	James	Till,	Ernest	McCulloch	and	others	in	
the	1960s.		Till	and	McCulloch	first	demonstrated	that	a	subset	of	bone	marrow	cells	could	
form	macroscopic	colonies	containing	differentiated	progeny	of	multiple	blood	lineages4,5.	A	
subset	of	these	colonies,	when	transplanted	into	secondary	hosts,	could	reconstitute	all	the	
blood	lineages6,7.	With	these	discoveries,	the	stem	cell	concept	has	gained	its	operational	
definition:	stem	cells	are	cells,	which	can	proliferate	indefinitely	(self-renewal)	and	give	rise	
to	one	or	more	specialized	cell	types	(potency).
The	stem	cell	 concept	has	ever	since	vastly	expanded	owing	 to	studies	 ranging	 from	the	
early	 embryo	 to	 adult	 organisms.	 In	 1981,	 Martin,	 Evans	 and	 Kaufman	 described	 the	
isolation	of	cells	from	the	inner	cell	mass	of	the	mouse	blastocyst	for	the	first	time8,9.	These	
cells,	referred	to	as	embryonic	stem	cells	(ESCs),	display	an	indefinite	self-renewal	capacity	
in vitro	 under	 proper	 culture	 conditions	 and	 retain	 the	 ability,	 known	 as	 pluripotency,	
to	develop	 into	all	 cell	 types	of	 the	embryo	proper.	On	the	contrary	 to	pluripotent	ESCs,	
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adult	stem	cells,	which	reside	in	postnatal	tissues	(e.g.	bone	marrow10,	liver11,	intestine12),	
are	multipotent,	meaning	 that	 they	are	 capable	of	 specializing	 into	 the	 cell	 types	of	 the	
respective	tissue	but	not	all	cell	types	of	the	organism.	Rare	populations	of	multipotent	adult	
stem	cells,	with	their	ability	to	self-renew,	play	essential	roles	in	the	maintenance	and	repair	
of	adult	tissues.		Therefore,	adult	stem	cells	are	also	very	valuable	for	therapeutic	purposes.	
Today,	hematopoietic	stem	cell	transplantation	is	routinely	used	in	clinical	applications	for	
treatment	of	a	variety	of	hematological	diseases13.	Moreover,	recent	advances	in	culture	of	
many	other	adult	stem	cell	types	including	stomach,	intestines	and	liver	offer	many	promises	
to	the	field	of	regenerative	medicine14–16.	Nonetheless,	much	remains	to	be	answered	about	
different	types	of	adult	stem	cells,	such	as	how	they	are	regulated,	and	how	and	for	what	
applications	they	can	be	used	in	medical	purposes.	
Hematopoietic stem and progenitor cells  
Hematopoiesis 
Hematopoiesis,	which	is	a	combination	of	two	Greek	words:	haima	(blood)	and	poien	(make/
create),	describes	the	process	by	which	all	 the	blood	cells	of	an	organism	are	generated.	
Through	 its	many	diverse	cell	 types	(erythrocytes,	megakaryoctyes/platelets,	monocytes/
macrophages,	granulocytes,	mast	cells,	dendritic	cells,	B-cells,	T-cells,	and	natural	killer	(Nk)	
cells),	 the	hematopoietic	 system	performs	discrete	 functions	 including	oxygen	 transport,	
removal	of	cellular	waste	and	defense	against	pathogens.	The	continuity	of	these	functions	
requires	generation	of	millions	of	blood	cells	per	second	in	an	adult	human13.	The	steady	
production	of	 sufficient	numbers	of	 cells	of	 all	 blood	 cell	 lineages,	daily	 and	 throughout	
one’s	entire	life,	is	based	on	a	highly	ordered	hierarchy	of	the	blood	system	(Figure	1).	With	
their	ability	to	self-renew	and	differentiate	into	all	blood	cell	lineages,	HSCs	are	the	primary	
cells	responsible	for	homeostatic	control	of	hematopoiesis	and	therefore	reside	at	the	top	
of	this	hierarchy.	The	fact	that	a	single	HSC	can	reconstitute	the	entire	blood	system	of	a	
mouse	 depleted	 of	 its	 own	hematopoietic	 system,	 highlights	 the	 importance	 of	HSCs	 as	
the	 foundation	of	hematopoiesis17.	Nonetheless,	under	normal	circumstances	HSCs	cycle	
very	infrequently,	and	a	significant	part	of	the	high	turnover	demand	is	met	by	the	highly	
proliferative,	more	committed	progenitors	with	restricted	self-renewal	and	differentiation	
capacity		(Figure	1)13.	
In	an	adult	organism,	HSCs	are	mainly	 located	 in	 the	bone	marrow	(BM)	where	they	are	
supported	by	microenvironmental	 cues	 to	 retain	 their	 characteristics.	 The	origins	 of	 BM	
resident	HSCs,	however,	go	back	to	early	embryonic	tissues.	During	mouse	ontogeny,	first	
definitive	HSCs	are	generated	in	the	aorta-gonads-mesonephros	(AGM)	region	at	embryonic	
day	10.5	(E10.5)18–20.	Starting	from	E11,	HSC	activity	is	also	observed	in	other	tissues	including	
yolk	sac,	placenta	and	fetal	liver21–23.	By	E12,	the	number	of	HSCs	dramatically	increases	in	
placenta	and	fetal	liver.	At	around	E14,	the	fetal	liver	surpasses	the	placenta	and	becomes	
the	major	HSC	site	until	these	cells	colonize	the	thymus,	spleen	and	finally	the	BM	at	E17.	
The	 generation	of	HSCs	 in	 the	 human	 embryo	 occurs	 in	 a	 similar	 fashion	 to	 that	 of	 the	
mouse,	and	the	bulk	of	the	HSCs	reside	in	BM	in	the	adulthood24.
In	 the	classical	hematopoietic	hierarchy	model	proposed	by	Weissmann	 laboratory13,	BM	
resident	HSCs	give	rise	to	multipotent	progenitors	 (MPP),	which	then	strictly	branch	 into	
oligo-potent	progenitors	of	myeloid	and	lymphoid	lineages	(Figure	1).	While	the	common	
myeloid	progenitor		(CMP)	contain	both	myeloid	and	erythroid	lineage	potentials,	common	
14
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lymphoid	progenitor	(CLP)	form	the	B-cells,	T-cells	and	Nk	cells.		This	model	suggests	that	
the	MPPs	diff	er	from	HSCs	only	in	their	self-renewal	capacity	and	an	oligo-progenitor	with	
combined	myeloid	and	lymphoid	capacity	should	not	exist.	An	alternati	ve	model	proposed	
by	 Adolfsson	 and	 colleagues,	 however,	 suggests	 the	 presence	 of	 a	 lymphoid	 primed	
multi	potent	 progenitor	 (LMPP)	 that	 maintains	 both	 myeloid	 and	 lymphoid	 potenti	al,	
but	 not	 the	megakoryocte-erythroid	 potenti	al25.	 Although	 the	 classical	model	 is	 strongly	
supported	by	the	prospecti	ve	 isolati	on	of	the	cell	subsets	 it	suggests	(CMP	and	CLP),	the	
alternati	ve	model	 is	also	compati	ble	with	the	presence	of	these	subsets.	 In	additi	on,	the	
studies	showing	evidence	for	thymic	progenitors	which	retain	myeloid	potenti	al	favors	the	
alternati	ve	model26,27.
Owing	 to	decades	of	 studies,	much	progress	 in	our	understanding	of	hematopoiesis	 has	
been	 made.	 Moreover,	 these	 studies	 have	 facilitated	 the	 therapeuti	c	 success	 of	 HSC	
Figure 1.  Schemati c overview of hematopoieti c hierarchy. 
Residing	at	the	top	of	the	hierarchy,	HSCs	self-renew	and	give	rise	to	a	number	of	multi	potent	progenitors	
(MPPs),	which	become	progressively	restricted	towards	a	specifi	c	blood	lineage.	The	hematopoieti	c	hierarchy	
model	proposed	by	Weismann	 laboratory	 (solid	arrows)	suggests	a	strict	 separati	on	of	myelopoiesis	and	
lymphopoiesis	via	formati	on	of	a	common	myeloid	progenitor	(CMP)	and	a	common	lymphocyte	progenitor	
(CLP)	 from	MPPs.	The	alternati	ve	model	by	 Jacobsen	 laboratory	 (dott	ed	arrows),	however,	proposes	 the	
presence	of	a	lymphoid	primed	multi	potent	progenitor	(LMPP)	with	both	myeloid	and	lymphoid	potenti	al,	
but	not	 the	megakoryocte-erythroid	potenti	al	 (MEP).	 The	progress	 from	 fairly	quiescent	HSCs	 through	a	
variety of progenitors	is	generally	associated	with	an	increase	in	the	proliferati	on	capacity	(as	indicated	by	
proliferati	ve	index),	which	supports	the	high	turnover	demand	of	blood	system.	HSC,	hematopoieti	c	stem	
cell;	GMP,	granulocyte-monocyte	progenitor;	NK,	natural	killer	cell.	(Adapted	from	ref13,191).
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transplantation,	which	 is	 the	most	widely	 applied	 stem-cell	 therapy	 today.	 Nonetheless,	
the	 use	 of	 HSC	 transplantation	 as	 a	 treatment	 is	 still	 limited	 due	 to	 lack	 of	 compatible	
donors	and	rareness	of	HSCs.	Therefore,	much	attention	has	been	put	to	ex vivo	HSC	and	
progenitor	expansion	approaches.		An	understanding	of	the	factors	involved	in	regulation	of	
hematopoietic	stem	and	progenitor	cells	cell-fate	decisions	is,	thus,	required.
Hematopoietic stem and progenitor cells identification and isolation
Since	 the	 first	 demonstration	 of	 HSC	 functionality	 in	 the	 1960s,	 the	 identification	 and	
characterization	of	HSCs	in	both	mouse	and	man	have	been	extensively	studied.	Advances	
in	flow	cytometry	and	transplantations	into	lethally	irradiated	mice	as	a	functional	stem-cell	
read-out	allowed	both	the	establishment	of	the	cell-surface	phenotype	of	HSCs	and	their	
prospective	isolation28.	Availability	of	cell-surface	markers	for	tracking	HSCs	and	downstream	
progenitors	 has	 facilitated	 investigations	 of	 important	 factors	 for	 ex vivo expansion or 
transplantation	of	pure	populations	of	cells.
In	 the	 adult	 mouse,	 all	 functional	 HSCs	 can	 be	 found	 among	 the	 population	 of	 bone	
marrow	 cells	 that	 lack	 lineage	 (Lin)	 specific	markers	 normally	 present	 in	 committed	 and	
differentiated	hematopoietic	cells,	and	express	high	levels	of	stem	cell	antigen-1	(Sca-1)	and	
c-Kit.	This	HSC	enriched	mouse	bone	marrow	cell	subset	is	known	as	LSK	(Lin-,	c-Kit+,	Sca-
1+)29,30.	Nevertheless,	only	a	portion	of	mouse	LSK	cells	possesses	the	ability	to	reconstitute	
the	hematopoietic	system	in	secondary	and	even	tertiary	recipients.	Since	the	vast	majority	
of	mouse	LSK	cells	are	multipotent	progenitors,	additional	cell-surface	markers	have	been	
identified	to	further	subdivide	this	heterogeneous	population.	It	has	been	shown	that	one-
third	of	the	LSK	cells	that	express	the	signal-lymphocyte-activating	molecule	CD150	and	are	
negative	for	CD48	and	CD34	(LSK,	CD48-,	CD150+,	CD34low/-	cells)	contains	functional	 long-
term	reconstituting	HSCs17,28,31.	
While	 the	 isolation	of	mouse	HSCs	has	greatly	progressed	over	the	past	decades,	due	to	
the	 lack	 of	 efficient	 in vivo	 assays,	 the	 characterization	 of	 human	 HSCs	 has	 been	more	
challenging.	The	first	 cell-surface	marker	 identified	 to	enrich	human	hematopoietic	stem	
and	progenitor	cells	(HSPC)	was	CD34,	which	is	expressed	on	less	than	5%	of	all	blood	cells32.	
In	humans,	the	majority	of	HSCs	are	CD34+,	as	evidenced	by	many	human	transplantations	
as	well	as	xenograft	repopulation	assays,	which	involves	the	injection	of	human	cells	 into	
immunodeficient	 mouse	 models32.	 However,	 CD34	 also	 marks	 more	 lineage-restricted	
progenitors.	 Therefore,	 isolation	 of	 cell	 subsets	 further	 enriched	 for	 human	 HSCs	 also	
necessitates	 concurrent	 use	 of	 several	 cell-surface	markers.	 Assessing	 long-term	 human	
hematopoiesis	 in	 non-obese	 diabetic	 (NOD)/severe	 combined	 immunodeficiency	 (SCID)	
mice	recipients,	Bhatia	and	colleagues	reported	that	human	HSPC	reside	in	the	Lin-	CD34+ 
CD38-/low	fraction33.	Moreover,	using	xenotransplantations	as	well	as	complementary	in vitro 
assays,	Majeti	and	colleagues	demonstrated	that	a	Lin-	CD34+	CD38-/low	CD90+	CD45RA-	cord	
blood	fraction	is	further	enriched	in	human	HSCs34.		
Hematopoietic stem and progenitor cells in clinics
The	start	of	the	hematopoietic	cell	transplantation	era	coincides	with	the	atomic	era	when	
the	lethal	effect	of	 ionizing	radiation	was	shown	to	be	due	to	BM	failure35.	The	rescue	of	
the	exposed	recipients	was	possible	by	 injection	of	bone	marrow	cells	 from	unirradiated	
donors36.	Over	the	last	six	decades,	intensive	research	has	been	done	on	the	use	of	HSPC	
16
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transplantations.	Today,	 transplantation	of	stem	and	progenitor	cells	 from	BM,	mobilized	
peripheral	 blood,	 or	 umbilical	 cord	 blood	 (UCB)	 is	 the	 treatment	modality	 of	 choice	 for	
a	 variety	 of	 hematological	 and	 genetic	 diseases.	 Nevertheless,	 successful	 use	 of	 HSPC	
treatment	is	limited	by	a	lack	of	human	leukocyte	antigen	(HLA)-matched	donors,	high	risk	
of	graft-versus-host	disease	 (GvHD)	after	transplantation	and	 inability	 to	expand	the	rare	
population	of	HSCs.	
Among	the	different	sources	of	HSPC	for	clinical	applications,	UCB	provides	some	advantages	
over	 bone	marrow	 or	mobilized	 peripheral	 blood.	 These	 include	 the	 ease	 of	 collection,	
little	or	no	risk	to	the	donors,	reduced	risk	of	infection	transmission,	less	stringent	human	
leucocyte	antigen	(HLA)-matching	criteria,	lower	risk	of	GvHD	and	rapid	availability	of	the	
cord	units37.	Indeed,	UCB	transplantation	has	been	shown	to	be	beneficial	in	treatment	of	
children	with	certain	hematologic	diseases	and	metabolic	disorders37–40.	 In	adult	patients,	
however,	the	use	of	UCB	as	a	source	has	resulted	in	delayed	engraftment,	a	major	cause	
of	 early	 morbidity	 and	 mortality41,42.	 This	 is	 most	 probably	 due	 to	 the	 low	 number	 of	
hematopoietic	cells	in	a	cord	unit43.	The	observation	that	cell	dose	is	a	critical	parameter	for	
engraftment	and	survival,	led	to	the	initiation	of	studies	focusing	on	increasing	the	number	
of	cells	being	transplanted.	
In	 trying	 to	 increase	 the	 cell	 dose	 in	 UCB	 transplantations,	 different	 approaches	 have	
been	 assessed.	 One	 of	 these	 strategies	 has	 been	 the	 use	 of	 double	 UCB	 units	 for	
transplantations44,45.	The	double	cord	transplantation	has	shown	advantages	over	the	use	
of	single	cord,	including	enhanced	median	time	to	achieve	neutrophil	recovery	and	lower	
relapse	rate43.	The	growing	interest	in	the	use	of	double	cord	transplantation,	however,	will	
increase	the	demand	for	UCB	units.		
Another	approach	to	reach	sufficient	cell	numbers	 in	UCB	has	been	ex vivo expansion of 
HSPC46,47.	 In	this	approach	the	primary	aim	is	to	increase	the	numbers	of	HSCs	present	in	
the	cord	unit,	which	will	result	in	permanent	reconstitution	of	all	blood	lineages.	However,	
it	 is	as	important	to	generate	higher	number	of	progenitors	for	rapid,	although	transient,	
reconstitution	 of	 the	 blood	 system,	 thereby	 decreasing	 early	 morbidity	 and	 mortality.	
For ex vivo	 expansion	of	UCB	HSPC,	many	 studies	have	 focused	on	 the	use	of	particular	
combinations	of	cytokines,	which	are	signaling	molecules	regulating	the	proliferation	and	
differentiation	of	progenitors48.	These	studies	suggested	a	requirement	for	the	presence	of	
cytokines	which	act	at	early	stages	of	the	hematopoietic	hierarchy,	including	stem	cell	factor	
(SCF),	Fms-related	tyrosine	kinase	3	ligand	(Flt3L),	and	thrombopoietin	(TPO),	for	expansion	
of	HSPC49–51.	Moreover,	it	has	been	shown	that	other	niche	factors	such	as	stromal	cells	or	
signaling	molecules,	in	addition	to	cytokines,	might	be	essential	for	ex vivo	expansion	of	HSCs	
and	progenitors52–54.	For	this	reason,	the	more	we	learn	about	the	regulation	mechanisms	
of	HSPC	and	their	microenvironment,	the	better	we	can	manipulate	them	ex vivo	for	clinical	
purposes.
Regulation of hematopoiesis
HSCs	are	functionally	characterized	by	their	ability	to	self-renew	and	their	broad	capacity	
to	 produce	 all	 the	 blood	 cell	 types.	 While	 adult	 HSCs	 mostly	 remain	 dormant	 during	
homeostasis,	upon	injury	they	dynamically	regulate	their	numbers	by	cell	divisions28.	Thus,	
to	ensure	persistent	blood	production	regardless	of	the	situation	and	throughout	the	entire	
life	span	of	an	organism,	the	cell-fate	decisions	of	HSCs	are	tightly	controlled	by	cell-intrinsic	
and	–extrinsic	mechanisms.	With	regards	to	extrinsic	factors,	adult	HSCs	are	mainly	found	
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in	 specialized	microenvironments	 of	 BM,	 referred	 to	 as	 niches,	 where	 they	 are	 in	 close	
proximity	 to	 supporting	 cells,	which	 provide	membrane	bound	 and	 secreted	 factors55.	 A	
wide	 variety	 of	 these	 factors	 including	 cell-adhesion	molecules,	 cytokines	 and	 signaling	
molecules,	 has	 been	 suggested	 to	 regulate	 HSC	 maintenance	 by	 establishing	 a	 balance	
between	self-renewal,	differentiation	and	survival.	
Among	 the	 numerous	 signaling	 pathways	 and	 adhesion	molecules	 constituting	 the	 HSC	
niche,	three	signaling	pathways,	namely	Notch,	Hedgehog	and	Wnt,	have	been	the	focus	
of	 studies	over	 the	 last	decade	due	 to	 their	putative	 roles	 in	adult	HSC	self-renewal	and	
differentiation28.	 Indeed,	 all	 these	 pathways	 are	 known	 to	 control	 numerous	 important	
processes	during	embryogenesis	and	adult	tissue	homeostasis.	Nevertheless,	their	role	in	
regulation	of	HSCs	remains	controversial.	While,	 in vitro	studies	as	well	as	mouse	models	
with	gain	of	function	mutations	suggest	a	positive	role	for	these	pathways,	in vivo	deletion	
of	the	key	components	of	these	pathways	such	as	RBPjk,	Smoothened	and	b-catenin	have	
been	shown	to	have	no	apparent	effect	on	the	HSC	function28.	Given	the	focus	of	this	thesis,	
the	early	studies	on	 the	role	of	Wnt	signaling	pathway	on	HSC	regulation	will	be	 further	
explained	later	in	this	chapter.	
Intestinal Stem Cells 
With	a	higher	turnover	rate	than	any	other	mammalian	tissue	and	its	unique	architecture,	
epithelium	of	the	intestine	has	been	a	prototype	for	the	study	of	adult	stem	cells	in	health	
and	disease.	Furthermore,	recent	developments	 in	the	field	of	 intestinal	stem	cells	(ISCs)	
have	 brought	many	 promises	 for	 therapeutic	 purposes.	 Here,	 I	 briefly	 explain	 the	 basic	
anatomy	of	the	small	intestine,	its	cellular	composition,	and	ISCs.	
Basic architecture of the small intestine
The	small	 intestine	is	one	of	the	distinct	organs	of	the	gastrointestinal	tract	between	the	
stomach	and	the	colon.	The	major	functions	of	the	small	intestine	are	digestion	of	food	and	
absorption	of	nutrients	and	minerals.	These	activities	are	supported	by	the	basic	structure	
of	the	small	intestine	consisting	of	three	layers:	an	outer	layer	of	smooth	muscle	responsible	
for	rhythmic	peristaltic	movements	that	direct	digested	food	along	the	intestine,	a	middle	
layer	of	connective	tissue	which	harbors	nerves,	capillaries	and	lymphatic	vessels	mediating	
transport	of	the	absorbed	nutrients	and	an	innermost	layer	composed	of	a	sheet	of	epithelial	
cells	called	the	mucosa	which	faces	the	lumen	of	the	intestine	and	mediates	absorption	of	
the	nutrients.	 To	maximize	 the	absorptive	 surface	area,	 this	epithelium	 is	organized	 into	
finger-like	protrusions	named	villi	projecting	into	the	lumen,	and	at	the	base	of	each	villus	
there	are	multiple	invaginations	called	crypts	of	Lieberkühn	(Figure	2)56.	
Anatomically,	the	small	intestine	can	be	subdivided	into	three	specialized	parts:	duodenum,	
jejunum	 and	 ileum	 (from	 proximal	 to	 distal).	 They	 can	 be	 distinguished	 based	 on	 their	
specific	 features:	 the	 presence	 of	 Brunner’s	 glands,	 producing	 a	 mucus-rich	 alkaline	
secretion,	in	duodenum;	the	presence	of	Peyer’s	patches,	lymphoid	accumulations	playing	
a	role	in	mucosal	immunity	in	ileum;	and	absence	of	both	of	these	structures	in	jejunum.	
While	the	cellular	composition	of	these	subdivisions	display	subtle	differences,	they	all	are	
composed	 of	 four	main	 types	 of	 differentiated	 epithelial	 cells	 (Figure	 2).	 The	 absorptive	
enterocytes,	which	are	characterized	by	 luminal	brush	borders,	are	 found	 in	 the	villi	and	
are	 the	most	 abundant	 cell	 type	 throughout	 the	 intestine.	Mucus-secreting	Goblet	 cells	
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are	responsible	for	lubrication	of	the	intestine,	providing	an	easier	passage	for	stool.	More	
rare	enteroedocrine	cells	secrete	hormones	aiding	in	the	control	of	the	gut	functions.	Both	
goblet	and	enteroendocrine	cells	can	be	found	in	the	villi	and	crypts.	Finally,	Paneth	cells,	
which	reside	exclusively	at	the	bottom	of	the	crypts,	secrete	bactericidals	such	as	lysozymes	
and	defensins.	
Epithelial renewal in the intestine
Fulfilling	its	activities,	the	small	intestine	is	exposed	to	considerable	environmental	insults,	
which	 impose	a	requirement	for	continuous	renewal	of	 the	epithelial	 lining	of	 its	 lumen.	
Indeed,	the	simple,	columnar	epithelium	lining	the	villi	and	the	crypts	is	completely	renewed	
every	3-5	days	in	mammals57.	Therefore,	this	extreme	turnover	rate	necessitates	an	efficient	
self-renewal	mechanism	to	maintain	the	intestinal	tissue	homeostasis.	While	the	epithelia	
covering	the	villus	are	post-mitotic,	the	crypts	harbor	vigorously	proliferating	epithelial	cells	
and	therefore	form	the	engines	of	this	dynamic	renewal	process.	Each	crypt	produces	about	
250	new	epithelial	cells	every	day	and	up	to	ten	crypts	supplies	cells	to	a	single	villus.	
Residing	 at	 the	 bottom	 of	 the	 crypts,	 intestinal	 stem	 cells	 (ISCs)	 are	 the	 driving	 force	
behind	the	dynamic	turnover	of	intestinal	epithelium	(Figure	2).	The	ISCs	generate	rapidly	
expanding	progenitors	known	as	transit-amplifying	(TA)	cells,	which	take	about	twelve	hours	
for	each	of	their	four	to	five	cell	cycles.	As	they	proliferate	and	move	upward,	TA	cells	start	
to	differentiate	into	enterocytes,	Goblet	or	enteroendocrine	cells	and	exit	the	crypt	onto	the	
villus.	These	differentiated,	functional	epithelial	cells	continue	migrating	along	this	conveyor	
belt	until	they	reach	the	tip	of	the	villus	where	they	undergo	apoptosis	and	are	shed	into	the	
lumen	of	the	intestine.	The	much	longer-lived	Paneth	cells,	which	are	the	only	differentiated	
cell	 type,	escape	 the	upward	migration	and	 reside	 in	 the	crypt	base	where	 they	 live	6-8	
weeks58.		
Enterocyte
Goblet cell
Enteroendocrine cell
Paneth cell
Transient -amplifying
cell
Lgr5+ CBC cell
Differentiated 
cells
Villus
Crypt base
TA 
compartment
+4 position
Crypt
Figure 2.  Structure of the small intestine and its cell types. 
Lgr5+	CBC	stem	cells	reside	at	the	crypt	base	together	with	
Paneth	 cells.	 The	 progeny of	 Lgr5+	 cells	 moves	 up	 and	
forms	the	villus	structure.	(Adapted	from	ref56,192).
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Adult stem cells of the intestine 
Early	studies	towards	 identifying	the	 intestinal	stem	cells	 led	to	two	alternative	stem	cell	
models59:	the	crypt	base	columnar	cell	(CBC)	model	and	the	+4	cell	model,	respectively.	
In	the	early	1970s,	Cheng	and	Leblond	discovered	the	presence	of	slender,	immature	cycling	
cells,	 known	 as	 crypt	 base	 columnar	 (CBC)	 cells,	 interspersed	 among	 the	 Paneth	 cells60.
Moreover,	 they	performed	a	 rudimentary	 lineage	 tracing	 study	by	 radiolabeling	 strategy	
which	supported	the	notion	that	CBC	cells	might	be	the	multipotent	cells	of	the	intestine61.	
Later	on,	by	using	a	genetic	marking	method	induced	by	chemical	mutagens,	Winton	and	
Ponder	demonstrated	the	clonal	nature	of	crypts	as	well	as	the	flow	of	cells	from	crypts	to	
villus	tips	as	‘ribbons’	for	the	first	time62.		By	use	of	a	similar	marking	strategy,	Bjerknes	and	
Cheng	showed	the	presence	of	both	long-lived	and	short-lived	crypt	cells	corresponding	to	
a	stem	cell	and	TA	cells	compartment,	respectively63.		These	long-lived	clones	consistently	
included	a	CBC	cell	and	gave	rise	 to	all	 four	differentiated	types	of	epithelial	 cells	of	 the	
intestine,	providing	additional	support	for	the	model	of	CBC	cells	as	 intestinal	stem	cells.	
With	 these	 observations,	 Bjerknes	 and	 Cheng	 further	 developed	 their	 stem	 cell	 zone	
hypothesis58,63,64,	 and	 stated	 that	 CBC	 stem	 cells	 reside	 at	 the	bottom	of	 the	 crypts	with	
Paneth	cells	and	only	exiting	the	stem	cell	zone	around	the	+5	position	(one	cell	diameter	
distance	from	the	uppermost	Paneth	cell)	lead	to	their	differentiation.	
The	 alternative	 of	 the	 CBC	 cell	 model,	 referred	 to	 as	 ‘position	 4’	 or	 ‘+4’	 model	 was	
proposed	based	on	the	prediction	of	a	common	cell	origin	at	position	4-5	 just	above	the	
Paneth	cell	compartment	(Figure	2)65.	Later,	Potten	and	colleagues	reported	the	presence	
of	radiation	sensitive,	DNA-label	retaining	cells	residing	directly	above	Paneth	cells	at	the	
+4	position66,67.	 The	 radiation	 sensitivity	 of	 these	 cells	was	 considered	 to	be	 a	 beneficial	
stem	 cell	 characteristic	 for	 prevention	 of	 accumulating	 carcinogenic	 genetic	 changes.	
Moreover,	 label-retention	is	usually	taken	as	 indicative	of	mitotic	quiescence,	however	in	
this	case	+4	cells	were	cycling	every	day.	This	label-retaining	trait	was	instead	proposed	to	
be	a	consequence	of	asymmetric	segregation	of	 the	 labeled	and	unlabeled	DNA	 into	the	
stem	cells	and	their	progeny,	respectively67.	Indeed,	the	‘immortal	strand’	theory68 suggests 
asymmetric	 segregation	 of	 chromosomes	 as	 a	 protection	 from	 accumulating	mutations.	
However,	this	hypothesis	has	not	been	proven	since.	On	the	contrary,	stem	cells	cycling	at	
the	intestinal	crypts	randomly	segregate	their	chromosomes69,70.	
Lgr5+ stem cells and organoids
Since	 the	 proposal	 of	 the	 intestinal	 stem	 cell	 models,	 many	 studies	 have	 focused	 on	
identification	of	 stem	cell	markers,	which	would	not	only	 enhance	 the	understanding	of	
small	intestine	biology	but	also	potentiate	the	isolation	and	exploitation	of	these	stem	cells	
for	regenerative	purposes.	However,	for	a	long	time	the	ISC	field	had	been	challenged	due	to	
the	fact	that	most	of	these	studies	were	solely	based	on	positional	information	of	potential	
markers	 expression,	 and	 they	 were	 not	 supported	 by	 direct	 evidence	 for	 stemness	 as	
assessed	by	lineage	tracing	or	transplantations59.	While	the	evidence	for	the	+4	cell	model	is	
still	confusing	and	controversial,	in	2007	Barker	and	colleagues	have	identified	an	exquisite	
CBC	cell	marker,	Lgr5,	confirming	Leblond’s	predictions	regarding	CBC	cells.	
The	road	to	the	discovery	of	Lgr5	as	stem	cell	marker	was	paved	with	accumulating	knowledge	
about	the	role	of	deregulated	Wnt	signaling	in	colon	cancer	and	physiological	Wnt	activation	
in	 crypt	 proliferation.	 The	 analysis	 of	Wnt	 target	 genes	 in	 human	 colon	 cancer	 cell	 lines	
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as	well	as	 intestinal	crypts	revealed	a	number	of	genes71,72	among	which	Lgr5	turned	out	
to	be	uniquely	 expressed	by	 the	CBC	 cells	 in	 the	 crypts	 of	 the	 small	 intestine12.	 Lineage	
tracing	studies	with	an	inducible	Lgr5	reporter	mouse	model	showed	the	formation	of	clonal	
ribbons,	which	persisted	 throughout	 the	 life	and	contained	all	different	 cell	 types	of	 the	
intestine.		These	further	demonstrated	the	longevity	and	multipotency	of	CBC	cells.	
In	contrast	to	many	other	adult	stem	cell	types,	Lgr5+	CBC	stem	cells	of	the	intestines	divide	
every	 day.	 This	 corresponds	 to	 around	 1000	 cell	 cycles	 in	 a	 laboratory	 mouse	 lifetime,	
thus	defies	the	Hayflick	phenomenon	which	states	that	normal	human	cells	have	 limited	
capacity	to	divide59.	However,	until	the	work	of	Sato	and	colleagues,	it	was	not	possible	to	
culture	these	highly	proliferating	stem	cells.	In	his	work,	Sato	carefully	analyzed	the	growth	
factor	requirements	of	the	mouse	intestinal	crypts	by	taking	into	consideration	the	genetic	
evidence	of	 stem	cells	 self-renewal,	 differentiation	and	 carcinogenesis.	 Consequently,	 he	
discovered	 that	 a	 combination	of	 three	 growth	 factors,	 namely	 epidermal	 growth	 factor	
(EGF),	Noggin	(a	bone	morphogenic	protein	(BMP)	signaling	inhibitor)	and	R-spondin	(a	Wnt	
signaling	enhancer),	were	essential	for	culture	of	ISCs	in vitro73.	Culturing	mouse	intestinal	
crypts	or	single	Lgr5+	CBC	cells	also	required	a	basement	membrane	extract,	also	known	
as	Matrigel,	as	a	scaffold	for	three-dimensional	(3-D)	growth.	In	this	culture	system	having	
the	proper	signals	and	conditions,	Lgr5+	cells	formed	ever-expanding	‘organoids’,	mimicking	
the	crypt-villus	structure	of	intestines	(Figure	3).	These	organoids,	also	known	as	‘mini-guts’	
occur	as	cysts	composed	of	a	central	lumen	and	surrounding	crypt-like	budding	structures	
(Figure	3).	While	post-mitotic	differentiated	cells	migrate	towards	the	central	area	facing	the	
lumen,	Paneth	and	Lgr5+	stem	cells	reside	together	in	these	buds.	With	their	self-renewal	
kinetics,	 longevity	and	capacity	to	generate	all	 the	cell	 types	of	the	tissue,	the	organoids	
form an in vitro	equivalent	of	mouse	small	intestinal	tissue.	
The	 functional	 readout	 proving	
the	 true	value	of	organoid	 system	
as	 a	 physiological	 model	 came	
from	 studies	 done	 with	 mouse	
colon	 organoids.	 Organoids	
derived	 from	 a	 single	 Lgr5+	
stem	 cell	 of	 mouse	 colon	 has	
proven	 to	 be	 transplantable	 into	
multiple	 recipient	 mice	 with	
chemically	 induced	 epithelial	
damage.	 The	 grafted	 organoids	
formed	 patches	 lasting	 at	 least	
six	 months	 without	 any	 apparent	
histological	 changes74.	 Thus,	 the	
invention	 of	 the	 groundbreaking	
organoid	 culture	 system	 further	
demonstrated	 the	 stemness	 of	 	 	
Lgr5+	stem	cells	in	the	intestines.	
The	establishment	of	organoid	culture	system	not	only	provided	a	system	to	study	intestinal	
biology	but	also	offered	a	great	 tool	 for	disease	modeling	and	therapeutic	purposes.	For	
example,	human	intestinal	organoids	were	successfully	applied	as	a	disease	model	for	cystic	
fibrosis16.	While	the	wild-type	organoids	swell	upon	cAMP	treatment	due	to	the	lack	of	cystic	
fibrosis	transmembrane	conductor	receptors	(CFTR),	organoids	derived	from	cystic	fibrosis	
or
Villus 
domain
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Lgr5+ cells
Crypts
Lgr5+ 
cells
Figure 3.  Schematic representation of a small intestinal 
organoid. Organoids	 generated	 from	 either	 crypts	 or	 single	
Lgr5+	stem	cells	consists	of	a	central	lumen	lined	by	villus-	and	
crypt-like	domains. (Adapted	from ref73).
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patients	 do	 not	 respond	 to	 this	 treatment.	 Furthermore,	 after	 restoring	 the	 CFTR	 locus	
via	genome-editing	tools,	the	diseased	organoids	regained	their	cAMP	responsiveness.	 In	
addition,	human	intestinal	organoids	could	be	engineered	to	mimic	the	 in vivo	situations	
of	 colon	 cancer75	 and	 the	 	 organoids	 derived	 from	 cancerous	 tissues	 can	 reflect	 their	
genetic	regulation	and	be	used	for	in vitro	drug	testing	for	clinical	treatment	predictions15.	
Collectively,	the	establishment	of	human	intestinal	organoids	not	only	provides	a	valuable	
tool	for	basic	research	but	also	offers	many	novel	strategies	for	translational	medicine.	
Liver stem cells 
Liver
The	 liver	 is	 a	 central	 organ	 for	maintenance	 of	 systemic	 homeostasis	 of	 an	 organism.	 It	
performs	 a	 wide	 range	 of	 functions	 including	 nutrient	 metabolism,	 drug	 detoxification,	
glycogen	storage,	production	of	serum	proteins	and	bile	secretion.	The	basic	architectural	
unit	responsible	for	these	functions	of	the	liver	is	called	a	hepatic	lobule	(Figure	4)76.	At	each	
corner	of	this	polygonal	lobule,	there	is	a	portal	triad	of	vessels	consisting	of	a	portal	vein,	
hepatic	artery	and	bile	duct.	Blood	from	the	portal	vein	and	hepatic	artery	flows	towards	a	
central	efferent	vein	through	sinusoids	lined	with	fenestrated	sinusoidal	endothelial	cells,	
which	facilitates	the	exchange	of	materials	between	blood	and	hepatocytes.	Most	of	the	
functions	of	the	liver	are	carried	out	by	hepatocytes,	which	are	the	main	parenchymal	cell	
type	of	the	liver.	These	highly	polarized	epithelial	cells	comprise	approximately	80%	of	total	
liver	volume	and	are	arranged	in	cords.	Tight	junctions	between	the	hepatocytes	form	bile	
canaliculi,	which	are	linked	to	bile	ducts.	Bile	ducts	are	composed	of	the	other	parenchymal	
cell	type	of	the	liver	known	as	biliary	epithelial	cells	or	cholangiocytes.	Bile	salts	produced	in	
mature	hepatocytes	are	excreted	through	bile	canaliculi	and	bile	ducts	into	the	duodenum	
of	the	small	intestine.	Kupffer	cells	and	hepatic	stellate	cells	(Ito	cells),	which	together	with	
fenestrated	endothelial	cells	reside	in	sinusoids,	are	the	other	non-parenchymal	cells	of	the	
liver.	While	Kupffer	cells,	resident	macrophages	of	the	liver,	are	located	at	the	luminal	side	
of	 sinusoids,	hepatic	stellate	cells,	playing	a	 role	 in	extracellular	matrix	 remodeling	upon	
damage	and	secretion	of	a	variety	of	growth	factors,	reside	at	the	opposite	side.		
As	 the	 liver	 filters	 the	blood	 it	 receives	 from	 the	portal	 vein,	 it	 is	 inherently	 exposed	 to	
harmful	compounds.	Moreover,	it	can	be	subjected	to	insults	from	a	variety	of	hepatotropic	
viruses,	leading	to	liver	injury.	Due	to	its	vital	roles,	however,	loss	of	liver	function	is	often	
fatal.	To	compensate	for	any	injury-induced	loss	of	liver	mass	and	to	continue	to	exert	its	
functions,	the	liver	displays	a	remarkable	regenerative	capacity77.	It	is	therefore	also	possible	
to	transplant	liver	tissue	from	a	living	donor.	
Liver regeneration 
In	an	adult	 liver	under	physiological	conditions	both	hepatocytes	and	cholangiocytes	are	
infrequently	dividing76.	The	normal	turnover	of	mature	hepatocytes	occurs	slowly	over	more	
than	several	months78.	Following	injury-induced	loss	of	liver	mass,	however,	an	adult	liver	
displays	great	regenerative	response.		When	two-thirds	of	a	rat	liver	is	removed	by	partial	
hepatectomy	(Phx),	the	remaining	hepatocytes	and	ductal	cells	from	the	undamaged	lobes	re-
enter	the	cell	cycle	and	replace	the	lost	hepatic	mass	within	5-7	days	(8-15	days	in	humans)77.	
The	regenerative	capacity	of	mature	hepatocytes	has	further	been	demonstrated	by	serial	
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transplantati	ons	upon	which	a	small	number	of	normal	hepatocytes	reconsti	tuted	diseased	
livers	multi	ple	ti	mes,	dividing	at	least	80	ti	mes	in	the	process79.	However,	in	situati	ons	where	
the	proliferati	on	capacity	of	hepatocytes	 is	compromised,	another	mode	of	 regenerati	on	
process	mediated	by	a	populati	on	of	liver	stem/progenitor	cells	(LSPCs)	is	proposed	to	take	
over	the	responsibility	of	diff	erenti	ati	on	towards	hepatocytes76.	The	concept	of	LSPCs	has	
originated	from	studies	in	rats	where	the	combinati	on	of	hepatocyte	proliferati	on	blockage	
by	DNA	damage	and	Phx	gave	 rise	 to	a	populati	on	of	 cells	with	oval	nuclei,	 thus	named	
as	oval	cells,	 from	the	biliary	tree80.	Rat	oval	cells	are	shown	to	express	both	hepatocyte	
and	cholangiocyte	markers,	and	appear	to	possess	bipotenti	al	capacity	to	diff	erenti	ate	into	
both	of	these	cell	types81.	The	term	oval	cell	has	since	been	used	as	an	anonym	to	LSPCs,	
at	least	in	rats.	However,	the	oval	cell	bipotenti	ality	was	not	clearly	demonstrated	in	rats.	
As	a	result	of	the	 lack	of	geneti	c	tools	 in	rats	and	a	specifi	c	marker	to	 identi	fy	oval	cells,	
the	mouse	has	become	the	organism	of	choice	for	LSPC	studies.	Soon,	it	was	realized	that	
the	 injury	regimens	 leading	to	oval	cell	response	 in	rats	did	not	result	 in	the	same	eff	ect	
in	mice.	Therefore,	 for	oval	cell	 inducti	on	 in	mice,	alternati	ve	 injury	models	mediated	by	
hepatotoxins	 (e.g.,	 3,5-diethoxycarbonyl-1,4-dihydrocollidine	 (DDC)-containing	 diet82 or 
choline-defi	cient	 ethionine-supplemented	 (CDE)	 diet83)	 have	 been	 devised.	 Despite	 the	
emergence	of	mouse	oval	cells,	the	injuries	sustained	in	these	models	diff	er	from	that	of	the	
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Figure 4. Schemati c overview of hepati c lobule.  
In	the	liver	lobule,	the	portal	vein,	hepati	c	artery,	and	bile	ducts	together	comprise	the	portal	triad.	Mixed	
blood	from	the	portal	vein	and	the	hepati	c	artery	proceeds	through	the	sinusoids	surrounded	by	fenestrated	
hepati	c	sinusoidal	endothelial	cells	towards	the	central	vein.	Bile	produced	by	the	hepatocytes	is	collected	via	
bile	canaliculus	and	fl	ows	in	the	opposite	directi	on	towards	the	bile	duct.	While	liver	resident	macrophages,	
Kupff	er	cells,	are	located	at	the	lumen	of	sinusoids,	stellate	cells	reside	in	the	space	between	hepatocytes	
and	sinusoids.	The	canal	of	Herring	forms	the	juncti	on	between	hepatocytes	and	bile	duct.	(Adapted	from	
ref76).
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rat	model.	It	has	also	been	shown	that	mouse	oval	cells,	which	constitute	a	heterogeneous	
population,	 display	 differences	 compared	 to	 their	 rat	 and	 human	 counterparts84.	 For	
example,	unlike	in	rat	and	human,	mouse	oval	cells	do	not	express	the	immature	hepatocyte	
marker,	alpha-fetoprotein85.	Despite	different	characteristics	and	etiology	of	LSPCs,	several	
common	markers	in	mice,	rats	and	humans,	including	CK19,	EpCAM,	and	CD133,	have	been	
identified	to	describe	these	cells86–89	.	Subsequent	isolation	of	LSPCs	based	on	these	markers	
and	their	in vitro	culture	have	demonstrated	that	LSPCs	contain	cells	that	are	clonogenic	and	
can	differentiate	into	both	hepatocytes	and	cholangiocytes90.	Interestingly,	cholangiocytes	
isolated	from	normal	 livers	based	on	the	same	markers	also	display	the	same	bipotential	
capacity	in vitro,	raising	the	question	whether	they	constitute	a	reserve	stem	cell	population	
that	can	give	rise	to	LSPCs	upon	damage76.	In	support	of	this	notion,	several	lineage-tracing	
studies	done	with	cholangiocyte-specific	Cre	driver	strains	collectively	indicated	that	LSPCs	
emerging	 upon	 certain	 injury	 conditions	 are	 indeed	 derived	 from	 cholangiocytes91–93.	
However,	a	variety	of	more	recent	studies	strongly	argue	against	the	presence	of	a	stem	cell	
population	as	a	genuine	source	of	hepatocyte	formation	in	liver94–97.	Nevertheless,	given	the	
capacity	of	hepatocytes	to	regenerate	even	in	severe	injury	models,	the	identification	of	a	
potential	stem	cell	population	becomes	rather	difficult.	Adding	up	to	the	complexity	of	the	
identification	of	liver	regenerating	populations,	it	has	been	suggested	that	if	regenerative	
capacity	of	one	of	the	epithelial	compartments	of	the	liver	is	compromised,	the	other	one	
can	give	rise	to	the	proliferation-defective	compartment81.	
Lgr5+ liver stem/progenitor cells and organoids
Despite	the	complications	of	in vivo	identification	of	stem	cell	populations,	several	groups	
isolated	liver	stem	cell	populations	from	the	adult	liver	based	on	marker	gene	expression.	
An	 important	 example	 for	 this	 comes	 from	 the	 studies	 of	 Huch	 and	 colleagues	 who	
demonstrated	 the	 appearance	 of	 Lgr5+	 LSPCs	 upon	 acute	 liver	 damage	 with	 carbon-
tetrachloride	(CCl4) as	well	as	upon	an	oval	cell	response	by	DCC	or	CDE	diets	
11.	Lgr5+	LSPCs	
are	shown	to	actively	contribute	to	liver	regeneration	by	giving	rise	to	both	hepatocytes	and	
cholangiocytes	in vivo.	More	importantly,	these	cells	can	be	cultured	as	organoids	for	over	
a	year,	while	they	maintain	their	bipotency	to	differentiate	into	hepatocytes	as	well	as	bile	
duct	epithelial	cells.	While	the	origin	of	Lgr5+	LSPCs	remains	to	be	determined,	liver	organoid	
cultures	can	also	be	initiated	with	bile	ducts	instead	of	Lgr5+	cells.	Owing	to	their	capacity	
to	expand	indefinitely	and	differentiate	into	hepatocytes,	organoids	also	repopulate	livers	of	
mice	with	congenital	metabolic	liver	disease	and	contributed	to	restoration	of	their	hepatic	
functions14.	With	this	study,	a	robust	culture	of	mouse	LSPCs	has	been	established	for	the	
first	time.	Furthermore,	recently	Huch	and	colleagues	also	established	long-term	culture	of	
genomically	stable	human	organoids	from	adult	human	liver98.	As	in	the	case	of	intestinal	
organoids,	the	liver	organoid	technology	opens	up	new	avenues	for	disease	modeling,	drug	
testing,	gene	therapy	and	transplantations99.	
Signal transduction pathways in regulation of self-renewal and differentiation of adult 
stem cells
A	 central	 question	 in	 applying	 stem	 cell	 technologies	 to	 clinics	 is	 how	 the	 self-renewal	
and	differentiation	of	stem	cells	are	controlled.	 In	order	 to	 increase	the	number	of	stem	
cells	 or	 guide	 them	 towards	 a	 specific	 lineage,	 it	 is	 of	 vital	 importance	 to	 know	how	 to	
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manipulate	 these	 cells	 in	 a	 predictable	 and	 reproducible	manner.	 Over	 the	 years,	many	
microenvironmental	 factors	 that	 regulate	 stem	 cell	 fate	decisions	 have	been	discovered.	
Among	these	external	cues	including	members	of	BMP,	Hedgehog,	Wnt	and	Notch	families,	
Wnt	proteins	stand	out	due	to	their	roles	 in	a	variety	of	stem	cells	types100.	Therefore,	 in	
the	next	part	of	this	introduction,	I	will	give	an	overview	of	the	Wnt	signaling	pathway,	Wnt	
proteins	and	their	roles	in	regulation	of	adult	intestinal,	hematopoietic	and	liver	stem	cells	
in	culture.		
WNT SIGNALING 
With	the	identification	of	the	segment	polarity	gene	Wingless (wg)	as	the	fly	homologue	
of	the	mouse	proto-oncogene	Integrase-1	(Int-1),	a	new	termed	was	coined	for	Int-1	and	
related	genes:	Wnt1	and	the	Wnt	gene	family,	respectively101.	 	Ever	since,	the	Wnt	genes	
and	encoded	proteins	have	been	widely	studied	in	a	variety	of	different	organisms	such	as	
worms,	flies,	mice	and	humans	and	in	many	different	contexts	including	development,	tumor	
formation,	and	stem	cell	regulation102,103.	Owing	to	these	studies,	our	understanding	of	the	
wide	range	of	processes	Wnt	ligands	control	as	well	as	how	Wnt	proteins	are	produced,	are	
secreted	and	signal	has	greatly	expanded.
Signaling	through	the	Wnt	family	of	secreted	glycoproteins	is	an	evolutionarily	conserved	
mechanism	 in	 all	metazoans104.	 In	mammalians,	Wnt	 ligands	 play	 key	 roles	 in	 numerous	
processes	 including	 cell	proliferation,	 cell	 fate	determination,	differentiation	and	 survival	
during	embryogenesis	and	adult	tissue	homeostasis102,103.	With	respect	to	maintenance	of	
adult	tissue	homeostasis,	the	effects	of	Wnt	signals	in	regulation	of	stem-cell	fates	from	a	
variety	of	different	tissues	including	intestines,	hair	follicles	and	hematopoietic	system,	are	
particularly	important105.	
Activation	of	Wnt	signaling	cascades	proceeds	in	a	series	of	events	including	the	production	
and	secretion	of	active	Wnts,	binding	to	transmembrane	receptors,	activation	of	cytoplasmic	
effectors,	and	transcriptional	regulation	of	gene	expression.	 	Wnt	proteins	can	relay	their	
signals	 through	 at	 least	 three	 different	 pathways,	 including	 the	 ‘canonical’	 b-catenin	
pathway,	 and	 the	 ‘noncanonical’	 planar	 cell	 polarity	 and	 Ca2+	 pathways106.	 The	 Wnt-b-
catenin	pathway	is	so	far	the	most	extensively	studied	and	best-understood	Wnt	signaling	
cascade	(Figure	5).	In	the	absence	of	a	Wnt	protein,	cytoplasmic	b-catenin	is	sequestered	
by	a	destruction	complex,	which	is	composed	of	the	scaffolding	protein	Axin,	adenomatous	
polyposis	coli	(APC),	casein	kinase	1	(CKI)	and	glycogen	synthase	kinase	3b	(GSK-3b)107.	The	
kinases	of	the	destruction	complex,	CKI	and	GSK3b,	sequentially	phosphorylate	b-catenin,	
which	is	then	recognized	by	a	ubiquitin	E3	ligase	subunit,	known	as b-Trcp,	and	targeted	for	
proteosomal	degradation.	Due	to	 its	elimination,	cytoplasmic	b-catenin	cannot	reach	the	
nucleus,	where	Wnt	target	genes	are	repressed	by	the	DNA	binding	T	cell	factor/lymphoid	
enhancer	 factor	 (TCF/LEF)	 family	 of	 proteins108.	 Upon	 binding	 of	 a	 Wnt	 protein	 to	 the	
N-terminal	cysteine-rich	domain	(CRD)	of	Frizzled	(Fz)	family	of	receptors	and	to	low-density	
lipoprotein	receptor-related	protein	5	(LRP5)	or	LRP6	co-receptors,	Axin	is	recruited	to	the	
receptor	complex	at	the	cell	membrane.	The	resulting	inhibition	of	the	destruction	complex	
leads	to	stabilization	of	cytoplasmic	b-catenin,	which	accumulates	and	translocates	into	the	
nucleus	where	it	forms	complexes	with	TCF/LEF	transcription	factors	to	activate	Wnt	target	
gene expression104.		
As	many	studies	 indicated	roles	 for	Wnt-b-catenin	pathway	 in	stem	cell	 self-renewal	and	
differentiation	in	diverse	tissues	in vivo103,	the	manipulation	of	this	pathway,	in	particular	by	
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Wnt	proteins	have	proved	to	be	important	for	the	study	of	stem	cells	in vitro	both	for	basic	
research	and	for	therapeutic	purposes15,98,109–111.	Therefore,	it	is	of	great	value	to	understand	
the	biochemistry	of	Wnt	proteins	in	terms	of	achieving	stably	active	Wnt	proteins	for	in vitro 
studies	of	stem	cells.
Wnt proteins: production and secretion
In	mammalian	 genomes,	 including	 the	 human	 genome,	 there	 are	 19	Wnt	 genes,	 which	
encode	 for	 cysteine-rich	 proteins	 of	 approximately	 350-400	 amino	 acids.	 These	 proteins	
bear	an	N-terminal	signal	peptide,	that	targets	them	to	the	endoplasmic	reticulum	(ER)104.	
Although	Wnt	proteins	were	discovered	more	 than	 three	decades	ago	and	are	 secreted,	
difficulties	 in	 efficient	 purification	 of	 Wnts	 have	 precluded	 their	 thorough	 biochemical	
Figure 5. The canonical Wnt signaling pathway.	In	the	absence	of	a	Wnt	ligand	(OFF	state),	the	destruction	
complex,	composed	of	a	scaffolding	protein	Axin,	adenomatous	polyposis	coli	(APC),	casein	kinase	1	(CKI)	
and	glycogen	synthase	kinase	3b	(GSK-3b),	phosphorylates	b-catenin.	Phosphorylated	b-catenin	is	targeted	
for	degradation	by	the	proteasome.	Therefore	cytoplasmic	b-catenin	remains	low	and	Wnt	target	genes	are	
repressed.	Binding	of	a	Wnt	 ligand	to	 its	cell	surface	receptors	Frizzled	(Fz)	and	co-receptors	 low-density	
lipoprotein	receptor-related	protein	5	(LRP5)	or	LRP6	(ON	state)	leads	to	inhibition	of	the	destruction	complex.	
In	turn,	stabilized	b-catenin	translocate	into	the	nucleus	where	it	interacts	with	TCF/LEF	transcription	factors	
to	regulate	transcription	of	Wnt	target	genes.		(Adapted	from	ref102).
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characterization	 and	 use	 for	 in vitro	 studies.	 Whereas	 early	 studies	 predicted	 a	 highly	
soluble	nature	for	Wnt	proteins	which	contain	several	highly	charged	amino-acids	and	many	
potential	 glycosylation	 sites,	 initial	 attempts	 to	 purify	 the	 founding	Wnt	 protein,	Wnt1,	
has	revealed	its	poor	solubility	and	high	association	with	the	cell	surface	and	extracellular	
matrix112.	Nevertheless,	some	other	Wnts	such	as	Wg	and	mouse	Wnt3a	have	proved	to	be	
relatively	more	 soluble113,114.	 Thus,	 biologically	 active	Wg	 and	Wnt3a	 could	 be	 harvested	
in	 the	 form	 of	 conditioned-media	 from	 the	 specific	 cell-lines	 overexpressing	 them.	 The	
cell-free,	 serum-containing	 conditioned-medium	 of	 mouse	 Wnt3a	 has	 been	 extensively	
used	in	many	studies,	despite	the	many	undefined	factors	it	harbors	that	may	complicate	
the	analysis	of	any	biological	assay.	With	respect	to	obtaining	a	more	defined	system,	the	
purification	of	biologically	active	mouse	Wnt3a	for	the	first	time	has	been	a	major	step	for	
the	Wnt	field115.	Moreover,	this	same	study	led	to	the	discovery	that	Wnt	proteins	are	lipid-
modified,	and	provided	insights	into	the	hydrophobicity	and	insoluble	nature	of	the	Wnts.	
During	 their	 journey	 from	the	ER	 to	 the	extracellular	environment,	Wnt	proteins	 (except	
Drosophila WntD116)	associate	with	several	enzymes	and	undergo	several	post-translational	
modifications,	 including	 N-glycosylations	 and	 lipidations	 (Figure	 6A).	 The	 numbers	 of	
glycosylations	appear	to	differ	among	Wnt	proteins.	For	example,	while	mouse	Wnt1	carries	
up	 to	 four	 glycosylation	 sites117,	mouse	Wnt3a	 is	 glycosylated	 at	 two	 sites118.	Moreover,	
while	mutations	in	the	glycosylations	sites	of	mouse	Wnt1	seem	to	have	only	minor	effects	
on	protein	activity,	glycosylations	of	Wnt3a	protein	have	been	suggested	to	be	necessary	for	
their	proper	folding	and	lipid	modifications118.	While	the	exact	functions	of	glycosylations	in	
different	Wnts	is	still	under	debate112,117,118,	it	is	now	clear	that	the	addition	of	lipid-moieties,	
in	particular	 the	addition	of	a	mono-saturated	fatty	acid,	known	as	palmitoleic	acid,	 to	a	
conserved	serine	residue	in	Wnt	proteins	is	absolutely	essential	for	their	activity	and	may	be	
crucial	for	their	secretion103,112.	The	addition	of	palmitoleic	acid	to	Wnt	proteins	is	thought	
to	 be	 mediated	 by	 an	 ER	 resident	 multipass	 transmembrane	 protein,	 called	 Porcupine	
(PORCN),	which	contains	an	O-acyl	transferase	domain	(Figure	6A)112,119.	This	is	evidenced	by	
the	observations	that	both	mutating	the	conserved	serine	residue	(S209	in	mouse	Wnt3a)	to	
be	lipid	modified	and	loss	of	PORCN	results	in	the	accumulation	of	the	mutant	Wnt	protein	
in	the	ER119.	
Release	of	Wnt	proteins	from	the	secretory	machinery	requires	the	action	of	two	additional	
proteins:	Wntless	(WLS)	(also	known	as	Evenness	 interrupted	(EVI)	or	Sprinter	(SRT))	and	
the	retromer	complex	(Figure	6A)112.	WLS	is	a	multipass	transmembrane	protein	localized	
to	the	ER,	Golgi,	the	plasma	membrane	and	the	endosomes	between	them,	and	is	essential	
for	Wnt	secretion120–123.	WLS	functions	as	a	sorting	receptor	by	binding	and	accompanying	
Wnts	to	the	cell	surface.	The	binding	of	WLS	to	Wnts	takes	place	only	when	Wnts	are	lipid-
modified,	 indicating	 that	WLS	 acts	 downstream	 of	 PORCN124.	 Once	WLS	 escorts	 a	 lipid-
modified	Wnt	protein	to	the	plasma	membrane,	it	is	recycled	back	from	endosomes	to	the	
Golgi	by	the	actions	of	retromer	complex	and	from	the	Golgi	to	the	ER	by	specific	vesicles	for	
multiple	rounds	of	Wnt	secretion123,125–129.	A	deficiency	of	retromer	complex	function	results	
in	degradation	of	WLS	in	the	lysosomes	and	a	strong	Wnt	secretion	defect.	
 
Solubility and purification of Wnt proteins 
The	 lipid	modifications	of	Wnts	are	necessary	 for	 their	 intracellular	 trafficking	as	well	 as	
for	their	activity	upon	secretion.	Structural	analysis	of	the	Xenopus	Wnt8	protein	as	bound	
to	Fz	has	 shown	 that	 specifically	palmitoleic	acid	 lipids	are	 involved	 in	engagement	with	
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the	 Fz	 receptors130.	 However,	 the	 questions	 of	 how	 such	 hydrophobic	molecules,	 which	
tend	 to	 tightly	 associate	 with	 membranes,	 move	 in	 the	 extracellular	 environment	 and	
are	 conveyed	 to	 their	 targets	 remains	 elusive.	 Several	mechanisms	 have	 been	proposed	
that	may	act	 together	 to	mediate	Wnt	solubility	 in	 the	extracellular	environment	 (Figure	
6B).	 	One	mechanism	 facilitating	Wnt	proteins	presentation	 throughout	 the	extracellular	
matrix	employs	heparan	sulfate	proteoglycans	(HSPGs)	consisting	of	a	core	protein	to	which	
heparan	sulfate	(HS)	glycosaminoglycan	(GAG)	chains	are	attached112.	It	has	been	suggested	
that	by	attaching	to	the	GAG	chains	of	HSPGs	at	the	cell	surface,	Wnt	proteins	retain	their	
solubility	and	might	move	along	the	extracellular	matrix,	creating	gradients	in	a	restricted	
diffusion	manner	(Figure	6B)131.	Nevertheless,	their	role	in	diffusion	of	Wnts	remains	unclear,	
as	most	recent	findings	argue	against	long-range	spreading	of	Wnts132.
Although	plasma	membrane	tethering	of	Wnt	proteins	is	a	feasible	model	for	their	activity,	
the	fact	that	biologically	active	Wnt	proteins	(e.g.	mouse	Wnt3a	and	Wnt5a)	can	be	obtained	
from	conditioned-media	and	upon	further	purification	suggests	that	Wnt	proteins	might	use	
alternative	carriers.	Indeed,	several	in vivo	carriers	such	as	lipoprotein	particles	or	exosomes	
have	been	suggested	to	incorporate	Wnt	proteins,	shielding	their	lipids	from	the	aqueous	
environment	and	enabling	Wnts	to	travel	in	the	extracellular	space	between	the	cells	(Figure	
6B)133–136.	Worthwhile	to	note	is	that	lipoproteins	have	been	shown	to	interact	with	HSPGs,	
Figure 6. Model of Wnt secretion. 
(A)	After	their	translation,	Wnt	proteins	are	lipid-modified	by	Porcupine	(PORCN)	in	the	endoplasmic	reticu-
lum	(ER),	where	newly	lipidated	Wnts	also	bind	to	their	sorting	receptors,	Wntless	(WLS).	WLS	escort	Wnt	
proteins	from	the	ER	to	the	plasma	membrane.		Efficient	Wnt	secretion	necessitates	recycling	of	WLS	from	
the	plasma	membrane	back	to	the	ER.	Retromer	complex	dependent	endosome	to	Golgi	trafficking	brings	
WLS	to	the	Golgi,	while	retrograde	movement	from	the	Golgi	to	the	ER	is	mediated	by	specific	vesicles.	(B)	
Wnt	proteins	release	and	solubility	at	the	extracellular	environment	includes	several	possible	mechanisms:	
Wnts	might	associate	with	the	heparan	sulfate	proteoglycans	(HSPGs)	 (1),	exosomes	(2),	 lipoprotein	par-
ticles	(3),	or	HSPGs	and	lipoprotein	particles	together.	(Adapted	from	ref112,123,193,194).	
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suggesting	 that	 these	 carriers	 can	work	 together	 in	Wnt	 distribution	 in	 the	 extracellular	
environment	(Figure	6B)137.	
During	 purification	 of	 Wnt	 proteins,	 in vivo	 carriers	 that	 maintain	 Wnt	 in	 an	 active	
confirmation	may	be	lost	and	might	be	partially	replaced	by	CHAPS	detergent	micelles138.	
Upon	dilution	in	cell-culture	media,	these	micelles	are	dissolved	and	purified	Wnt	proteins	
tend	 to	aggregate	unless	 stabilized	by	 serum115,138–140.	 It	has	been	demonstrated	 that	 the	
addition	of	HSPGs	could	maintain	the	solubility	and	activity	of	purified	Wnt3a	in	the	absence	
of serum138.	 Besides	 this,	 association	 with	 liposomes,	 which	 are	 spherical	 nanovesicles	
composed	 of	 phospholipid	 layer(s),	 also	 promote	 the	 solubility	 and	 activity	 of	 purified	
Wnt3a	protein141,142.	
Given	the	importance	of	Wnt	signals	for	a	number	of	cellular	processes	including	regulation	
of	 stem-cell	 fate	 in vitro,	 the	 engineering	 of	 purified	 Wnt	 molecules	 with	 hydrophobic	
carriers	such	as	liposomes,	to	achieve	high	level	of	stable	Wnt	activity	in	serum-free	culture	
conditions,	bears	significant	potential	for	practical	use.	
Wnt signaling in regulation of HSPC
With	the	realization	that	many	Wnt	proteins	are	expressed	in	blood	cells	of	both	mouse	and	
human,	and	the	Wnt	signaling	pathway	is	deregulated	in	several	hematological	malignancies,	
much	interest	has	been	directed	to	a	possible	role	for	Wnt	signaling	in	the	control	of	self-
renewal	 of	 HSC	 and	 proliferation	 of	 progenitors143–146.	 However,	 varied	 experimental	
approaches	resulted	in	conflicting	outcomes	leading	to	a	controversy	in	the	field	and	making	
the	role	of	Wnt	signaling	in	HSPC	difficult	to	generalize.
Following	their	observation	on	the	activation	of	a	Wnt-b-catenin	reporter	in	mouse	HSPC,	
Reya	and	Willert	demonstrated	that	stimulation	of	Wnt	signaling	by	either	a	constitutively	
active	 form	 of	 b-catenin	 or	 by	 purified	Wnt3a	 protein	 induced	 expansion	 of	 apoptosis-
resistant,	 transgenic	mouse	HSPC	ex vivo115,147.	The	 importance	of	Wnts	 in	hematopoiesis	
has	 been	 heightened	 by	 studies	 showing	 defective	 fetal	 liver	 and	 bone	 marrow	 HSC	
self-renewal	 in	mouse	models	 carrying	a	null	 allele	of	Wnt3a	or	overexpressing	 the	Wnt	
receptor	antagonist	Dickkopf1148,149.	However,	using	mouse	models	in	which	continuous	Wnt	
activation	was	achieved	via	inducible	stabilization	of	b-catenin,	two	other	studies	reported	
multilineage	 differentiation	 block	 and	 exhaustion	 of	 HSCs150,151.	 Together,	 these	 studies	
suggest	that	the	context	and/or	duration	of	Wnt	activation	might	be	important	determinants	
of	the	physiological	outcome,	and	other	factors	in	conjunction	with	Wnt	signals	might	play	
a	role	in	maintenance/expansion	of	HSPC.	
Given	the	importance	of	HSPC	for	therapeutic	purposes,	several	studies	have	investigated	
the	potential	use	of	Wnt	signals	for	ex vivo	expansion	of	normal	HSPC.	In	this	regard,	Nemeth	
and	colleagues	analysed	the	impact	of	both	mouse	Wnt3a	and	Wnt5a	proteins	in	ex vivo 
culture	of	HSPC	and	reported	that	while	Wnt3a	protein	induce	a	decrease	in	the	number	
of	HSPC,	Wnt5a	improve	repopulation	capacity	of	mouse	HSPC152.	However,	in	their	study	
Oziemlak	and	colleagues	showed	an	opposite	effect	of	purified	Wnt5a,	which	was	shown	
to	obstruct	the	repopulation	capacity	of	mouse	HSPC153.	The	different	outcomes	of	these	
studies	can	be	attributed	to	culture	systems	with	varying	parameters,	including	the	amount	
and	the	type	of	cytokines	used	and	level	and	duration	of	Wnt	activity.	However,	the	question	
of	whether	Wnt	signals	could	inhibit	differentiation	and	induce	proliferation	of	HSPC	ex vivo,	
in	mice	and	particularly	in	humans,	remains	unanswered.	
The	maintenance	 of	 homeostasis	 in	 the	 hematopoietic	 system	 is	 achieved	 via	 balancing	
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the	proliferation,	apoptosis	and	differentiation	of	HSPC.	This	intricate	tuning	underlies	the	
difficulty	in	assigning	the	role	of	Wnt	signals	in	complex	systems	or	in	systems	where	several	
factors	are	missing.	With	respect	to	this,	a	line	of	studies	suggested	that	active	b-catenin	
increases	 apoptosis	 of	 HSPC,	 which	 might	 require	 survival	 signals	 for	 maintenance/
expansion154,155.	 Moreover,	 it	 has	 been	 reported	 that	 the	 activation	 of	 Wnt	 pathway	 in	
recipient	mice	 via	 a	GSK3b	 inhibitor,	which	 activates	 other	 cascades	 in	 addition	 to	Wnt,	
increases	the	numbers	of	HSPC	and	repopulation	in vivo156.	However,	the	study	of	Luis	et	al.	
suggested	that	activation	of	Wnt	signals	at	a	low	level	enhances	the	repopulation	capacity	
of	HSPC,	regardless	of	activation	of	another	pathway.	Taken	together,	these	studies	suggest	
a	role	for	Wnt	signaling	in	HSPC	maintenance/expansion	given	it	is	delivered	in	the	right	way	
and/or	with	the	adequate	accessory	signals.
Wnt signaling in ISCs and organoids
The	early	genetic	analyses	of	intestinal	crypt	physiology	revealed	that	the	dominant	force	
behind	the	crypt	proliferation	in	the	intestine	is	canonical	Wnt	signaling.	Inhibition	of	Wnt	
activity	by	deletion	of	Wnt	effector	TCF4	was	reported	to	completely	block	the	development	
of	 intestinal	 crypts	 in	 neonatal	 mice157.	 Expression	 of	 the	 Wnt	 inhibitor	 Dickkopf1158 
in	 adult	 mice	 resulted	 in	 loss	 of	 crypts.	 The	 same	 phenotype	 was	 also	 observed	 upon	
conditional	 deletions	 of	b-catenin159 or TCF4160	 underlying	 the	Wnt-dependence	 of	 adult	
crypt	homeostasis.	Given	 the	 importance	of	Wnt	signaling	 in	crypt	proliferation,	 it	 is	not	
surprising	 that	 aberrant	 activation	 of	 the	Wnt	 pathway	 is	 frequently	 observed	 in	 colon	
cancers.	Comparative	analysis	of	colon	cancer	lines	and	normal	colonic	epithelium	revealed	
that	most	Wnt	regulated	genes	are	expressed	throughout	the	crypt71,	fitting	the	role	of	Wnts	
in	 regulation	of	 stem	and	TA	 cell	 proliferation157,	 as	well	 as	Paneth	 cell	 differentiation161.
Further	investigation	of	a	small	set	of	Wnt	regulated	genes	whose	expression	was	restricted	
to	the	crypt	base72,	led	to	the	discovery	of	Lgr5	as	an	exquisite	ISC	marker12.	
The	essential	role	of	Wnt	signaling	in	intestine	biology	has	also	been	reflected	in vitro	with	the	
establishment	of	small	intestinal	organoids	which	require	addition	of	Wnt	signaling	agonists,	
R-spondins73.	R-spondins	were	later	on	shown	to	be	the	ligands	for	Lgr5	proteins162–164.	By	
binding	to	these	receptors,	R-spondins	stabilize	the	Wnt-Fz-Lrp	receptor	complex,	enhancing	
the	 duration	 and	 strength	 of	Wnt	 activity165.	 This	 also	 suggested	 a	 requirement	 for	Wnt	
producing	cells	for	small	intestinal	organoid	cultures.	In	this	regard,	the	formation	of	self-
organizing	mini-guts	from	single	Lgr5+	stem	cells	in	the	absence	of	a	non-epithelial	niche	
was	both	surprising,	and	suggestive	of	the	presence	of	epithelial	niche	cells.	Adjacent	to	the	
Lgr5+	ISCs	both	in vivo	and	in vitro,	Paneth	cells	were	hypothesized	to	constitute	such	niche	
cells.	Indeed,	the	efficiency	of	organoid	formation	dramatically	increased	for	isolated	stem	
cell/Paneth	cell	doublets	in	comparison	to	single	Lgr5+	stem	cells,	which	very	inefficiently	
survived166.	Microarray	analysis	of	Paneth	cells	revealed	the	expression	of	important	growth	
factors,	such	as	Wnt3,	EGF	and	Notch	 ligands,	 remarkably	similar	 to	 the	mini-gut	culture	
system.	Supporting	the	notion	of	Paneth	cells	as	niche	components,	Wnt3	mutant	Paneth	
cells	 fail	 to	 support	 organoid	 growth,	which	 could	 be	 rescued	 by	 addition	 of	 exogenous	
Wnt167.	
Another	 example	 for	 the	 importance	 of	 proper	 signals	 or	 niche	 components	 for	 in vitro 
culture	of	stem	cells	came	from	the	mouse	colon.	The	normal	mouse	colon	epithelium	which	
also	bears	Lgr5+	stem	cells12,	 lacks	the	Paneth	cells	and	produces	 insufficient	amounts,	 if	
any,	of	secreted	Wnt	ligands	for	colon	crypt	culture168.	In	line	with	this,	the	growth	of	mouse	
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colon	organoids	requires	an	additional	Wnt	source109.	Similar	to	the	mouse	colon	example,	
the	culture	of	organoids	from	human	tissue	samples	was	initially	not	successful.	Screening	
a	 number	 of	 different	 growth	 factors,	 Sato	 and	 colleagues	 discovered	 the	 necessity	 for	
additional	factors	among	which	exogenous	Wnt	takes	the	first	place.	By	addition	of	a	Wnt3a	
conditioned-medium,	it	became	possible	to	culture	human	small	intestine	and	colon	tissues	
long-term109,169.
 
Wnt signaling in liver stem/progenitor cells and organoids
Whereas	the	factors	that	maintain	stem	cells	 in	the	intestine	are	extensively	studied,	the	
niche	 that	 provides	 essential	 cues	 for	 facultative	 liver	 stem/	 progenitor	 cells	 is	 less	well	
defined.	Nonetheless,	the	injury-induced	appearance	of	Lgr5+	LSPCs	in	liver	has	indicated	
that	 Wnt	 signaling	 constitute	 a	 core	 signaling	 pathway	 involved	 in	 stimulation	 of	 a	
regenerative	response11.
Upon	chronic	liver	damage,	myofibroblasts	and	macrophages	have	been	shown	to	surround	
the	 emerging	 progenitor	 cells170.	 The	 secretion	 of	Wnt	 ligands,	 in	 particular	Wnt3a	 and	
Wnt7a,	by	macrophages,	has	been	shown	to	promote	hepatocyte	regeneration	from	LSPCs.	
The	importance	of	Wnts	in	emergence	of	liver	progenitors	has	further	been	highlighted	by	
studies	demonstrating	a	role	of	b-catenin	for	the	oval	cell	response171,172.	While	inhibition	of	
Wnt	signaling	via	conditional	deletion	of	b-catenin	dramatically	decreased	the	number	of	
emerging progenitors171,	a	constitutively	active	form	of	b-catenin	expands	the	pool	of	these	
cells172.	Similar	to	Wnt	proteins,	R-spondin	levels	have	been	shown	to	increase	in	the	livers	
of	CCl4-treated	mice
11,	 as	well	 as	 in	 chronically	damaged	human	 livers173.	 	Moreover,	 the	
establishment	of	liver	organoid	cultures	bearing	the	bipotential	LSPCs	requires	activation	of	
Wnt	signaling	by	Wnt3a	and	R-spondin	both	in	mice	and	humans11,98.	
LIVER ORGANOIDS FOR STEM CELL BASED THERAPIES 
For	 end-stage	 liver	diseases	 as	well	 as	 for	 certain	 liver-based	metabolic	 disorders,	 organ	
transplantation	 forms	 the	 only	 curative	 therapy174.	 However,	 currently	 liver	 organ	
transplantations	cannot	satisfy	the	demands	due	to	the	low	number	of	available	donors174.	
This	prompted	scientists	to	investigate	cell	therapy	as	an	alternative	treatment	for	restoration	
of	deficient	 liver	 functions	 in	patients.	Several	studies	 in	animal	models	and	people	with	
chronic	 liver	 failure	or	 liver	enzyme-defects	have	 shown	 that	hepatocyte	 transplantation	
could	possibly	replace	organ	transplantation175.	Besides	this,	owing	to	liver’s	well	vascularized	
structure	and	capacity	to	secrete	into	the	bloodstream,	liver	cell	therapy	has	been	indicated	
to	be	applicable	for	patients	with	enzyme	deficiencies,	including	coagulation	disorders	and	
metabolic	diseases175.	
For	widespread	applications	of	 liver	 cell	 therapy,	 it	 is	 important	 to	have	high	number	of	
suitable	 liver	 cells.	 However,	 hepatocytes	 have	 proved	 to	 be	 difficult	 to	 culture,	 despite	
their	 remarkable	proliferation	 capacity	 in vivo176.	With	 respect	 to	 the	utility	of	 liver	 cells	
for	 therapeutic	purposes	 including	 transplantations,	 the	establishment	of	 long-term	 liver	
organoid	 cultures	 from	 adult	 human	 liver	 has	 been	 a	major	 step98.	 Owing	 to	 their	 high	
expandability,	genetic	stability	and	bipotentiality,	liver	stem	cells	in	human	organoids	offer	
a	 safe	 source	 of	 liver	 cells	 for	 transplantation	 and	 subsequent	 treatment	 of	 a	 variety	 of	
diseases.	Additionally,	it	is	noteworthy	that	targeted	genetic	manipulation	of	liver	stem	cells	
is	 possible	 and	 important	 for	 gene	 therapy	 approaches.	 Furthermore,	 given	 the	 already	
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proven	suitability	of	liver	as	an	organ	for	gene	therapies	in	treatment	of	metabolic	disorders	
such	as	lysosomal	storages	disorders177,178,	it	is	tempting	to	investigate	a	liver	organoid	based	
gene	therapy	approach	for	treatment	of	such	diseases.	
Lysosomal storage diseases (LSDs): Hurler disease
With	 their	 content	of	more	 than	40	hydrolytic	enzymes,	 lysosomes	constitute	 the	major	
site	 of	 digestion	 in	 a	 cell179.	 Therefore,	mutations	 in	 genes	 that	 encode	 these	 hydrolytic	
enzymes	or	lysosomal	membrane	or	accessory	proteins	lead	to	a	blockage	in	degradation	
of	macromolecular	substrates180.	The	progressive	accumulation	of	undigested	metabolites	
results	 in	 cellular	 and	 tissue	 damage	 with	 subsequent	 multiorgan	 dysfunctions	 and,	
frequently,	 neurodegeneration.	 These	 systemic	 and	 clinically	 heterogeneous	 disorders,	
known	as	lysosomal	storage	diseases	(LSDs),	represent	a	family	of	more	than	50	monogenic,	
heritable	diseases	and	collectively	affect	1	in	5000	new	born	children180.		The	age	at	onset	of	
clinical	symptoms	and	severity	of	LSDs	vary,	depending	on	the	degree	of	residual	functional	
protein,	chemical	properties	of	the	stored	macromolecule,	and	the	cell	types	where	storage	
takes	place181.	
Mucopolysaccharidosis	 type	 I	 (MPS-I),	which	 is	 caused	 by	 an	 inherited	 deficiency	 in	 the	
enzyme	α-L-iduronidase	 (IDUA),	 constitutes	 one	 of	 the	most	 frequent	 LSDs182.	 The	most	
severe	form	of	MPS	I,	known	as	Hurler	syndrome,	occurs	mainly	due	to	a	homozygous	or	
a	 compound	 heterozygous	 nonsense	mutation	 in	 the	 IDUA	 gene183.	 Deficiencies	 in	 IDUA	
enzyme	result	 in	defects	 in	the	degradation	of	 its	substrates,	glycosaminoglycans	(GAGs).	
The	 accumulation	 of	 GAGs	 causes	 a	 variety	 of	 pathological	 processes	 in	 the	 skeletal,	
cardiac,	digestive,	respiratory,	and	central	nervous	systems183.	Hurler	disease	manifestations	
include	 significant	developmental	delay,	 coarse	 facial	 features,	 skeletal	dysplasia,	 cardiac	
insufficiency	and	hepatic	disease	along	with	cognitive	decline	and	start	as	early	as	six	months	
after	birth182.	Without	treatment,	the	life	expectancy	of	Hurler	patients	ranges	between	six	
to	ten	years.	
Treatment modalities for Hurler disease 
The	 current	 and	potential	 therapies	 of	Hurler	 disease,	 and	other	 LSDs,	which	occur	 due	
to	 soluble	 enzyme	 deficiencies,	 are	 based	 on	 normal	 lysosomal	 enzyme	 trafficking	 and	
a	 phenomenon	 referred	 to	 as	 cross-correction.	 Newly	 synthesized	 hydrolytic	 enzyme	
precursors,	 including	 IDUA,	 are	 glycosylated	 in	 the	 ER	 and	 phosphorylated	 in	 the	 Golgi	
where	 they	 are	 recognized	 by	 their	 specific	 glycoprotein	 receptors	 and	 trafficked	 into	
lysosomes184,185.	A	small	percentage	of	enzyme	precursors	escape	from	this	route	and	are	
secreted	 to	 the	extracellular	matrix	where	 they	 can	be	 recovered	 via	 receptor-mediated	
endocytosis	and	targeted	to	 lysosomes	on	neighboring	cells,	at	near	or	distant	sites184,185.	
This	secretion-uptake	or	cross	correction	mechanism	enables	wild	type	enzymes	to	be	taken	
up	and	targeted	to	lysosomes	of	otherwise	enzyme-deficient	cells.	
Exploiting	 the	 cross-correction	 mechanism,	 current	 therapies	 of	 Hurler	 patients	 include	
enzyme	replacement	therapies	(ERT)	and	hematopoietic	stem	cell	(HSC)	transplantations183.	
ERT	involves	repeated	intravenous	administrations	of	a	recombinant	IDUA	enzyme	into	Hurler	
patients,	and	has	been	reported	to	have	clinical	benefits	such	as	decreased	hepatomegaly,	
improved	pulmonary	 function	and	walking	capacity183.	However,	 since	 the	half-life	of	 the	
recombinant	enzyme	is	short,	ERT	requires	regular	and	life-long	treatment	of	the	patient	
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and	is	very	costly186.	Unlike	ERT,	HSC	transplantations	(using	bone	marrow,	peripheral	blood	
or	UCB	as	a	source)	offer	a	widespread	and	long-lasting	source	of	functional	enzyme	to	the	
patients.	Although	HSC	engraftment	has	been	shown	to	lead	to	rapid	reduction	of	GAG	in	
liver,	spinal	fluid	and	urine187,	allogeneic	HSC	transplantation	bears	limitations	and	significant	
risks	associated	with	the	procedure	itself	such	as	finding	a	suitable	donor	and	graft-vs-host	
disease,	early	morbidity	and	mortality.	
Hurler	disease,	along	with	other	LSDs,	is	a	particularly	good	candidate	for	stem	cell	mediated	
gene	therapy	approaches	for	various	reasons184,186.	As	Hurler	disease	is	caused	by	a	single	
gene	 defect,	 the	 correction	 of	 the	 gene	 can	 be	 relatively	 straightforward.	 Besides	 this,	
overexpression	of	 lysosomal	 enzymes	 appears	 to	be	well	 tolerated184,186	 and	even	5-10%	
of	normal	enzyme	levels	might	be	therapeutic.	Moreover,	several	studies	 in	mice	models	
have	suggested	that	HSC	transplantation	could	be	more	successful	when	coupled	to	gene	
therapy	by	which	higher	 levels	of	 the	enzyme	could	be	achieved188–190.	Nevertheless,	 the	
use	of	HSCs	for	ex vivo	gene	therapy	approaches	retains	the	same	hurdles	related	to	HSC	
transplantations.	Moreover,	it	is	not	possible	to	apply	targeted	modifications	in	HSCs	and	to	
eliminate	the	risk	of	insertional	mutagenesis184.	
Given	 the	 fact	 that	 the	 liver	serves	as	a	good	depot	organ	 for	secretion	of	enzymes,	 the	
recently	established	adult	 liver	organoids	can	be	tested	as	a	stem	cell	 source	 for	genetic	
modifications,	as	an	alternative	to	ex vivo	gene	therapy	directed	to	the	HSCs.	Exploitation	
of	 this	 approach	might	 offer	 an	 additional	 therapy	modality	which	 could	 provide	Hurler	
patients	with	a	safe	and	long-lasting	source	of	IDUA	enzyme.		
AIMS OF THE THESIS
Due	to	their	biological	properties	and	medical	value,	stem	cells	are	a	subject	of	increasing	
interest	for	basic	research.	With	regards	to	the	applicability	of	stem	cells	for	therapy	related	
purposes,	the	identification	of	the	molecular	pathways	involved	in	the	regulation	of	stem	
cell	activity	 in vitro	 is	especially	necessary.	Over	the	years,	Wnt	signaling	molecules	have	
been	implicated	in	the	control	of	stem	cells	from	a	variety	of	tissues.	Therefore,	the	studies	
in	chapters	2-5	of	this	thesis	aim	to	assess	the	role	and	use	of	Wnt	signaling	proteins	for	
expansion	of	stem	cells	in vitro	from	multiple	mammalian	tissues	including	intestine,	liver	
and	blood,	for	enhancing	the	applicability	of	adult	stem	cells	in	clinical	purposes.	
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Abstract 
The	Wnt	signaling	pathway	has	been	implicated	to	play	a	role	in	the	regulation	of	mouse	
hematopoietic	 stem	 and	 progenitor	 cell	 (HSPC)	 fate	 decisions	 between	 self-renewal	 and	
differentiation.	 However	 the	 role	 of	 Wnt	 proteins	 in	 ex vivo culture	 of	 HSPC	 remains	
controversial.	Here,	we	show	that	while	Wnt	signals	have	no	apparent	effect	on	the	number	
and	functionality	of	mouse	Lin-,	Sca1-,	and	c-Kit+	 (LSK)	cells	 in	stroma-supported	cultures,	
it	 leads	 to	a	 reduction	 in	 the	number	of	 these	cells	 in	a	 stroma-free,	 serum-free	culture	
system.	The	same	negative	effect	on	the	number	of	LSK,	CD48-,	CD150+,	CD34low	cells	was	
observed	even	when	a	more	stable	Wnt	signal,	provided	 in	 the	 form	of	a	 lipid-stabilized	
Wnt3a	protein	or	by	the	GSK3-β	inhibitor	CHIR99021,	was	used.	The	decrease	in	mouse	LSK	
number	occurred	at	later	stages	of	the	culture.	Overexpression	of	the	anti-apoptotic	BCL2	
protein	did	not	prevent	the	Wnt-induced	loss	of	LSK,	CD48-,	CD150+,	CD34low	cells,	suggesting	
that	 the	 loss	was	not	due	 to	apoptosis.	These	data	suggest	 that	Wnt	signals	 impede	the	
maintenance	of	HSPC	in	stroma-	and	serum-free	cultures.	
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Introduction
Wnt	signals	have	been	shown	to	act	as	self-renewal	factors	for	both	embryonic1	and	adult	
stem	 cells	 in	 a	 diversity	 of	mammalian	 tissues,	 including	 intestines,	 skin	 and	mammary	
gland2.	They	also	provide	critical	cues	for	maintenance	or	expansion	of	stem	cells	in	cultures	
of	a	variety	of	adult	stem	cells	both	from	mouse	and	human3–8.	Several	signal	transduction	
cascades	 may	 be	 induced	 upon	 binding	 of	 Wnt	 ligands	 to	 their	 receptors9,	 the	 best-
characterized	one	being	the	canonical	or	b-catenin	pathway.	In	this	pathway,	b-catenin	is	
phosphorylated	by	glycogen	synthase	kinase-3b	 (GSK-3b)	 to	be	targeted	 for	proteasomal	
degradation.	Upon	binding	 of	 a	Wnt	 protein	 to	 the	 Frizzled	 (Fz)	 family	 of	 receptors	 and	
to	 low-density	 lipoprotein	 receptor-related	 protein	 5	 (LRP5)	 or	 LRP6	 co-receptors,	 the	
phosphorylation	of b-catenin	is	inhibited.	Stabilized b-catenin	translocates	into	the	nucleus	
where	it	interacts	with	TCF/LEF	transcription	factors	to	activate	targeted	gene	expression10.	
Over	 the	past	decades,	a	variety	of	 studies	have	 implicated	a	possible	 role	 for	 canonical	
Wnt	signaling	in	the	control	of	mammalian	hematopoietic	stem	and	progenitor	cell	(HSPC)	
function.	Mice	carrying	a	null	allele	of	Wnt3a11	or	overexpressing	the	Wnt	inhibitor	Dickkopf1 
in	the	bone	marrow	niche12	display	 impaired	hematopoietic	stem	cell	 (HSC)	self-renewal.	
When	stimulated	by	a	constitutively	active	form	of	b-catenin	or	by	purified	Wnt3a	protein,	
Wnt	 signaling	 increased	 self-renewal	 capacity	 of	 apoptosis-resistant,	 transgenic	 HSPC	 ex 
vivo13,14.	However,	mouse	models	with	constitutively	activated	Wnt	 signalling	displayed	a	
multilineage	differentiation	block	and	loss	of	HSCs15,16,	and		later	studies	using	purified	Wnt	
proteins in ex vivo	cultures	of	normal	mouse	HSPC	reported	controversial	outcomes.	In	one	
study,	Wnt5a	was	suggested	to	improve	repopulation	capacity	of	mouse	HSPC	by	inhibiting	
canonical	 Wnt	 pathway	 induced	 by	Wnt3a	 protein17,	 while	 in	 another	 it	 was	 shown	 to	
impede	maintenance	of	HSPC18.	Recently,	we	showed	that	purified	Wnt3a	protein-mediated	
activation	 of	 canonical	Wnt	 signaling	 reduces	 expansion	 of	 human	 umbilical	 cord	 blood	
(UCB)-derived	HSPC	by	 inducing	their	differentiation19.	Several	other	studies	showed	that	
active	b-catenin	 induces	apoptosis	 in	HSPC20,21.	 Taken	 together,	 these	 studies	underscore	
the	controversies	on	the	effect	of	Wnt	activation	on	HSPC	proliferation,	differentiation	and	
apoptosis.	
It	has	been	known	for	some	time	that	Wnt	proteins	have	a	very	short	half	 life	 in	serum-
free	 cell	 culture	 media22,	 losing	 its	 activity	 within	 several	 hours19,22.	 This	 complicates	
the	 interpretation	 of	 the	 results	 obtained	 for	 the	 role	 of	 Wnt	 signals	 on	 ex	 vivo	 HSPC	
proliferation.	Thus,	addition	of	Wnt3a	protein	to	cell	cultures	would	result	in	intermittent	
rather	than	continuous	activation	of	the	pathway,	which	may	be	insufficient	to	inhibit	HSPC	
differentiation.	 In	 this	study,	we	revisited	the	effect	of	Wnt	signals	on	ex vivo	 cultures	of	
mouse	HSPC	and	 investigated	 in	more	depth	the	role	of	apoptosis	and	of	Wnt3a	protein	
stability	on	the	response	of	the	cells	to	Wnt	signals.		
Methods and Materials
Mice
C57BL/6	and	TRE-BCL2	mice	used	 in	 this	 study	were	bred	and	maintained	 in	 the	animal	
facility	 at	 Erasmus	Medical	 Center	 (Erasmus	MC),	 and	handled	 according	 to	 institutional	
guidelines.	All	procedures	were	carried	out	in	compliance	with	the	Standards	for	Care	and	
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Use	of	Laboratory	Animals.		All	mice	were	used	at	12-24	weeks	of	age.		
For	 generation	 of	 TRE-BCL2	 mice,	 a	 human	 BCL2	 cDNA	 (accession	 number	 BC027258)	
was	amplified,	and	a	Kozak	sequence	and	C-terminal	FLAG	tag	added.	The	vector	p2Lox.
GFP23	was	digested	with	XhoI	and	NotI	 to	remove	the	GFP	sequence,	and	the	XhoI/NotI-
digested	BCL2-FLAG	sequence	ligated	into	its	place	to	create	p2Lox.BCL2.	25	µg	of	p2Lox.
BCL2	was	electroporated	into	A2Lox.Cre	ES	cells,	followed	by	induction	of	the	cells	with	1	
µg/ml	doxycycline	overnight	 to	 induce	 recombination,	and	 the	cells	 selected	on	250	μg/
mL	of	G418,	as	previously	described24.	The	cells	were	 then	used	 for	blastocyst	 injections	
into	 C57Bl/6	 blastocysts.	 Chimeras	 were	 mated	 against	 C57Bl/6	 mice	 and	 readily	 gave	
germline	 transmission.	Mice	 containing	 the	 BCL2	 transgene	 and	 the	 reverse	 tetracycline	
transactivator	(rtTA,	expressed	from	the	Rosa26	locus	in	A2Lox.Cre	ES	cells)	were	identified	
by	PCR	using	the	following	primers:	
BCL2	forward:	GGATGCCTTTGTGGAACTGT;	
BCL2	reverse:	GCTCACTTGTCGTCATCGTC;	
rtTA	forward:	GGACGAGCTCCACTTAGACG	;	
rtTA	reverse:	GGCATCGGTAAACATCTGCT.
Isolation of LSK and LSK CD48- cells
For	 LSK	 or	 LSK	 CD48-	 cells	 isolation,	 femurs	 and	 tibias	 from	 mice	 were	 removed,	 BM	
flushed,	and	mononuclear	cells	were	isolated	by	Lymphoprep™	according	to	manufacturer’s	
instructions	 (Stem	Cell	Technologies,	Grenoble,	France).	Lineage-positive	 (Lin+)	 cells	were	
depleted	by	magnetic	cell	sorting	(MACS)	with	the	use	of	a	lineage	cell	depletion	kit	according	
to	manufacturer’s	instructions	(Miltenyi	Biotech,	GmBH,	Bergisch	Gladbach,	Germany).	Lin	
depleted	 cells	were	 further	 stained	with	 a	 Lin-PE	 cocktail	 (anti-CD3e-PE,	 anti-CD45R-PE,	
anti-CD11b-PE,	anti-Gr1-PE,	and	anti-Ter119-PE)	as	well	as	with	anti-c-Kit-APC	and	anti-Sca-
1-PE-Cy7	 (all	 from	BD	 Pharmingen,	 Heidelberg,	 Germany)	where	 indicated.	 Hoechst	 (BD	
Biosciences,	San	Jose,	CA,	USA)	was	added	to	allow	live/dead	cell	discrimination.	Cell	sorting	
for Lin-,	c-Kit+,	Sca-1+	(LSK)	cells	was	performed	using	BD	FACSAriaIII™	(BD	Biosciences,	San	
Jose,	CA,	USA).	
For	 sorting	 LSK	 CD48-	 population,	 cells	 were	 stained	 with	 Lin-PE	 cocktail,	 anti-CD48-PE	
(BD	 Pharmingen,	Heidelberg,	 Germany)	 anti-c-Kit-APC-Cy7	 (eBioscience,	 Vienna,	 Austria)	
and	 anti-Sca-1-PE-Cy7.	 For	 further	 analysis	 of	 the	 starting	 population,	 these	 cells	 were	
also	 stained	with	 CD34-FITC	 (BD	 Pharmingen,	 Heidelberg,	 Germany),	 and/or	 CD150-APC	
(Biolegend,	London,	UK)	where	indicated.	
 
Co-culture of LSK with stromal layer
UG26-1B6	cells	were	maintained	as	previously	described25.	For	co-cultures	with	LSK	cells,	
stromal	cells	were	grown	on	0.1%	gelatin	(Sigma,	St.	Louis,	MO,	USA)	coated	6-well	plates	
(Corning,	Lowell,	MA,	USA).	Once	cells	reached	confluence,	they	were	irradiated	at	20	Gy.	
1500	FACS-sorted	LSK	cells	were	cultured	on	stroma	at	33oC	and	5%	CO2.	The	cells	were	
cultured	in	2	ml	of	long-term	culture	(LTC)	medium	(MyeloCult	M5300,	Stem	Cell	Technologies,	
Grenoble,	France),	which	contains	horse	and	fetal	bovine	serum	with	hydrocortisone	(10−6 
M,	Stem	Cell	Technologies,	Grenoble,	France).	250	ng/ml	purified	Wnt3a	or	2	µM	IWP2	or	
both	were	added	to	LTC	medium,	and	half	the	medium	was	refreshed	every	three	days	for	2	
weeks.	After	2	weeks,	cells	were	harvested	for	FACS	analysis	and	CFU	assays.
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Colony-forming unit (CFU) assay
Fresh	or	culture	progeny	were	plated	at	various	dilutions	in	triplicate	in	methylcellulose	semi-
solid	medium	(MethoCult	GF	m3434,	Stem	Cell	Technologies	Inc.,	Grenoble,	France)	with	
with	100	U/ml	Penicillin	and	100	μg/ml	Streptomycin	(both	Invitrogen,	Life	Technologies,	
Bleiswijk,	The	Netherlands).	All	 cultures	were	 incubated	at	37°C	and	5%	CO2
 for	12	days.	
Hematopoietic	 colony	 types	 (erythroid-burst-forming	 unit	 (BFU-E),	 colony-forming	 unit-
granulocyte	 (CFU-G),	 colony-forming	 unit-macrophage	 (CFU-M),	 colony-forming	 unit-
granulocyte,	 macrophage	 (CFU-GM)	 and	 colony-forming	 unit-granulocyte,	 erythrocyte,	
macrophage,	megakaryocyte	(CFU-GEMM))	were	distinguished	by	morphology	and	counted	
with	an	inverted	microscope.
Stroma-free, serum-free cultures
Sorted	LSK	or	LSK	CD48-	cells	were	cultured	in	StemSpan™	Serum-Free	Expansion	Medium	
(SFEM,	 Stemcell	 Technologies,	 Grenoble,	 France)	 supplemented	 with	 1%	 penicillin/
streptomycin	(Sigma,	St	Louis,	MO,	USA),	10	μg/ml	low	molecular	weight	heparin	(Abbott,	
Wiesbaden,	Germany),	 SCF	 (10	 ng/ml,	 Biovision,	Milpitas,	 CA,	USA)	 and	 TPO	 (20	 ng/ml,	
Cell	 Sciences,	 Canton,	MA,	 USA).	 Cells	 were	 cultured	 in	 a	 volume	 of	 200	 µl	medium	 in	
a	U-bottom	96-well	plate	at	a	 range	of	3000-30.000	cells/ml	at	37	 °C	 in	5%	CO2.	Where	
indicated	 purified	Wnt3a	 (250	 ng/ml,	 if	 not	 indicated	 otherwise),	 liposomal	Wnt3a	 (250	
ng/ml),	Wnt	antagonist	Fz8CRD	(5	µg/ml)	and	CHIR99021	(1uM,	Stemgent	Cambridge,	MA,	
USA)	were	added	to	the	cultures	daily	by	half	medium	refreshment	or	splitting.	
To	induce	BCL2	expression	in	sorted	cells	derived	from	TRE-BCL2	mice,	doxycycline	(1µg/ml,	
Sigma,	St	Louis,	MO,	USA)	was	added	to	cultures	at	the	start	of	the	experiment	as	well	as	
during	the	refreshments	or	splitting.	
FACS analysis of cultures
For	 analysis	 of	 cultures	 after	 the	 indicated	 culture	period,	 cells	were	harvested,	washed	
and	resuspended	in	PBS	containing	10%	FCS.	After	co-cultures,	total	cells	were	counted	in	
trypan	blue	on	a	Neubauer	hemocytometer.	For	stroma-free,	serum	free	cultures,	absolute	
numbers	of	viable	HSPC	populations	(LSK,	LSK	CD48-,	and	LSK,	CD48-,	CD150+,	CD34low	)	cells	
were	determined	by	a	 single	platform	flow	cytometric	 analysis,	using	 the	 same	panel	of	
monoclonal	 antibodies	 that	was	 used	 for	 sorting	 and	 a	 calibrated	 number	 of	 Cyto-Cal™	
Control	Count	counting	microspheres	(Thermo	Scientific,	Waltham,	MA,	USA).
For	apoptosis	analysis,	cells	were	simultaneously	stained	with	anti-Annexin	V-APC	in	binding	
buffer	 (BD	 Biosciences,	 San	 Jose,	 CA,	 USA)	 in	 PBS	 containing	 10%	 FCS.	 Flow	 cytometric	
analysis	was	performed	using	a	BD	FACSFortessa™	(BD	Biosciences,	San	Jose,	CA,	USA)	and	
data	was	analyzed	using	FlowJo	software	(Tree	Star	Inc,	Ashland,	OR,	USA).	
Purification of Wnt3a protein and preparation of liposomal Wnt3a
Mouse	Wnt3a	was	purified	 from	Wnt3a-conditioned	medium,	 collected	 from Drosophila 
S2	 cells,	 using	 Blue	 Sepharose	 affinity	 and	 gel	 filtration	 chromatography	 as	 described	
previously14.	
Liposomes	 containing	 DMPC	 (1,2-dimyristoyl-sn-glycero-3-phosphocholine),	 DMPG	
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(1,2-dimyristoyl-sn-glycero-3-phospho-rac-glycerol)	 (both	 Lipoid	 AG,	 Ludwigshafen,	
Germany)	and	Cholesterol	(Sigma,	St	Louis,	MO,	USA)	at	a	10:1:10	molar	ratio	were	prepared	
as	described	previously19.	Briefly,	purified	Wnt3a	was	mixed	with	liposomes	and	incubated	
for	one	hour	by	 rotating	at	4°C.	 	CHAPS	was	removed	by	dialysis	with	a	membrane	with	
molecular	weight	cut-off	of	10	kDa	(Thermo	Scientific,	Waltham,	MA,	USA)	in	HBS	at	4°C.	
The	Wnt	 liposomes	were	stored	at	4°C.	Activity	of	purified	Wnt3a	protein	and	 liposomal	
Wnt3a	were	determined	in	a	luciferase	reporter	assay	as	described	previously19.	
Luciferase reporter assay
Mouse	 LSL	 cells,	 which	 express	 luciferase	 in	 response	 to	 TCF	 promoter	 binding26,	 were	
routinely	 cultured	at	 37oC	and	5%	CO2	 in	 culture	medium	containing	DMEM	 (Invitrogen,	
Life	 Technologies,	 Bleiswijk,	 The	 Netherlands),	 10%	 FCS	 (HyClone,	 Thermo	 Scientific,	
Waltham,	MA,	USA),	100	U/ml	Penicillin	and	100	µg/ml	Streptomycin	(both	from	Invitrogen,	
Life	Technologies,	Bleiswijk,	The	Netherlands).	Prior	to	the	activity	assays,	25,000	LSL	cells	
were	plated	in	each	well	of	a	96-well	plate	and	grown	for	24	hours.	Wnt3a	reagents	were	
separately	incubated	in	culture	medium	with	or	without	serum	for	various	periods	of	time	
at 37oC	in	96-well	plates.	After	the	incubation	intervals,	media	with	Wnt3a	reagents	were	
added	to	LSL	cells.	Upon	an	additional	overnight	 incubation	with	 the	 indicated	reagents,	
relative	luciferase	units	were	measured	with	a	Glomax	multiplate	reader.
Western blotting
Lineage-negative	(Lin-)	cells	were	isolated	by	FACS	sorting	as	described	above.	100,000	cells	
were	seeded	for	each	condition	and	were	cultured	for	24h	with	and	without	doxycycline	
(1µg/ml,	 Sigma,	 St	 Louis,	 MO,	 USA)	 treatment.	 Whole-cell	 extracts	 were	 then	 isolated	
from	total	cells.	Cells	were	washed	twice	in	PBS	and	lysed	in	RIPA	buffer	(Thermo	Scientific,	
Waltham,	MA,	USA)	including	protease	and	phosphatase	inhibitors.	Protein	concentrations	
were	measured	by	BCA	protein	assay	kit	(Thermo	Scientific,	Waltham,	MA,	USA)	and	equal	
amounts	of	protein	were	subjected	to	SDS-PAGE,	followed	by	western	blot	analysis	using	
anti-Flag	antibody	(1:1500,	Sigma,	St	Louis,	MO,	USA).	
Statistical analysis
Data	are	presented	as	mean	±	SD.	Statistical	significance	was	detemined	by	a	Student’s	two-
tail	t-test	(unpaired	and	ratio-paired),	performed	using	GraphPad	Prism	software	(version	
6.0;	GraphPad),	and	p<0.05	was	defined	as	statistically	significant.
Results
Effect of exogenous and endogenous Wnt signals in stroma-supported LSK cultures
Previously,	 a	murine	urogenital-ridge	derived	 stromal	 cell	 line,	UG26-1B6,	was	 shown	 to	
induce	proliferation	and	differentiation	of	mouse	progenitor	cells	and	support	maintenance	
of	mouse	HSC	25,27.	Wnt5a,	which	is	expressed	by	this	stromal	layer,	has	been	suggested	to	be	
one	of	the	factors	involved	in	this	maintenance27.	To	assess	whether	exogenous	Wnt3a	protein	
enhances	UG26-1B6	stroma-mediated	effects	on	HSPC,	we	co-cultured	adult	mouse	bone	
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marrow	Lin-,	c-Kit+,	Sca-1+	(LSK)	cells,	which	are	enriched	for	HSPC28,	on	confluent,	irradiated	
UG26-1B6	stromal	cell	 layers	 in	the	presence	of	purified	Wnt3a	protein.	We	observed	no	
change	in	total	cell	numbers	in	response	to	the	Wnt3a	treatment	(Figure	1A,	p=0.56).	FACS	
analysis	 of	 2-week	 progeny	 demonstrated	 that	 the	majority	 of	 cells	were	 differentiated,	
regardless	of	the	presence	of	exogenous	Wnt3a	(Figure	1B).	Although	Lin-	cells	did	expand	
in	our	co-culture	system	regardless	of	the	absence	or	presence	of	exogenous	purified	Wnt3a	
(Figure	1C,	p=0.51),	only	a	small	percentage	of	cells	retained	the	c-Kit	and	Sca-1	markers,	
constituting	the	HSC	enriched	LSK	population	(Figure	1D).	As	a	consequence,	the	number	
of	LSK	cells	cultured	with	purified	Wnt3a	also	remained	similar	to	control	condition		(Figure	
1E,	p=0.40).	
To	 test	whether	we	achieved	 stable	Wnt	activity	 in	our	 co-culture	 system,	we	 incubated	
purified	Wnt3a	protein	for	various	periods	of	time	in	the	co-culture	medium	(LTC	medium	
containing	serum)	at	37°C	and	assayed	the	remaining	activity	using	the	LSL	reporter	assay26.	
LSL	cells	contain	a	Wnt	responsive	 luciferase	reporter,	allowing	a	quantitative	readout	of	
Wnt	activity.	This	showed	that	purified	Wnt3a	protein	 retained	 its	activity	 for	over	 three	
days	in	LTC	medium	(Figure	1F).	This	suggests	that	the	lack	of	effect	of	Wnt3a	protein	was	
not	due	to	absence	of	activity.	
To	address	whether	endogenous	Wnt	proteins,	produced	by	the	stromal	cells,	played	a	role	
in	the	UG26-1B6	stroma-mediated	effects	on	LSK	cells,	we	inhibited	their	production	using	
the	small	molecule	 inhibitor	 IWP229.	Addition	of	 IWP2	to	co-cultures	of	 irradiated	UG26-
1B6	cells	and	LSK	cells	had	 little	effect	on	expansion	of	total	cells	 (Figure	1A,	p=0.23),	or	
on	the	frequency	(Figure	1B)	and	expansion	of	Lin-	cells	(Figure	1C,	p=0.96).	Furthermore,	
inhibition	of	endogenous	Wnt	proteins	did	not	significantly	change	the	frequency	of	c-Kit+,	
Sca-1+	cells	(Figure	1D)	or	the	number	of	LSK	cells	(Figure	1E,	p=0.92).	
To	 further	 evaluate	 the	 impact	 of	Wnt	 signals	 on	 the	proliferation	and	differentiation	of	
progenitors	in	our	co-cultures,	we	performed	CFU	assays.	The	total	number	of	CFUs	slightly	
increased	compared	to	input	in	all	conditions	(Figure	1G).	However,	we	found	no	significant	
differences	in	the	frequencies	of	BFU-E,	CFU-G,	CFU-M,	CFU-GM,	or	CFU-GEMM	regardless	
of	addition	of	Wnt3a	protein	or	inhibition	of	Wnt	production	(Figure	1G).	Collectively,	these	
results	 suggest	 that	neither	exogenous	Wnt3a	activity	nor	 inhibition	of	endogenous	Wnt	
proteins	plays	a	role	in	maintenance	of	LSK	cells	in	co-culture	with	UG26-1B6	stromal	cells.	
Wnt/beta-catenin signals reduce the number of mouse LSK cells in stroma- and serum-
free cultures
Since the	complex	nature	of	stroma	–	LSK	co-culture	systems	might	hamper	the	evaluation	of	
the	role	of	Wnt3a,	we	assessed	its	effect	in	stroma-	and	serum-free	culture	of	mouse	HSPC.	
For	this,	FACS-sorted	LSK	cells	were	cultured	for	10	days	in	serum-free	medium	containing	
stem	 cell	 factor	 (SCF)	 and	 thrombopoietin	 (TPO).	 Addition	 of	 Wnt3a	 protein	 did	 not	
significantly	affect	the	expansion	of	total	nucleated	cells	in	this	culture	system	(Figure	2A).	
However,	treatment	with	purified	Wnt3a	protein	resulted	in	a	2-fold	decrease	in	the	number	
of Lin-	cells	relative	to	control	condition	(Figure	2B,	p<0.01).	Moreover,	while	approximately	
half	of	the	LSK	cells	were	maintained	in	control	conditions,	treatment	with	Wnt3a	led	to	a	
6-fold	decrease	in	the	number	of	LSK	cells	(Figure	2C	and	2D,	p=0.01).	These	effects	were	
reversed	upon	simultaneous	addition	of	Fz8CRD,	a	soluble	domain	of	the	Wnt	receptor	that	
sequesters	Wnt	proteins30,	indicating	they	were	specific	for	the	Wnt3a	protein	(Figure	2A-D).	
A	similar	effect	on	the	number	of	total	nucleated	cells,	Lin-	cells	and	LSK	cells	was	observed	
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Figure 1. Wnt signals do not promote expansion of LSK cells in UG26-1B6 stromal cell co-culture
1500	LSK	cells	were	co-cultured	with	UG26-1B6	that	had	been	irradiated	at	20	Gy.	Aft	er	2	weeks	of	culture,	
(A)	total	cell	number	was	enumerated	to	determine	cell	expansion.	(B)	Representati	ve	plots	of	FACS	analysis	
of	the	progeny	for	lineage	markers.	Percentages	of	Lin-	cells	among	viable	cells	(gated	region)	are	shown.	(C)	
Quanti	fi	cati	on	of	Lin-	cells	fold	expansion	aft	er	culture	in	the	presence	of	indicated	molecules.	(D)	Lin-	cells	
were	further	analyzed	for	c-kit	and	Sca-1	markers.	Percentages	of	c-kit+,		Sca-1+	cells	among	Lin-	populati	on	
(gated	region)	are	shown.	(E)	Fold	change	of	LSK	relati	ve	to	 input	 is	calculated.	(F)	Quanti	fi	cati	on	of	Wnt	
acti	vity	retained	aft	er	incubati	on	for	0,	8,	24,	48	and	72	hours	at	37°C	in	co-culture	medium	(LTC	medium).	
Acti	vity	plot	displays	average	increase	of	luminescence	relati	ve	to	background.	Purifi	ed	Wnt3a	was	added	
at	250	ng/ml	(Error	bars	indicate	S.E.M.,	n=3).	(G)	Progeny	of	co-cultures	were	plated	in	CFU	assay.	Plott	ed	
are	absolute	numbers	of	BFU-E,	CFU-G,	CFU-M,	CFU-GM	and	CFU-GEMM.	(Error	bars	indicate	S.D.)	(n=2).	
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when	the	canonical	Wnt	pathway	was	acti	vated	using	the	GSK3	inhibitor	CHIR99021	(Figure	
2A-D),	 indicati	ng	that	the	eff	ect	was	specifi	c	for	the	b-catenin	pathway.	The	frequency	of	
Lin+	cells	was	not	signifi	cantly	aff	ected	by	Wnt3a	protein	(Figure	2E,	p=0.09).	However,	we	
observed	a	higher	frequency	of	Lin+	cells	when	cells	were	induced	with	CHIR99021,	which	
might	be	due	to	a	stronger	or	more	prolonged	acti	vati	on	of	the	Wnt	pathway,	or	by	eff	ects	
other	than	Wnt/b-catenin	inducti	on	(Figure	2E,	p<0.05).	These	data	collecti	vely	show	that	
the	additi	on	of	Wnt3a	protein	decreased	the	number	of	LSK	cells	 in	serum-free,	stroma-
free	cultures	and	that	 this	 is	a	consequence	of	 the	binding	of	Wnt3a	to	 its	 receptor	and	
subsequent	acti	vati	on	of	the	canonical	Wnt	pathway.
Recent	data	 indicates	 that	stability	of	purifi	ed	Wnt	proteins	depends	on	 the	presence	of	
detergent	or	 serum22,	 implying	 that	 its	 acti	vity	may	be	 rapidly	 lost	 in	 serum-free	 culture	
systems.	 This	may	 explain	 its	 inability	 to	 support	HSPC	 in	 serum-free	 culture.	 Luciferase	
reporter	assays	demonstrated	that	purifi	ed	Wnt3a	protein,	while	retaining	 its	acti	vity	 for	
several	days	in	medium	containing	serum,	loses	its	acti	vity	within	a	few	hours	in	serum-free	
medium	(Figure	3A).	Even	daily	additi	on	of	purifi	ed	Wnt3a	 to	serum-free	cultures	would	
therefore	result	in	brief	pulses	of	Wnt3a	acti	vity	instead	of	a	sustained	Wnt	signal,	which	
may	be	insuffi		cient	to	support	HSPC.	
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 Figure 2. Purifi ed Wnt3a protein reduces the 
number of LSK cells in stroma-free, serum-free 
cultures
FACS-sorted	 LSK	 cells	 were	 cultured	 in	 serum-
free	 medium	 containing	 SCF	 and	 TPO,	 with	
treatment	 of	 purifi	ed	 Wnt3a	 (1	 µg/ml),	
CHIR99021	 or	 Wnt-antagonist	 Fz8CRD.	 Aft	er	
10	days,	the	cells	were	harvested	and	analysed	
by	 FACS.	 (A-B)	 Fold	 change	 of	 total	 the	 total	
nucleated	 cells	 (A)	 and	 Lin-	 cells	 (B)	 relati	ve	 to	
input.	 (C)	 Analysis	 of	 Lin-	 populati	on	 for	 c-kit	
and	 Sca-1	markers.	 Percentages	 of	 c-kit+Sca-1+ 
cells	 among	 Lin-	 populati	on	 (gated	 region)	 are	
shown.	(D)	Fold	change	of	LSK	relati	ve	to	input	
is	plott	ed.	(E)	The	frequency	of	Lin+	cells	within	
total	 cells.	 (Error	 bars	 indicate	 S.D.)	 (n=2).	
Stati	sti	cal	signifi	cance	was	determined	by	a	two-
tail	t-test.	(*p<0.05).
Chapter 3
74
We	 recently	 showed	 that	 association	 with	 lipid	 vesicles	 prolongs	 the	 stability	 of	 Wnt	
ligands19,31,32,	 allowing	 us	 to	 achieve	 a	 more	 sustained	Wnt	 signal	 in	 serum-free	 culture	
(Figure	3B).	We	therefore	investigated	whether	lipid-stabilised	Wnt3a	protein	would	be	able	
to	support	LSK,	CD48-	cells	in	stroma-free,	serum-free	conditions.	After	7	days	of	culture,	we	
observed	no	significant	differences	between	regular	and	liposomal	Wnt3a	for	total	nucleated	
cell	 expansion	 (Figure	 3C),	 and	 the	 frequency	 of	 Lin+	 CD48+ cells	 remained	 similar	 in	 all	
conditions	(Figure	3D).	Moreover,	like	purified	Wnt3a,	liposomal	Wnt3a	induced	a	decrease	
in	the	more	immature	LSK,	CD48-,	CD150+,	CD34low	population,	which	is	highly	enriched	for	
HSCs	(Figure	3E,	p<0.05	and	p<0.01	for	purified	and	liposomal	Wnt3a,	respectively).	Thus,	
the	failure	of	purified	Wnt3a	to	support	mouse	HSPC	in	our	serum-free	culture	system	was	
not	due	to	insufficient	stability	of	the	Wnt	ligand	since	it	also	occurred	in	the	presence	of	
lipid-stabilized	Wnt3a	protein.
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Figure 3. Stable Wnt activity by liposomal Wnt3a reduces the number of primitive LSK cells in vitro 
(A)	Quantification	of	Wnt	 activity	 retained	 after	 incubation	 for	 0,	 8,	 24,	 48	 and	72	hours	 at	 37°C	 in	 cell	
culture	media	with	or	without	serum.	Activity	plot	displays	average	 increase	of	 luminescence	relative	to	
background.	Purified	Wnt3a	was	added	at	250	ng/ml	(Error	bars	 indicate	S.E.M.,	n=6).	 (B)	Quantification	
of	Wnt3a	 activity	 retained	 after	 incubation	of	 the	 indicated	 reagents	 in	 serum-free	 cell	 culture	medium	
at	37°C	for	0,8	and	24	hours.	Purified	and	liposomal	Wnt3a	were	added	at	250	ng/ml.	(Error	bars	indicate	
S.E.M.,	n=10).	(C-E)	FACS	sorted	LSK	CD48-	cells,	were	cultured	with	purified	Wnt3a,	liposomal	Wnt3a,	and	
Fz8CRD.	Total	cells	were	analysed	by	FACS	after	7	days	of	culture.	The	graphs	display	the	total	nucleated	cell	
expansion	relative	to	input	(C),	the	frequency	of	Lin+	cells	within	total	cells	(D),	and	the	fold	change	of	LSK	
CD48-CD150+CD34low	cells	compared	to	input	(E).	(Error	bars	indicate	S.D.)	(n=2).	Statistical	significance	was	
determined	by	a	two-tail	t-test	(*:p<0.05;	**:p<0.01).
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Wnt3a signaling does not induce apoptosis in short-term cultures 
Previous	studies	suggest	that	Wnt	signals	may	induce	apoptosis	in	HSPC,	and	that	combined	
acti	vati	on	 of	Wnt	 signaling	 and	 inhibiti	on	 of	 apoptosis	may	 be	 required	 to	 support	 HSC	
expansion17,20.	To	assess	whether	Wnt	acti	vati	on	leads	to	early	apoptosis,	we	cultured	FACS-
sorted	LSK	CD48- cells	in	our	stroma-free,	serum-free	system.	Aft	er	4	days	of	culture,	we	did	
not	observe	any	diff	erence	in	total	cell	numbers	or	in	the	frequency	of	Hoechst-,	Annexin	V+ 
early	apoptoti	c	cells	(Figure	4A-C).	In	contrast	to	longer-term	cultures,	as	described	above,	
there	was	 no	diff	erence	 in	 the	numbers	 of	 LSK	CD48-	 and	 LSK	CD48-	 CD34low	 cells	when	
cultured	with	purifi	ed	Wnt3a	in	comparison	to	control	(Figure	4D-E).	Moreover,	we	observed	
no	increase	in	levels	of	early	apoptoti	c	LSK	cells	in	the	presence	of	Wnt3a	(Figure	4F-G).	This	
suggests	that	Wnt-mediated	reducti	on	in	the	number	of	LSK	occurs	at	later	stages	of	culture	
and	cannot	be	explained	by	an	increase	in	early	apoptoti	c	events.		
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 Figure 4. Wnt3a protein does not induce apoptosis of LSK cells in short-term stroma-free, serum-free 
cultures
FACS-sorted	LSK	cells	were	cultured	in	our	serum-free	conditi	ons	with	the	additi	on	of	purifi	ed	Wnt3a.	Cells	
were	analysed	by	fl	ow	cytometry	aft	er	4	days	of	culture.	(A-B)	The	graphs	display	fold	change	of	total	nucleated	
cells	(A)	and	the	frequency	of	Annexin-V+Hoechst-	early	apoptoti	c	cells	among	the	same	populati	on	(B).	(C)	
Representati	ve	FACS	plots	for	Annexin-V	analysis	within	Hoechst-	viable	total	cells.	Percentages	of	Annexin-
V-Hoechst-	and	Annexin-V+Hoechst-	cells	are	shown.	Shown	are	graphs	for	fold	change	of	LSK	CD48-	(D),	and	
LSK	CD48-CD34low	cells	(E).	(F)	The	graph	displays	the	frequency	of	Annexin-V+Hoechst-	early	apoptoti	c	LSK	
CD48-CD34low	cells	among	the	same	populati	on.	(G)	Representati	ve	FACS	plots	for	Annexin-V	analysis	within	
LSK	CD48-CD34low	cells.	Percentages	of	Annexin-V+Hoechst-	cells	are	shown.	(Error	bars	indicate	S.D.)	(n=2).
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Inhibition of apoptosis does not rescue Wnt3a-induced loss of LSK cells 
To	 further	 investigate	 a	 possible	 role	 for	 apoptosis	 in	Wnt-induced	 loss	 of	 HSPC	 in	 our	
cultures,	we	developed	a	novel	transgenic	anti-apoptotic	mouse	model.	Using	Cre-mediated	
transgenesis	in	embryonic	stem	cells,	we	placed	an	anti-apoptotic	FLAG-tagged	human	BCL2	
transgene	under	control	of	a	doxycycline-responsive	promoter	targeted	in	the	HPRT	locus.	
The	 reverse	 tetracycline	 transactivator	was	constitutively	expressed	 from	the	Rosa	 locus.	
Thus,	the	cells	could	be	induced	to	express	BCL2	upon	treatment	with	doxycycline,	inhibiting	
the	 induction	of	apoptosis.	Transgenic	mice	were	generated	using	blastocyst	 injection	of	
the	 cells,	which	 allowed	us	 to	obtain	 LSK	 cells	 carrying	 the	 transgenes.	We	verified	 that	
doxycycline	indeed	induced	BCL2	in	primitive	hematopoietic	Lin- progenitors	by	Western	blot	
analysis	(Figure	5A).	This	system	enabled	us	to	investigate	the	effect	of	BCL2	overexpression	
in	otherwise	fully	comparable	cell	populations.	
Doxycycline	treatment	substantially	enhanced	total	nucleated	cell	expansion	upon	culture	of	
LSK	CD48-	cells	for	10	days	(Figure	5B,	p<0.05),	confirming	the	effectivity	of	BCL2	induction.	
Moreover,	a	strong	increase	in	LSK	CD48-	cells	and	of	the	more	immature	LSK	CD48-	CD150+ 
CD34low	 population	was	 observed	upon	doxyxycline	 induction	 (Figure	 5C	 and	 5D,	 p<0.05	
and	p<0.01,	respectively),	indicating	that	apoptosis	was	indeed	an	important	factor	limiting	
the	expansion	of	these	cells	in	culture.	However,	with	combined	doxycycline	and	liposomal	
Wnt3a	treatment,	the	total	nucleated	cell	expansion	was	reduced	compared	to	doxycycline	
only	condition	 (Figure	5B,	p<0.05).	Likewise,	 the	expansion	of	LSK	CD48-	 cells	and	of	LSK	
CD48-	 CD150+	 CD34low	 cells	 in	 response	 to	 BCL2	 induction	 was	 repressed	 by	 liposomal	
Wnt3a	treatment	(Figure	5C,	p<0.05,	and	Figure	5D,	p<0.01	and	p<0.001).	Combined,	our	
data	showed	no	evidence	that	Wnt3a	induced	early	apoptosis	in	HSPC,	or	that	inhibition	of	
apoptosis	by	BCL2	supported	HSPC	expansion	in	response	to	Wnt3a	protein.	
Discussion
In	this	study,	we	investigated	the	role	of	Wnt3a-induced	signaling	in	regulation	of	mouse	HSPC	
ex vivo.	While	purified	Wnt3a	protein	showed	little	impact	on	the	number	and	functionality	
of	LSK	cells	when	cultured	in	a	stromal	context,	it	induced	a	decrease	in	the	number	of	HSPC	
in	a	stroma-free,	serum-free	culture	system.	This	effect	was	reversed	by	a	competitive	Wnt	
antagonist,	indicating	that	it	was	due	to	binding	of	Wnt3a	to	its	receptor.	We	explored	the	
hypothesis	that	the	failure	of	Wnt3a	protein	to	support	HSPC	in	a	serum-free	context	was	
due	 to	 its	very	short	half-life	 in	 these	conditions,	and	developed	a	 lipid-stabilized	Wnt3a	
formulation	able	to	provide	a	sustained	Wnt	signal.	However,	lipid-stabilized	Wnt3a	protein	
induced	 a	 similar	 reduction	 in	 the	 number	 of	 HSPC.	 In	 addition,	 GSK3-b	 inhibition	 also	
resulted	in	a	similar	reduction	of	HSPC	number,	strongly	suggesting	that	the	effect	was	due	
to	activation	of	the	canonical	Wnt	pathway.	Finally,	we	investigated	whether	the	induction	
of	apoptosis	by	Wnt	signals	caused	the	loss	of	HSPC.	However,	we	found	no	evidence	that	
Wnt	signals	induced	apoptosis.	Moreover,	we	developed	a	transgenic	mouse	model	in	which	
apoptosis	can	be	inhibited	by	the	inducible	expression	of	BCL2.	While	on	its	own	this	greatly	
supported	the	expansion	of	HSPC,	it	did	not	prevent	the	loss	of	HSPC	in	response	to	Wnt	
signals.	Combined,	these	data	indicate	that	Wnt	signals	do	not	support	expansion	of	mouse	
HSPC	 in	 stroma-free	 serum-free	 culture	but	 instead	 induce	 loss	 of	 these	 cells.	 Since	 the	
loss	was	not	mediated	by	apoptosis,	the	most	likely	explanation	would	be	that	Wnt	signals	
induce	differentiation	of	the	cells.	
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A	 number	 of	 studies	 indicate	 an	 important	 role	 for	 Wnt	 ligands	 in	 the	 maintenance/
expansion	 of	 HSC	 in vitro13,14,27.	 For	 instance,	 addition	 of	 anti-Wnt5a	 antibodies	 to	
inhibited	 the	 repopulation	 capacity	 of	HSCs,	 suggesting	 that	Wnt5a	 protein	 is	 necessary	
for	maintenance	of	HSPC	 in	 these	co-cultures27.	However,	we	observed	that	 inhibition	of	
endogenous	Wnt	protein	production	by	IWP2	in	UG26-1B6	co-cultures	affected	neither	the	
number	of	LSK	cells	nor	the	number	of	CFU.	This	discrepancy	might	be	due	to	the	use	of	
antibodies	by	Buckley	et al.,	which	might	induce	other	effects,	such	as	provoking	an	immune	
response,	acting	in	the	bone	marrow	niche,	or	interfering	with	homing	capacity.	Moreover,	
addition	of	exogenous	Wnt5a	to	the	UG26-1B6	co-cultures	did	not	impact	the	repopulation	
capacity	of	HSCs27.	Similarly,	we	did	not	observe	an	effect	of	Wnt3a	proteins	on	the	number	
of	HSPC	or	CFU,	suggesting	that	Wnt	ligands	do	not	impact	on	the	expansion	of	HSPC	in	this	
co-culture	system.	Nevertheless,	a	co-culture	system	containing	serum	and	growth	factor-
producing	stromal	cells,	which	is	highly	differentiation	inducing	(see	Figure	1B),	might	mask	
differentiation-inducing	effects	of	Wnt	signals	on	HSPCs.
Willert	et al.	and	Reya	et al.	report	that	Wnt	signaling	activation	by	either	purified	Wnt3a	
protein	or	 a	 constitutively	 active	 form	of	β-catenin	 in vitro	 induced	expansion	of	mouse	
BCL2-overexpressing	HSPC13,14.	 In	contrast,	Nemeth	et al.	observed	that	activation	of	Wnt	
signaling	by	purified	Wnt3a	proteins	induced	a	decrease	in	the	number	of	wild-type	mouse	
LSKI	(Lineage	negative,	Sca-1+,	c-kit+,	IL-7Rα-)	cells	during	culture	in	serum-free	medium17.	
However,	this	study	did	not	account	for	the	rapid	loss	of	Wnt	protein	activity	that	occurs	in	
the	absence	of	 serum22.	We	show	here	 that	 lipid-stabilized	Wnt3a	protein,	which	 retains	
activity	for	more	than	24	hrs	 in	the	absence	of	serum,	also	 induced	 loss	of	mouse	HSPC.	
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Figure 5. The negative effect of Wnt 
signals on LSK cell number is not 
reversed by BCL2 overexpression
(A)	Western	blotting	for	FLAG	protein	
in Lin-	cells	cultured	for	one	day	with	
doxycyline	 treatment.	 (B-D)	 LSK	
CD48-	cells	from	TRE-BCL2	mice	were	
cultured	with	and	without	 liposomal	
Wnt3a	 and	 doxycyline	 treatment	
for	 10	 days.	 The	 graphs	 display	 fold	
change	 of	 the	 total	 nucleated	 cells	
(B),	 LSK	 CD48-	 (C)	 and	 LSK	 CD48-
CD150+CD34low	 cells	 (D)	 normalized	
to	 control.	 (Error	 bars	 indicate	 S.D.)	
(n=3).	 Statistical	 significance	 was	
determined	 by	 a	 two-tail	 t-test.	
(*p<0.05,	**	p<0.01	and	0.001).
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Moreover,	we	previously	showed	that	the	number	of	human	HSPC	was	also	reduced	upon	
induction	of	Wnt	signaling	via	purified	or	lipid-vesicle	stabilized	Wnt3a	proteins19.	Several	in 
vivo	studies	indicated	increased	apoptosis	of	HSPC	by	activated	Wnt	signaling,	suggesting	
the	need	for	additional	survival	signals20,21.	This	could	explain	the	observations	of	Reya	et al. 
and	Willert	et al.	as	they	used	HSPC	carrying	a	constitutively	expressed	BCL2	transgene13,14.	
In	our	stroma-	and	serum-free	culture	system	however,	the	level	of	apoptotic	cells	did	not	
respond	to	Wnt	agonists.	Moreover,	induction	of	the	BCL2	anti-apoptotic	protein	could	not	
rescue	 the	negative	 impact	of	Wnt	 signals	on	HSPC.	Although	 the	different	outcomes	of	
our	studies	and	the	ones	indicating	increased	numbers	of	HSPC	upon	Wnt3a	treatment13,14 
might	 still	 be	attributed	 to	 the	differences	 in	 the	 culture	 systems,	 the	 latter	 studies	 lack	
direct	 comparisons	 to	 control	 conditions:	while	HSCs	 cultured	with	Wnt3a	 protein	were	
shown	to	repopulate	recipient	mice,	the	repopulation	efficiency	in	the	absence	of	Wnt3a	
protein	was	not	reported.	
A	 tripartite	 balance	 of	 proliferation,	 apoptosis	 and	 differentiation	 is	 of	 vital	 importance	
to	maintain	functional	HSPC	in vivo.	Skewing	the	balance	towards	proliferation	to	achieve	
ex vivo	expansion	of	functional	HSPC,	therefore,	requires	inhibition	of	both	apoptosis	and	
differentiation.	Since	our	data	indicates	that	Wnt3a	has	no	apparent	effect	on	the	total	cell	
proliferation	and	that	loss	of	HSPC	is	not	mediated	by	apoptosis,	the	most	likely	explanation	
would	be	that	Wnt	signals	induce	differentiation	of	the	HSPC.	Indeed,	we	observed	a	small	
increase	in	the	number	of	differentiated	cells	in	the	presence	of	Wnt	signaling	agonists	(Figure	
2E).	In	line	with	this,	we	previously	observed	that	Wnt3a	protein	promoted	differentiation	of	
human	HSPC	without	affecting	their	proliferation	or	survival19.		
Investigating	 the	 role	 of	Wnt	 signals	 on	 the	 control	 of	HSCs	 in vivo,	 Luis	 and	 colleagues	
considered	a	possible	role	of	the	dosage	of	canonical	Wnt	signaling33,	showing	that,	while	low	
level	Wnt	activation	results	in	enhanced	HSC	function,	high	levels	of	Wnt	activation	result	in	
impaired	repopulation	capacity.	Moreover,	two	other	studies	report	that	in vivo	constitutive	
activation	of	Wnt	signaling	blocks	differentiation	of	HSPC	and	causes	loss	of	repopulation	
capacity15,16.	In	our	setting,	however,	with	the	Wnt3a	concentrations	we	used,	we	did	not	
observe	a	block	in	differentiation	of	HSPC,	which	would	have	led	to	increased	numbers	of	
HSPC.	Therefore,	it	is	unlikely	that	the	negative	effect	on	the	number	of	HSPC	was	due	to	too	
high	levels	of	Wnt	activation	in	our	in vitro	culture	system.	Regarding	enhanced	repopulation	
capacity	 of	 HSCs	 in	 APC	mutant	mice	with	 a	 low	 level	 of	Wnt	 signaling	 activation33,	 the	
observed	effect	might	be	due	to	enhanced	motility	or	homing	capacity	of	APC	mutant	HSCs	
rather	than	a	result	of	their	proliferation,	which	was	indeed	not	demonstrated.	
Collectively,	 this	 study	 shows	 that	Wnt	 signaling	 induced	 by	Wnt3a	 protein	 reduces	 the	
expansion	of	mouse	LSK	cells	 in	 serum-free	expansion	 cultures	by	apparently	promoting	
their	differentiation	without	affecting	their	survival.	Future	studies	may	address	whether	
additional	differentiation-blocking	signals	may	promote	HSC	expansion.
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Abstract
Ex vivo	expansion	of	hematopoietic	stem	and	progenitor	cells	(HSPC)	is	a	promising	approach	
to	 improve	 insufficient	 engraftment	 after	 umbilical	 cord	 blood	 stem	 cell	 transplantation	
(UCB-SCT).	 Although	 culturing	 HSPC	 with	 hematopoietic	 cytokines	 results	 in	 robust	
proliferation,	 it	 is	 accompanied	 with	 extensive	 differentiation	 and	 loss	 of	 self-renewal	
capacity.	Wnt	signaling	has	been	 implicated	 in	regulating	HSPC	fate	decisions	 in vivo	and	
in	promoting	HSPC	self-renewal	by	inhibition	of	differentiation,	but	the	effects	of	Wnt	on	
the	 ex	 vivo	 expansion	 of	 HSPC	 are	 controversial.	 Here,	we	 demonstrate	 that	 exogenous	
Wnt3a	protein	suppresses	rather	than	promotes	the	expansion	of	UCB-derived	CD34+	cells	
in	 serum	 free	 expansion	 cultures.	 The	 reduced	 expansion	was	 also	 observed	 in	 cultures	
initiated	with	Lin-CD34+CD38lowCD45RA-CD90+	 cells,	which	are	highly	enriched	 in	HSC	and	
was	also	observed	in	response	to	activation	of	beta-catenin	signaling	by	GSK3	inhibition.	The	
presence	of	Wnt3a	protein	during	the	culture	reduced	the	frequency	of	multilineage	CFU-
GEMM	and	the	long-term	repopulation	ability	of	the	expanded	HSPC.	These	data	suggest	
that	Wnt	 signaling	 reduces	expansion	of	human	HSPC	 in	growth	 factor-driven	expansion	
cultures	by	promoting	differentiation	of	HSPC.	
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Introduction
Allogeneic	hematopoietic	stem	cell	 transplantation	 is	an	 important	part	of	 treatment	 for	
patients	 suffering	 from	 hematological	 disorders,	 including	 leukemia,	 myelodysplastic	
syndromes,	and	aplastic	anemia.	However,	many	patients	lack	a	suitable	sibling	or	human	
leucocyte	 antigen	 (HLA)	 matched	 unrelated	 donor.	 Because	 of	 its	 rapid	 availability	 and	
less	 stringent	matching	 criteria1,	 umbilical	 cord	 blood	 (UCB)	 is	 an	 important	 alternative	
source	 for	hematopoietic	 stem	and	progenitor	 cells	 (HSPC).	However,	UCB-derived	HSPC	
significantly	 differ	 from	bone	marrow-	 and	 peripheral	 blood-derived	HSPC	quantitatively	
and	qualitatively.	UCB	grafts	contain	a	relatively	low	number	of	HSPC	which	are	relatively	
more	primitive,	resulting	in	impaired	engraftment	and	a	delayed	hematopoietic	recovery1-5,	
during	which	patients	are	at	 increased	 risk	 for	 severe	 complications,	 including	 infections	
and	bleeding.	 Several	approaches	have	been	pursued	 to	 improve	engraftment	after	UCB	
transplantation,	including	the	ex vivo expansion	of	HSPC.
HSC	 are	 defined	 by	 their	 self-renewal	 capacity	 and	 the	 ability	 to	 generate	 all	 different	
hematopoietic	 lineages.	 Although	 in vivo studies	 demonstrated	 that	 HSPC	 expand	 after	
transplantation6,	 robust	 ex vivo	 expansion	 of	 long-term	 repopulating	 HSC	 remains	 a	
challenge.	Culturing	HSPC	with	different	combinations	of	hematopoietic	cytokines	such	as	
stem	cell	 factor	 (SCF),	Fms-related	tyrosine	kinase	3	 ligand	 (Flt3L),	 thrombopoietin	 (TPO)	
and	 granulocyte-macrophage	 colony-stimulating	 factor	 (GM–CSF)	 resulted	 in	 massive	
expansion	of	 committed	HPC	which	 is	 accompanied	by	a	 loss	or	 at	best	maintenance	of	
primitive	 HSC	 with	 long-term	 repopulation	 ability7-11.	 Additional	 signals	 are	 needed	 to	
support	 	the	expansion	of	primitive	HSC	in	ex vivo	culture	systems.	Several	novel	factors,	
such	 as	 the	 immobilized	 Notch-ligand	 Delta1,	 copper	 chelator	 tetra-ethylenepentamine	
(TEPA)	and	signals	derived	from	mesenchymal	stromal	cells,	were	identified	that	may	affect	
self-renewal	of	HSC	and	inhibit	differentiation,	thereby	having	the	potential	to	improve	ex 
vivo	expansion	protocols12-14.	In	addition,	numerous	promising	factors	have	been	tested	in	
a	pre-clinical	setting,	 including	developmental	regulators	such	as	fibroblast	growth	factor	
signaling,	insulin-like	growth	factor,	Angiopoietin-like	proteins	and	Pleiotrophin	and	chemical	
modulators	 like	 all-trans	 retinoic	 acid,	 stemregenin1	 and	 prostaglandin	 E2	 (reviewed	 by	
Walasek	et al.15).
The	Wnt/beta-catenin	signaling	pathway	regulates	cell	fate	decisions	in	many	developmental	
processes	in	embryo	and	adult.	Stimulation	of	cells	with	Wnt	signaling	proteins	induces	the	
stabilization	and	accumulation	of	 the	 signal	 transducer	protein	beta-catenin,	which	 then	
localizes	into	the	nucleus	where	it	regulates	target	gene	expression	(reviewed	by	Clevers	et 
al.16).	When	combined	with	other	growth	factors,	Wnt	proteins	can	promote	self-renewal	
in	several	types	of	stem	cells,	such	as	mammary,	 intestinal	and	embryonic	stem	cells17-20.	
Several	studies,	using	different	approaches	to	 inhibit	 the	Wnt	signaling	pathway,	showed	
that	Wnt	signaling	is	pivotal	for	normal	HSC	function	in	mouse21-23.	In	addition,	some	reports	
show	 that	 treatment	 with	 recombinant	 Wnt3a	 protein	 or	 overexpression	 of	 activated	
beta-catenin	enhances	 the	self-renewal	capacity	of	mouse	HSC	ex vivo24-26.	These	studies	
offer	hope	that	Wnt	signals	may	be	of	use	in	the	expansion	of	human	UCB-derived	HSPC.	
However,	other	studies	show	that	constitutive	activation	of	beta-catenin	blocks	multilineage	
differentiation27	and	that	active	beta-catenin	induces	apoptosis	in	HSPC28,	29.	
In	 this	 study	 we	 investigate	 the	 effect	 of	 Wnt	 signals	 on	 growth	 factor-driven	 ex	 vivo	
expansion	of	human	HSPC.	We	 show	 that	Wnt3a	 signaling	 reduces	 growth	 factor	driven	
expansion	of	human	HSPC	by	promoting	differentiation.	
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Material and Methods
Cord blood processing, CD34+ cell selection and HSC sorting
Umbilical	 cord	 blood	was	 collected	 in	 several	 hospitals	 using	 Stemcare/CB	 collect	 blood	
bag	system	 (Fresenius	Kabi	Norge	AS)	 containing	citrate	phosphate	dextrose	 (CPD)	as	an	
anticoagulant.	Approval	 for	 collection	was	obtained	 from	 the	Medical	Ethical	Committee	
of	the	Erasmus	University	Medical	Centre	(MEC-2009-410)	and	written	 informed	consent	
from	the	mother	was	obtained	prior	to	donation	of	the	cord	blood.	Within	48	hours	after	
collection,	 mononuclear	 cells	 were	 isolated	 using	 ficoll	 (Lymphoprep,	 Fresenius	 Kabi	
Norge	 AS).	 CD34+	 cells	 were	 isolated	 with	 double	 positive	 immunomagnetic	 selection	
using	 Magnetic	 Activated	 Cell	 Sorting	 (MACS)	 technology	 according	 instructions	 of	 the	
manufacturer	 (Miltenyi	 Biotech	 GmBH,	 Bergisch	 Gladbach,	 Germany).	 MACS-selected	
CD34+ cells	were	either	used	directly	in	experiments	or	stained	with	anti-Lin-FITC,	anti-CD38-
PerCP-Cy5.5,	anti-CD90-PE	(all	from	eBioscience,	Vienna,	Austria),	anti-CD34-PE-Cy7,	anti-
CD45RA-APC-H7	(both	from	BD	Biosciences,	San	Jose,	CA,	USA)	and	DAPI	 (Sigma-Aldrich,	
St	 Louis,	MO,	USA)	 after	which	 viable	 DAPI-Lin-CD34+CD38lowCD45RAlowCD90+-cells,	 highly	
enriched	for	hematopoietic	stem	cells	(HSC)30,	were	sorted	using	BD	FACSAria	Cell	Sorting	
System	(BD	Biosciences,	San	Jose,	CA,	USA).
Expansion cultures 
Selected	CD34+	cells	and	sorted	DAPI-Lin-CD34+CD38lowCD45RAlowCD90+-cellswere	cultured	
in	serum	free	Glycostem	Basic	Growth	Medium	(GBGM,	Glycostem,	Oss,	The	Netherlands)	
or	 StemSpan	 Serum-Free	 Expansion	 Medium	 (SFEM,	 Stemcell	 Technologies,	 Grenoble,	
France)	supplemented	with	20	μg/ml	 low	molecular	weight	heparin	(Abbott,	Wiesbaden,	
Germany)	and	the	early	acting	growth	factors	SCF	(50	ng/ml,	Cellgenix,	Freiburg,	Germany),	
Flt3L	 (50	 ng/ml,	 Cellgenix,	 Freiburg,	 Germany)	 and	 TPO	 (50	 ng/ml,	 Cellgenix,	 Freiburg,	
Germany)	(from	now	on	referred	to	as	‘SFT	medium’)	with	or	without	the	addition	of	250	
ng/ml	purified	Wnt3a	unless	indicated	otherwise.	Cells	were	cultured	in	a	volume	of	1	ml	in	
24-well	plate	at	a	concentration	of	105/ml	at	37	°C	in	5%	CO2.	Every	2	to	3	days,	wells	were	
split	or	half	of	the	medium	was	refreshed.	In	some	experiments,	we	used	GSK3β	inhibitor	
CH99021	(1	µM,	Stemgent,	Cambridge,	MA,	USA)	as	an	alternative	activator	of	the	canonical	
Wnt	pathway.	Frizzled8CRD	(Fr8CRD,	which	blocks	the	binding	of	Wnt3a	to	its	receptor)	was	
produced	as	described31	and	used	at	a	concentration	of	15	µg/ml.	 	Wnt3a	was	combined	
in	some	experiments	with	the	Aryl	hydrocarbon	Receptor	(AhR)	antagonist	StemRegenin1	
(SR1,	1	µM,	Cellagen	Technology,	San	Diego,	CA,	USA).
Purification of Wnt3a and preparation of liposomal Wnt3a
Wnt3a-conditioned	medium	was	 collected	 from	Drosophila	 S2	 cells	 grown	 in	 suspension	
culture.	 Wnt3a	 was	 further	 purified	 using	 Blue	 Sepharose	 affinity	 and	 gel	 filtration	
chromatography	 as	 described24.	 Liposomes	 containing	 DMPC	 (1,2-dimyristoyl-sn-glycero-
3-phosphocholine),	DMPG	(1,2-dimyristoyl-sn-glycero-3-phospho-rac-glycerol)	(both	Lipoid	
AG)	 and	 Cholesterol	 (Sigma-Aldrich,	 St	 Louis,	 MO,	 USA)	 at	 a	 10:1:10	 molar	 ratio	 were	
prepared	by	extrusion	method. Purified	Wnt3a	was	mixed	with	liposomes	at	a	1:7.5	ratio	
to	achieve	a	total	concentration	of	7-10	µg/ml	of	Wnt3a.	After	mixing,	the	Wnt	liposomes	
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were	incubated	for	at	least	one	hour	on	the	roller	coaster	at	4	°C.	Next,	CHAPS	was	removed	
from	the	Wnt	liposomes	by	dialysis	at	least	three	times	in	PBS	1	hour	each,	using	dialysis	
membrane	 with	 molecular	 weight	 cut-off	 of	 10	 kDa	 at	 4	 °C.	 The	 Wnt	 liposomes	 were	
stored	at	4	°C.	Activity	of	purified	Wnt3a	protein	and	liposomal	Wnt3a	was	determined	in	a	
luciferase	reporter	assay	(see	below).
Luciferase reporter assay
Mouse	 LSL	 cells,	 which	 express	 luciferase	 in	 response	 to	 TCF	 promoter	 binding,	 were	
routinely	cultured	at	37	°C	and	5%	CO2	in	culture	medium	composed	of	DMEM	(Invitrogen,	
Life	 Technologies,	 Bleiswijk,	 The	Netherlands),	 10%	 FCS,	 and	 1%	Penicillin/Streptomycin.	
For	the	activity	assays,	Wnt3a	reagents	at	a	concentration	of	250	ng/ml	were	incubated	in	
culture	medium	without	FCS	for	various	periods	of	time	at	37	oC	in	U-bottom	96-well	plates.	
These	media	were	then	transferred	to	F-bottom	96-well	plates	containing	LSL	cells,	which	
were	plated	the	day	before	at	a	density	of	25,000	cells/well.	After	overnight	incubation	with	
the	indicated	Wnt	reagents,	relative	luciferase	units	were	measured	with	Glomax	multiplate	
reader.
Flowcytometry
At	serial	time	points	 in	culture,	absolute	numbers	of	viable	CD34+	cells	were	determined	
by	a	single	platform	flowcytometric	assay,	using	anti-CD45-FITC,	anti-CD34-PE,	DAPI	and	a	
calibrated	number	of	Stem-Count	Fluorospheres	(all	from	Beckman	Coulter,	Fullerton,	CA,	
USA).	Within	the	CD34+	population,	the	frequency	of	DAPI-Lin-CD34+CD38lowCD45RAlowCD90+-
cells	was	determined	using	the	antibody	panel	as	described	above	for	the	sorting	of	these	
cells.	 Absolute	 numbers	 of	 DAPI-Lin-CD34+CD38lowCD45RAlowCD90+-cells	 were	 determined	
by	multiplying	the	absolute	number	of	CD34+	cells	obtained	in	the	single	platform	analysis	
by	 the	 percentage	 of	 DAPI-Lin-CD34+CD38lowCD45RAlowCD90+-cells	 within	 the	 CD34+	 cell	
population.	Flowcytometric	analysis	was	performed	using	a	BD	FACSCanto	(BD	Biosciences,	
San	Jose,	CA,	USA)	and	data	was	analyzed	using	FlowJo	software	(Tree	Star	Inc,	Ashland,	OR,	
USA).	
Transplantation of human hematopoietic cells into NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ 
(NSG) mice
This	 study	 was	 carried	 out	 in	 accordance	 to	 the	 Dutch	 law	 on	 Animal	 Welfare	 and	
Experiments.	 The	 protocol	 was	 approved	 by	 the	 Committee	 on	 the	 Ethics	 of	 Animal	
Experiments	 of	 the	 Erasmus	 University	 Medical	 Centre	 Rotterdam,	 The	 Netherlands.	
Intrabone	transplantations	were	performed	under	isoflurane	anesthesia.		All	animals	were	
housed	in	groups	in	individually	ventilated	cages.	Food	and	water	were	available	ad	libitum. 
NSG	 mice	 were	 sublethally	 irradiated	 (3	 Gy)	 and	 subsequently	 transplanted	 with	 the	
progeny	generated	 from	1,00E+05	UCB-derived	CD34+	 cells	 cultured	 in	our	 SFT	medium,	
with	 or	 without	 the	 addition	 of	 250	 ng/ml	 Wnt3a	 for	 7	 days.	 Each	 group	 contained	 5	
mice.	 Engraftment	was	assessed	every	2	weeks	 starting	at	3	weeks	after	 transplantation	
by	flowcytometric	analysis	of	the	peripheral	blood,	using	a	flowcytometric	panel	including	
anti-mouseCD45-eFluor450,	 (eBioscience,	Vienna,	Austria)	and	anti-humanCD45-APC-Cy7	
(BioLegend,	London,	UK).	Mice	were	considered	engrafted	when	human	CD45	levels	were	
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higher	than	0.1%.	At	17	weeks	after	transplantation,	the	mice	were	sacrificed	by	cervical	
dislocation	and	cells	from	femurs	were	analysed.	
Results
Wnt3a reduces growth factor-driven expansion of UCB derived CD34+ cells 
To	 assess	whether	Wnt	 signals	 affect	 expansion	 of	 human	HSPC	 in	 culture,	UCB-derived	
CD34+	 cells	were	 cultured	 in	 serum-free	medium	supplemented	with	 SCF,	 Flt3L	 and	TPO	
(SFT	medium)	with	or	without	purified	Wnt3a	protein.	After	14	days,	no	significant	change	
in	 total	nucleated	cell	expansion	was	observed	 in	 response	to	Wnt3a	protein	 (Figure	1A,	
p=0.74).	However,	Wnt3a	accelerated	the	decline	in	the	frequency	of	CD34+	cells	that	was	
observed	during	culture	(Figure	1B	,	p<0.001	for	both	7	and	14	days	of	culture	and	Figure	
1C),	 resulting	 in	a	significantly	reduced	expansion	of	CD34+	cells	after	2	weeks	of	culture	
(Figure	1D).		In	addition,	we	observed	a	higher	frequency	of	cells	expressing	lineage	markers	
after	 14	 days	 of	 culture	 in	 the	 presence	 of	Wnt3a	 protein	 compared	with	 SFT	medium	
only	 (Figure	1E,	p<0.05).	Next,	we	assessed	 the	 functionality	of	 the	 cultured	CD34+	 cells	
by	performing	 	 colony	 forming	unit	 (CFU)	 assays.	 The	presence	of	Wnt3a	during	 culture	
reduced	the	frequency	of		multi-lineage	CFU-GEMM	(granulocyte,	erythrocyte,	monocyte,	
megakaryocyte)	 ,	while	no	effect	was	seen	 in	 the	 frequency	of	 lineage	committed	BFU-E	
(Burst	Forming	Unit-Erythrocyte)	and	CFU-GM	(granulocyte,	macrophage)	(Figure	1F).	The	
reduction	in	frequency	of	most	immature	CFU	and	the	higher	frequency	of	lineage	positive	
cells	suggest	that	exogenous	Wnt3a	protein	promotes	rather	than	 inhibits	growth	factor-
driven	differentiation	of	CD34+	 cells	 in	expansion	 cultures.	Next,	we	evaluated	 the	dose-
response	relationship	of	Wnt	signaling	on	the	in	vitro	expansion	of	CD34+	cells.	At	the	lowest	
concentration	of	25	ng/ml,	Wnt3a	had	no	effect	on	the	expansion	of	CD34+	cells	relative	to	
control	SFT	cultures	(Figure	1G).	On	the	other	hand,	the	highest	concentration	of	2500	ng/
ml	Wnt3a	protein	resulted	 in	a	decline	of	 total	cell	number	 (not	shown)	and	a	complete	
loss	 of	 CD34+	 cells	 (Figure	 1G).	 The	 effect	 of	 Wnt3a	 on	 the	 repopulating	 ability	 of	 the	
expanded	CD34+	cells	was	assessed	by	transplantation	of	the	expanded	population	of	cells	
into	sublethally	irradiated	NSG	mice	after	7	days	of	culture.	All	transplanted	mice	showed	
engraftment	(defined	as	>0.1%	human	CD45+	cells	in	the	peripheral	blood	at	7	weeks	after	
transplantation).	 	 However,	 the	 kinetics	 of	 human	 chimerism	development	 in	 peripheral	
blood	appeared	delayed	when	cells	were	cultured	 in	the	presence	of	Wnt3a	(Figure	1H).	
Lower	 levels	 of	 human	 chimerism	 were	 also	 observed	 in	 the	 bone	marrow	 of	 mice	 17	
weeks	 after	 transplantation	of	 cells	 cultured	 in	 the	presence	of	Wnt3a	 (Figure	1I,	 36.9%	
versus	10.1%	respectively,	p<0.05).	This	indicates	that	Wnt3a	protein	reduces	the	long-term	
repopulation	ability	of	cultured	CD34+	cells.	
Wnt3a reduces growth factor-driven expansion of HSC
CD34+	cells	constitute	a	heterogeneous	population,	including	only	a	minor	fraction	of	the	
most	immature	HSC	subset.	Wnt3a	may	act	differentially	on	primitive	HSC	and	CD34+	cells	
with	committed	progenitor	properties	A	putative	differentiation-inhibiting	effect	of	Wnt3a	
on	HSC	may	 be	 obscured	 by	 a	 differentiation-inducing	 effect	 on	 the	 large	 population	 of	
committed	progenitor	cells	in	culture.	To	study	the	effects	of	Wnt3a	on	the	most	immature	
HSC	 subset,	 we	 expanded	 Lin-CD34+CD38low	 CD45RAlowCD90+-cells,	 highly	 enriched	 for	
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Figure 1. Exogenous Wnt3a reduces growth factor-driven expansion of CD34+ cells.
UCB-derived	CD34+	cells	were	cultured	in	serum	free	SFT	medium	with	or	without	the	addition	of	Wnt3a.	
Cells	were	analyzed	using	flow	cytometry	at	7	and	14	days	of	culture.	Shown	are	(A)	the	total	nucleated	
cell	expansion	compared	to	input	(n=8),	(B)	the	frequency	of	CD34+	cells	within	the	TNC	population	during	
culture	(n=8),	(C)	expression	of	CD45	and	CD34	after	14	days	of	culture	in	SFT	with	(lower	panel)	or	without	
(upper	panel)	Wnt3a	(representative	of	n=	8),	(D)	the	expansion	of	CD34+	cells	compared	to	input	(n=8)	and	
(E)	the	frequency	of	cells	expressing	lineage	markers	after	7	and	14	days	of	culture	(n=6).	(F)	Frequency	of	
CFU-GEMM,	BFU-E	and	CFU-GM	in	250	CD34+	cells	cultured	for	2	weeks	in	SFT	or	SFT+Wnt3a	(n=2,	3	dishes	
per	experiment).	(G)	CD34+	cell	expansion	compared	to	SFT	medium	after	14	days	of	culture	with	different	
dosages	of	Wnt3a	(n=2).	(H)	Levels	of	human	chimerism	at	several	time	points	after	transplantation	with	the	
progeny	of	105	CD34+	cells	cultured	for	7	days	in	SFT	or	SFT+Wnt3a	medium	(n=5	mice	per	group).	(I)	Levels	
of	human	chimerism	in	bone	marrow	17	weeks	after	transplantation	with	the	progeny	of	105	CD34+	cells	
cultured	for	7	days	in	SFT	or	SFT+Wnt3a	medium	(n=5	mice	per	group).		 * p<0.05, ** p<0.01, *** p<0.001
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HSC30	in	the	presence	or	absence	of	Wnt3a.	A	similar	effect	of	Wnt3a	was	observed	on	the	
expansion	of	the	sorted	Lin- CD34+ CD38low	CD45RAlow	CD90+-cells.	A	robust	total	nucleated	
cell	expansion,	approximately	100-fold,	was	observed	regardless	of	the	presence	of	Wnt3a	
(Figure	 2A).	 However,	 Wnt3a	 again	 accelerated	 the	 decline	 in	 the	 frequency	 of	 CD34+ 
cells	(Figure	2B,	p<0.05	and	p<0.01	for	7	and	14	days	of	culture,	respectively)	and	led	to	a	
significantly	reduced	expansion	of	CD34+	cells	(Figure	2C,	p<0.01).	Moreover,	Wnt3a	strongly	
reduced	the	number	of	Lin-CD34+ CD38low	CD45RAlow	CD90+-cells	obtained	after	culture,	while	
these	cells	were	maintained	in	the	absence	of	Wnt3a	(Figure	2D).	These	data	suggest	that	
Wnt3a	inhibits	the	expansion	of	both	multilineage	committed	progenitors	and	HSC.
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Figure 2.  Wnt3a reduces growth factor-driven expansion of HSC. 
UCB-derived	DAPI-Lin-CD34+CD38lowCD45RAlowCD90+-cells	were	sorted	out	of	CD34-selected	cells	and	were	
cultured	in	SFT	medium	with	or	without	Wnt3a.	Flowcytometric	analysis	was	performed	at	day	7	and	14.	De-
picted	are	(A)	the	total	nucleated	cell	expansion	in	SFT	and	SFT+Wnt3a	medium	at	7	and	14	days	of	culture	
(n=4),	(B)	the	CD34+	cell	frequency	during	culture	(n=4),	(C)	the	fold	expansion	of	CD34+	cells	at	day	7	and	14	
of	culture	(n=4)	and	(D)	the	total	number	of	DAPI-Lin-CD34+CD38lowCD45RAlowCD90+-cellsat	input	and	after	14	
days	of	culture	in	SFT	or	SFT+Wnt3a	medium	(n=4).	*	p<0.05,	**	p<0.01
Prolongation of Wnt3a activity does not result in increased expansion of CD34+ cells
Purified	Wnt3a	 has	 been	 shown	 to	 have	 a	 half-life	 that	 is	 considerably	 shorter	 than	 24	
hours	upon	dilution	 in	 serum	 free	media32.	 Thus,	daily	 addition	of	Wnt3a	protein	 to	 cell	
cultures	would	result	 in	 intermittent	rather	than	continuous	activation	of	the	pathway.	A	
possible	explanation	for	our	observations	of	reduced	HSPC	expansion	in	response	to	daily	
Wnt3a	addition	is	that	these	intermittent	pulses	are	unable	to	inhibit	HSC	differentiation.	
At	the	same	time,	Wnt	signals	may	promote	the	differentiation	of	more	mature	CD34+	cells,	
leading	 to	an	overall	 reduction	of	HSPC.	The	stability	of	Wnt3a	protein	can	be	 increased	
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by	association	with	 liposomes33,	34,	 and	we	 therefore	 tested	whether	 such	 stabilized	Wnt	
ligands	were	able	to	prevent	the	decline	in	HSPC	that	we	observed	in	response	to	regular	
Wnt3a	protein.	We	compared	the	stability	of	purified	Wnt3a	protein	and	of	Wnt3a	protein	
associated	with	 liposomes	by	 incubating	the	proteins	 in	serum	free	medium	at	37°C	and	
assessing	the	remaining	Wnt-activity	at	several	time	points	by	a	luciferase	reporter	assay.	
Whereas	purified	Wnt3a	lost	its	activity	within	8	hours,	liposomal	Wnt3a	retained	significant	
activity	after	24	hours	(Figure	3A).	Despite	this	increased	stability	however,	liposomal	Wnt3a	
induced	a	3.3-fold	decline	of	CD34+	cell	expansion	(Figure	3B),	similar	to	purified	Wnt3a.	In	
conclusion,	prolongation	of	Wnt3a	activity	does	not	result	in	increased	expansion	of	CD34+ 
cells.
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Figure 3. Liposomal Wnt3a reduces expansion of CD34+ cells. 
(A)	Purified	Wnt3a	and	liposomal	Wnt3a	were	incubated	for	0,	8,	and	24	hours	at	37oC	in	cell	culture	media,	
and	 transferred	 to	LSL	cells.	Remaining	Wnt	activity	was	assayed	by	 luminescence	measurements.	Activ-
ity	plot	displays	average	increase	of	luminescence	over	incubation	time	relative	to	background	(n=10).	(B)	
CD34+	cell	expansion	in	SFT	medium	with	or	without	liposomal	Wnt3a	after	7	days	of	culture	(n=1).	
Enhanced differentiation of CD34+ cells is dependent on activation of the canonical Wnt 
pathway
Binding	of	Wnt3a	to	its	receptor	can	be	blocked	with	the	Wnt	antagonist	Fz8CRD,	a	soluble	
domain	 of	 the	 Wnt	 receptor	 that	 sequesters	 Wnt	 proteins31.	 To	 demonstrate	 that	 the	
observed	effects	of	Wnt3a	were	indeed	dependent	on	binding	to	its	receptor	on	HSPC,	CD34+ 
cells	were	cultured	with	or	without	Wnt3a	and/or	Fz8CRD.	The	negative	effect	of	exogenous	
Wnt3a	on	the	expansion	of	CD34+	cells	and	the	decline	in	frequency	of	CD34+	cells	during	
culture	was	reversed	by	the	addition	of	Fz8CRD.	(Figure	4A	and	4B).	An	alternative	way	to	
activate	the	canonical	Wnt	pathway	 is	by	 inhibiting	glycogen	synthase	kinase	3β	(GSK3β)	
which	results	in	stabilization	of	the	cytoplasmic	β-catenin	pool	and	subsequent	transfer	to	
the	nucleus.	To	confirm	that	activation	of	the	canonical	Wnt	pathway	by	exogenous	Wnt3a	
underlies	the	inhibitory	effects	of	Wnt3a	on	the	expansion	of	CD34+	cells	we	used	a	synthetic	
GSK3β-inhibitor	 (CHIR99021).	 Addition	 of	 CHIR99021	 supressed	 the	 expansion	 of	 CD34+ 
cells	(Figure	4C)	to	a	similar	extend	as	purified	Wnt3a	protein	(Figure	1D).	Collectively	these	
data	show	that	the	reduced	expansion	of	CD34+	cells	is	due	to	binding	of	Wnt3a	protein	to	
its	receptor	on	HSPC	and	subsequent	activation	of	canonical	Wnt	pathway.
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Wnt3a inhibits expansion of CD34+ cells driven by the Aryl hydrocarbon receptor 
antagonist Stemregenin1
The	Aryl	hydrocarbon	Receptor	 (AhR)	 is	 implicated	to	play	a	role	 in	 the	proliferation	and	
differentiation	of	HSPC.	AhR-KO	mice	have	increased	number	of	LSK	cells	in	the	bone	marrow	
and	these	LSK	are	hyperproliferative35	and	hematopoietic	progenitors	of	donor	mice	treated	
with	 the	 AhR	 agonist	 TCDD	 show	 impaired	 competitive	 engraftment36.	 In	 addition,	 the	
AhR	antagonist	StemRegenin1	(SR1)	has	been	shown	to	effectively	enhance	the	expansion	
of	human	HSPC37,	38.	We	 included	SR1	 in	our	 cultures	as	a	positive	control	 for	enhancing	
growth	factor-driven	CD34+	cell	expansion	and	in	addition,	to	evaluate	putative	cooperative	
effects	of	the	Wnt	and	AhR	signalling	pathways.	Expectedly,	SR1	 indeed	promoted	CD34+ 
cell	expansion	to	a	similar	extent	as	reported	before37,	indicating	the	suitability	of	our	SFT	
medium,	while	Wnt3a	reduced	CD34+	cell	expansion	(Figure	5).	Addition	of	both	Wnt3a	and	
SR1	resulted	in	an	increased	expansion	compared	to	Wnt	alone,	but	a	reduced	expansion	
compared	to	SR1	alone	(Figure	5,	p<0.01	and	p<0.05	respectively),	showing	that	even	in	the	
presence	of	AhR	pathway	inhibition,	Wnt3a	suppresses	the	expansion	of	CD34+	cells.	
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Figure 4. Wnt3a-mediated inhibition of HSPC expansion is 
due to activation of the canonical Wnt3a pathway.
	 (A)	 Expansion	 of	 CD34+	 cells	 after	 7	 and	 14	 days	 of	 culture	
in	 SFT,	 SFT+Wnt3a,	 SFT+Fr8CRD	 and	 SFT+Wnt3a+Fr8CRD	
(n=2).	(B)	CD34+	cell	frequency	within	the	TNC	population	dur-
ing	 these	cultures	 (n=2).	 (C)	CD34+	 cell	expansion	 in	SFT	and	
SFT+CHIR99021	after	7	and	14	days	of	culture	(n=2).	
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Figure 5. Wnt3a inhibits SR1-enhanced CD34+ cell expan-
sion. 
UCB-derived	 CD34+	 HSPC	 were	 cultured	 for	 14	 days	 in	
SFT	 or	 SFTSR1	medium	with	 or	without	 the	 addition	 of	
Wnt3a.	Flowcytometric	analysis	was	performed	at	day	14.	
Depicted	is	the	CD34+	cell	expansion	after	14	days	of	cul-
ture	(n=5).	* p<0.05, ** p<0.01
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Discussion
The	 effects	 of	 Wnt	 signaling	 on	 human	 HSPC	 proliferation,	 differentiation	 and	 survival	
are	still	poorly	understood.	 In	 this	 study,	we	show	that	Wnt3a	protein	suppresses	 rather	
than	promotes	growth	 factor-driven	expansion	of	UCB-derived	CD34+	 cells	 in	 serum-free	
expansion	cultures.		Wnt3a	induced	accelerated	differentiation	of	both	HSC	and	multipotent	
progenitors,	resulting	in	the	production	of	more	differentiated	cells.	The	reduced	expansion	
of	human	HSPC,	appeared	to	be	dependent	on	activation	of	 the	canonical	Wnt	signaling	
pathway	upon	binding	of	Wnt3a	to	its	receptor	at	the	cell	surface.		
Our	findings	compare	well	to	those	by	Nemeth	et	al.	,	who	observed	a	decrease	in	expansion	
of	mouse	 LSKI	 (Lineage	 negative,	 Sca-1+,	 c-kit+,	 IL-7Rα-)	 cells	 after	 culture	 in	 serum-free	
medium	 containing	 SCF,	 Flt3L	 and	 Wnt3a	 compared	 to	 culture	 conditions	 with	 growth	
factors	 only.	 In	 addition,	 they	 showed	 no	 enhanced	 repopulation	 capacity	 of	 Wnt3a-
cultured	LSKI	cells	compared	to	control-cultured	cells25.	Earlier,	several	studies	showed	that	
overexpression	of	beta-catenin	in	HSC	resulted	in	a	functional	defect	of		hematopoiesis	and	
loss	of	repopulating	activity27,	39.	These	results	are	in	line	with	our	observations	of	enhanced	
differentiation	of	HSPC	upon	stimulation	of	the	canonical	Wnt	pathway.	However,	Malhotra	
et	al.	reported	that	overexpression	of	activated	beta-catenin		may	expand	the	pool	of	HSC,	
both	phenotypically	and	functionally	 in	 long	term	cultures40	 .	 In	addition,	overexpression	
of	 the	Wnt	 inhibitor	Dickkopf-related	protein	1	 (Dkk1)	was	 shown	 to	 significantly	 impair	
the	self-renewal	capacity	of	adult	HSC21,	22.	How	to	 reconcile	 these	contradictory	 results?	
Although	at	first	sight	contradictory,	the	many	differences	in	types	of	cultures,	cells	growth	
factors	added	may	explain	some	of	the	observed	differences.	
Willert	et	al.	and	Reya	et	al.	earlier	showed	that	purified	Wnt3a	induced	proliferation,	while	
inhibiting	differentiation	of	HSC	 in	 growth-factor	 based	 cultures	 of	mouse	 LSKT	 (Lineage	
negative,	Sca-1+,	c-kit+,	Thy-1.1lo)24,	26.	However,	they	used	cells	derived	from	BCL2	transgenic	
mice.	 The	 BCL2	 anti-apoptotic	 signal	 in	 HSPC	may	 counteract	 possible	 apoptotic	 signals	
induced	 by	 Wnt3a	 signaling.	 Moreover,	 they	 used	 serum,	 which	 may	 supply	 additional	
signals	 that	allow	canonical	Wnt	 signaling	 to	exert	a	differentiation	 inhibitory	effect	or	a	
more	pronounced	effect	on	self-renewal.	It	would	compare	well	to	several	other	studies28,	
41,	which	show	that	the	presence	of	additional	factors	is	required	to	balance	the	activated	
Wnt	 pathway.	 Trowbridge	 et	 al.	 showed	enhanced	 long-term	 repopulation	 after	 treating	
mice	with	a	GSK3beta	inhibitor,	which	regulates		the	canonical	Wnt	pathway	and		several	
other	pathways	as	well41.	 	Perry	et	al.	 showed	 	 that	 the	combination	of	a	PTEN	deletion	
and	 activation	 of	 beta-catenin	 results	 in	 enhanced	 self-renewal	 and	 expansion	 of	 HSC28.	
Another	important		pathway	involved	in	HSC	self-renewal	and	inhibition	of	differentiation	
is	the	pathway	initiated	by	the	aryl	hydrocarbon	Receptor	(AhR).		It	is	now	well	established	
that	AhR-KO	mice	have	increased	number	of	LSK	cells	 in	the	bone	marrow	and	these	LSK	
are	hyperproliferative35,	while	hematopoietic	progenitors	of	donor	mice	treated	with	AhR	
agonist	 TCDD	 show	 impaired	 competitive	engraftment36.	 In	 addition,	 the	AhR	antagonist	
StemRegenin1	 (SR1)	 promotes	 expansion	 of	 human	 hematopoietic	 stem	 cells37,	 38.	 We	
evaluated	 whether	 combined	 inhibition	 of	 the	 AhR	 pathway	 and	 activation	 of	 the	Wnt	
pathway	would	result	in	enhanced	expansion	of	HSPC.	However,	Wnt	signaling	also	reduced	
the	expansion	of	CD34+	HSPC	in	the	presence	of	the	aryl	hydrocarbon	receptor	antagonist	
SR1.	Another	important	factor	that	may	affect	the	response	of	HSPC	to	Wnt	signaling	is	the	
level	of	oxygenation.	Expansion	cultures	are	usually	performed	at	normoxic	levels.	However,	
it	is	well	established	that	the	response	of	HSPC	to	hematopoietic	cytokines	is	different	under	
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normoxic	and	hypoxic	conditions,	which	mimics	the	in	situ	bone	marrow	environment42.	The	
effect	of	stimulation	of	the	canonical	Wnt	pathway	on	HSC	expansion	may	be	modulated	by	
the	level	of	oxygenation,	which	was	already	shown	for	the	effect	of	the	Wnt4-dependent	
pathway	on	the	functional	capacities	of	mesenchymal	stem	cells43.		
	Apart	from	other	cytokines	and	pathways	involved,	the	dose	and	timing	of	Wnt	activation	
might	play	an	important	role.		Our	data	show	that	both	intermittent	pulses	of	Wnt3a	and	
more	continuous	exposure	to	Wnt3a	have	a		similar	negative	effect	on	the	expansion	of	CD34+ 
cells	in	serum-free	expansion	cultures.		Luis	et	al	reported	that	Wnts	are	tightly	regulated	
in	a	dose-dependent	fashion44,	which	may	affect	their	biological	activity.	Thereby,	varying	
results	 (exerted	 via	 the	 canonical	Wnt	 pathway)	may	 result	 from	different	 levels	 of	Wnt	
signaling,	such	as	can	be	achieved	in	different	experimental	conditions.	The	optimal		level	of	
Wnt	signaling	for	HSC	was	suggested	to	be	only	slightly	increased	over	normal	physiological	
values,	while	higher	levels	resulted	in	impaired	engraftment	potential	of	HSC	fashion44.	
Collectively,	 we	 show	 that	 exogenous	Wnt3a	 proteins	 reduces	 the	 expansion	 of	 human	
HSPC	 in	 serum-free	 growth	 factor-driven	 HSPC	 expansion	 cultures	 by	 promoting	 their	
differentiation	 without	 apparently	 affecting	 their	 proliferation	 or	 survival.	 It	 cannot	 be	
excluded	 that	 additional	 signals,	 such	 as	 the	 induction	 of	 a	 hypoxic	 cellular	 response,	
are	needed	 for	 a	possible	 positive	effect	of	 canonical	Wnt	 signaling	on	HSPC	expansion.	
Future	studies	may	address	the	fragile	balance	between	canonical	Wnt	signaling	and	other	
pathways	to	determine	whether	combined	activation	of	Wnt	signaling	and	other	signaling	
pathways	may	promote	human	HSPC	expansion.
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With	their	abilities	to	self-renew	and	mature	into	specialized	cell	types	of	a	particular	tissue,	
adult	stem	cells	are	at	the	foundation	of	the	maintenance	and	repair	of	adult	tissues.	Owing	
to	their	functions	in	restoration	of	lost,	damaged,	or	aging	cells	and	tissues	in	the	human	
body,	 adult	 stem	 cell	 populations	 are	 also	 valuable	 for	 therapeutic	 applications.	 Today,	
hematopoietic	stem	and	progenitor	cells	(HSPC)	are	routinely	used	in	therapeutic	settings1.	
Furthermore,	 recent	advances	 in	cultures	of	several	other	 types	of	adult	stem	cells	 from	
a	variety	of	tissues	 including	 liver	and	 intestine	opens	up	new	experimental	avenues	 for	
disease	modeling,	toxicology	studies,	regenerative	medicine,	and	gene	therapy2.	However,	
several	shortcomings	of	stem	cell	sources,	including	lack	of	suitable	donors,	low	numbers	
of	 stem	cells,	 and	undefined	culture	 conditions,	 limit	 their	applicability.	 The	ability	 to	ex 
vivo	expand	adult	 stem	cell	populations	 in	a	 robust	and	defined	manner	would	certainly	
facilitate	 exploitation	 of	 their	 massive	 regeneration	 potential.	 Therefore,	 it	 is	 of	 vital	
importance	to	provide	the	cultures	of	adult	stem	cells	with	the	essential	factors	that	govern	
their	 cell	 fate	 decisions.	 Among	 the	many	 pathways	 that	 are	 implicated	 in	 regulation	 of	
stem	cell	self-renewal	and	differentiation,	the	Wnt	signaling	cascade	is	distinctive	due	to	its	
roles	in	maintenance	of	multiple	stem	cells	types3.		With	the	aim	of	developing	cell	culture	
conditions	to	expand	stem	cells,	in	this	thesis,	the	effects	and	possible	use	of	Wnt	signaling	
proteins	for	propagation	of	adult	stem	cells	from	intestine,	liver	and	blood	tissue	in	defined	
culture	conditions	were	investigated.	Subsequently,	we	applied	our	advances	to	address	a	
genetic	disease	using	these	stem	cells.
The	findings	described	in	this	thesis	provide	new	insights	into	the	importance	of	achieving	
stable	Wnt3a	activity	via	hydrophobic	carriers	 for	 the	culture	of	human	organ	stem	cells	
from	 intestine	 and	 liver	 in	 serum-free	 conditions.	 Moreover,	 this	 thesis	 demonstrates	
that	 regardless	of	 the	stability	of	 the	Wnt3a	protein,	Wnt3a	 induced	signaling	 leads	 to	a	
reduction	rather	than	an	increase	in	the	number	of	HSPC	both	in	mice	and	humans.	Finally,	
it	shows	preliminary	data	and	points	out	the	necessary	steps	to	be	taken	for	a	liver	stem	
cell-mediated	gene	therapy	approach	for	treatment	of	lysosomal	storage	disorders	(LSDs),	
exemplified	by	Hurler	disease.	
Stabilizing Wnt proteins with hydrophobic carriers for their implementation in organ stem 
cell cultures
The	recent	development	of	methods	 to	expand	human	adult	organ	stem	cells	 in vitro as 
organoids	offers	novel	opportunities	 in	 regenerative	medicine,	e.g.	organ	stem	cells	may	
be	used	to	restore	organ	function,	or	to	correct	genetic	defects4–10.	Moreover,	as	organoids	
exhibit	specific	functions	and	characteristics	of	the	organ	of	origin,	they	are	promising	tools	
for	 diagnostic	 or	 drug	 screening	 purposes	 and	might	 allow	personalized	 therapy	 design.	
Efforts	 are	under	way	 to	use	organoids	 from	cystic	fibrosis	 and	 colon	 cancer	patients	 to	
screen	drugs	for	each	individual,	bringing	truly	personalized	medicine	to	patients11,12.	
Human	organoids	require	Wnt	signals,	provided	by	a	serum-containing	medium	conditioned	
by	 a	 Wnt3a-producing	 cell	 line.	 Nevertheless,	 serum	 batches	 have	 to	 be	 screened	 and	
support	only	some	types	of	organoids,	complicating	culture.		Moreover,	conditioned	media	
introduce	differentiation-inducing	and	undefined	components	that	are	undesirable	for	drug	
screens	 or	 clinical	 applications.	 The	 use	 of	 purified	Wnt	 proteins	 is	 therefore	 preferred.	
However,	attempts	to	replace	conditioned	media	with	purified	Wnt3a	protein	and	establish	
a	defined	culture	system	have	been	unsuccessful.	In	the	chapter	2	of	this	thesis,	we	show	
that	purified	Wnt3a	is	inefficient	in	organoid	cultures	for	two	reasons:	Wnt3a	protein	has	a	
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short-half	life	in	serum-free	medium	due	to	its	hydrophobic	nature,	and	it	requires	a	toxic	
detergent,	CHAPS,	which	is	incompatible	with	the	high	concentrations	of	Wnt3a	required	to	
support	stem	cells.	Here	we	solve	both	problems	by	exploiting	Wnt’s	hydrophobic	nature	
to	stabilize	it	using	lipid-modified	nanoparticles	instead	of	detergents.	This	both	preserves	
Wnt	activity	 in	the	absence	of	CHAPS,	and	prolongs	 its	stability	 in	serum-free	media.	We	
show	that	lipid-stabilized	Wnt3a	is	extremely	effective	in	supporting	self-renewal	of	various	
stem	cells	in	defined	conditions,	and	supports	the	establishment	of	organoids	from	human	
duodenum,	jejunum	and	liver,	all	in	defined	media.	
Our	work	removes	a	major	obstacle	impeding	the	clinical	application	of	human	adult	stem	
cells.	Moreover,	 the	prolonged	activity	of	 lipid-stabilized	Wnt3a	protein	and	 the	absence	
of	 CHAPS	 offer	 advantages	 for	 all	 tissue	 culture	 uses	 of	 Wnt3a	 protein.	 To	 make	 our	
technology	widely	 available,	we	developed	 lipid-coated	nanoparticles	 that	 can	be	added	
to	any	cell	culture	to	instantly	extend	the	lifetime	of	Wnt	proteins.	Moreover,	as	another	
alternative	we	 show	 that	Wnt3a	 liposomes	 can	 be	 freeze-dried	 and	 retain	 their	 activity	
upon	reconstitution.	Both	of	these	alternative	technologies	provide	efficient	ways	to	store	
and	distribute	stabilized	Wnt	ligands.	Highlighting	the	ability	of	lipid	vesicles	to	replace	the	
toxic	detergent	CHAPS	for	obtaining	active	Wnt	proteins	in	our	study,	we	also	propose	that	
readdressing	 the	purification	of	Wnt	proteins	by	 involving	hydrophobic	carrier	molecules	
might	further	advance	the	Wnt	field.	
Our	findings	 in	this	chapter	also	demonstrate	the	 importance	of	supplying	the	necessary	
signals	at	the	adequate	levels	for	in vitro	expansion	of	adult	organ	stem	cells.		With	respect	
to	 necessary	 signals,	 the	 organoid	 cultures	 of	 organ	 stem	 cells	 also	 requires	 a	 laminin	
and	collagen-rich	matrix,	known	as	Matrigel	 (BD	Biosiences)	or	Cultrex	BME	(Amsbio)	by	
its	 trade	name,	which	provides	a	 scaffold	 for	3D	growth4–7,10,13.	 These	matrices	consist	of	
Englebreth-Holm-Swarm	 mouse	 sarcoma	 cells-derived	 gelatinous	 protein	 mixtures	 that	
mimic	the	extracellular	environment	in	many	tissues14.	However,	Matrigel	or	BME	are	not	
well-defined	matrices	and	besides	the	extracellular	components,	they	also	contain	sarcoma	
cell-originated	growth	factors.	Therefore,	 in	particular	due	to	batch-variations,	they	are	a	
source	of	variability,	which	should	be	avoided	for	reliable	experimental	analyses.	Hence,	a	
further	step	in	facilitating	clinical	and	diagnostic	applications	of	organ	stem	would	be	the	
development	of	artificial,	well-defined	matrices.	
The effect of Wnt3a-induced signaling in hematopoietic stem and progenitor cells ex vivo
The	widespread	use	of	hematopoietic	stem	and	progenitor	cell	 (HSPC)	 transplantation	 in	
treatment	of	a	variety	of	hematological	and	genetic	diseases	is	limited	by	the	shortage	of	
compatible	donors.	Owing	to	its	ease	of	availability	and	less	stringent	matching	criteria15,	
umbilical	 cord	 blood	 (UCB)	 offers	 advantages	 over	 other	 sources	 of	HSPC.	However,	 the	
use	of	the	UCB	as	a	source	of	HSPC	has	resulted	in	a	delayed	hematopoietic	recovery	and	
impaired	engraftment	in	adult	patients16,17.	This	has	been	shown	to	be	due	to	the	low	number	
of	HSPC	in	a	single	cord	unit18.	Therefore,	strategies	for	development	of	an	ex vivo	HSC	and	
progenitor	expansion	system	have	attracted	much	attention.	Early	attempts	to	increase	the	
number	of	HSPC	in	culture	by	the	use	of	cytokines	have	largely	been	unsuccessful,	pointing	
to	a	need	of	additional	factors	to	support	HSC	amplification	in vitro.	In	this	respect,	a	variety	
of in vivo	loss-of-function	studies	indicated	a	requirement	of	canonical	Wnt	signaling	for	HSC	
self-renewal19–21.	However,	studies	using	purified	Wnt3a	protein	for	the	expansion	of	mouse	
HSPC	in vitro	have	generated	controversial	outcomes22–24.	While	Reya	and	Willert	suggested	
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increased	self-renewal	of	apoptosis-resistant,	transgenic	HSPC	ex vivo	upon	stimulation	with	
Wnt3a,	Nemeth	 and	 colleagues	 reported	 a	 decrease	 in	 the	 number	 of	wild	 type	mouse	
HSPC	 cultured	 with	 Wnt3a	 protein22–24.	 Nevertheless,	 these	 studies	 either	 did	 not	 take	
into	account	the	 importance	of	the	normal	physiology	or	did	not	consider	the	activity	of	
purified	Wnt3a	protein,	which	may	be	insufficient	to	promote	HSPC	expansion	in	serum-free	
cultures.	Furthermore,	the	role	of	Wnt3a	induced	signaling	in	the	expansion	of	human	UCB-
derived	HSPC	was	not	assessed.	Therefore,	in	the	chapters	3	and	4	of	this	thesis,	the	impact	
of	Wnt3a-induced	signaling	in	the	culture	of	HSPC	from	mouse	BM	(Chapter	3)	and	human	
UCB	(Chapter	4)	was	investigated.	
The	data	presented	 in	 chapter	3	 show	 that	 in	 a	 serum-free	 stroma-free	 system,	purified	
Wnt3a-induced	signaling	 led	to	a	decrease	 in	the	number	of	mouse	HSPC.	Moreover,	we	
observed	a	similar	reduction	of	mouse	HSPC	number	when	we	provided	a	more	stable	Wnt	
activity	via	Wnt3a	liposomes.	In	line	with	our	observations	in	mouse,	we	demonstrated	in	
chapter	4	that	Wnt3a-induced	signaling	also	reduced	rather	than	improved	growth	factor-
driven	expansion	of	human	UCB-derived	HSPC	 in	 serum-free	 cultures.	With	 respect	 to	 a	
negative	effect	of	Wnt	signaling	on	the	number	of	HSPC,	several	studies	suggested	that	in 
vivo	constitutive	activation	of	Wnt	signaling	leads	to	a	block	in	differentiation	and	exhaustion	
of	HSCs25,26.	Several	other	studies	suggested	that	the	decrease	in	the	number	of	HSPC	upon	
Wnt	activation	might	result	from	increased	apoptosis27,28.	This	could	well	explain	the	results	
of	Reya	and	Willert,	which	indicated	increased	self-renewal	of	apoptosis-resistant	HSPC	upon	
treatment	with	purified	Wnt3a	protein22,23.	However,	in	our	cultures	we	observed	neither	a	
block	 in	differentiation	nor	an	 increase	 in	apoptosis.	 Furthermore,	we	 found	 that	Wnt3a	
did	not	promote	self-renewal	when	apoptosis	was	inhibited	using	an	inducible	BCL2.	These	
results	argue	against	a	role	for	apoptosis	in	the	loss	of	HSPC	in	response	to	Wnt3a	protein	in 
vitro.		Moreover,	since	no	effect	of	Wnt3a	protein	on	total	cell	proliferation	in	mouse	HSPC	
cultures	was	observed,	the	decreased	number	of	HSPC	is	mostly	likely	due	to	promotion	of	
differentiation.	 Indeed,	 in	chapter	4	we	also	demonstrated	a	pro-differentiation	effect	of	
Wnt	signals	in	cultures	of	human	UCB-derived	HSPC.	
Regarding	the	different	outcomes	of	our	studies	and	those	implying	a	block	of	differentiation	
or	 increased	 apoptosis	 as	 an	 explanation	 for	 loss	 of	 HSPC	 upon	 Wnt	 activation,	 it	 is	
noteworthy	to	mention	that	the	latter	studies	are	based	on	constitutive	activation	of	Wnt	
signaling	in vivo	via	a	constitutively	active	form	of	β-catenin25–28,	and	therefore	do	not	serve	
as	good	comparisons	for	an	 in vitro	system	where	transient	activation	of	Wnt	signaling	is	
achieved	by	Wnt	proteins.	Moreover,	the	in vitro	studies	of	Willert	and	Reya,	which	suggest	
an	increased	self-renewal	of	HSPC	upon	Wnt3a	treatment,	demonstrate	that	HSCs	cultured	
with	Wnt3a	protein	repopulate	the	recipient	mice,	but	not	that	the	cells	cultured	without	
Wnt3a	protein	did	not	engraft.	Therefore,	these	studies	do	not	reflect	a	clear	discrepancy	
to	our	observations.	
By	using	different	combinations	of	mutant	alleles	of	a	negative	regulator	of	Wnt	signaling,	
Apc,	Luis	et	al	generated	a	series	of	Wnt	signaling	levels	in	mice	to	observe	the	effect	on	
HSC	self-renewal29.	 There,	 they	observed	 that	while	a	 low	dose	of	Wnt	 signals	enhances	
HSC	 function,	 higher	 levels	 resulted	 in	 impaired	 repopulation	 capacity.	 In	 our	 settings,	
however,	different	concentrations	of	Wnt3a	proteins	did	not	induce	ex vivo	proliferation	of	
HSPC	neither	in	mouse	nor	in	human.	Here,	one	can	argue	that	the	right	dosage	with	the	
Wnt3a	has	not	been	achieved	to	induce	HSC	proliferation.	Nevertheless,	translating	an	 in 
vivo	constitutive	activation	of	Wnt	signaling	approach	to	an	 in vitro	culture	system	where	
activation	of	Wnt	pathway	is	obtained	by	transient	Wnt	proteins	to	achieve	expansion	of	
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HSPC	might	not	be	feasible.	Moreover,	the	enhanced	repopulation	capacity	of	HSCs	in	Apc	
mutant	mice	with	low	Wnt	signaling	dosage	might	not	be	a	result	of	their	proliferation,	but	
their	enhanced	motility	or	homing	capacity.	Indeed,	in	their	study	Luis	and	colleagues	did	
not	demonstrate	an	increased	number	of	HSCs.	
Our	findings	in	chapter	3	and	4	indicate	that	the	goal	to	induce	ex vivo	amplification	of	HSPC	
will	 not	 benefit	 from	 the	 addition	of	Wnt3a	 proteins	 in	 the	 serum-free	 culture	 systems.	
Nevertheless,	a	library	of	other	growth	factors	manipulating	different	signaling	pathways,	
which	might	cooperate	with	Wnt	signals	in	expansion	of	HSPC,	can	be	tested.
Liver organoid technology for a gene therapy approach of lysosomal storage disorders 
In	 chapter	 2,	we	 demonstrated	 how	we	brought	 organoid	 technology	 a	 step	 further	 for	
clinical	applications,	by	establishing	and	expanding	these	stem	cells	in	serum-free	conditions	
via	Wnt3a-liposomes.	As	another	further	step,	 in	chapter	5,	we	investigated	the	utility	of	
liver	organ	stem	cells	in	development	of	a	gene	therapy	approach	for	treatment	of	lysosomal	
storage	disorders	(LSDs),	with	initial	application	towards	Hurler	disease.		
The	treatments	of	LSDs	are	based	on	the	phenomenon	of	‘cross-correction’,	which	allows	
lysosomal	enzymes	secreted	by	one	cell	type	to	be	taken	up	and	targeted	to	the	lysosomes	
of	 otherwise	 enzyme-deficient	 cells.	 The	 two	 current	 therapies	 of	 Hurler	 patients	 are	
enzyme	replacement	therapies	(ERT)	and	HSC	transplantations30.	However,	both	treatment	
modalities	bear	significant	drawbacks.	Although	ERT	can	slow	the	progression	of	some	LSDs,	
it	is	very	costly	and	rapid	clearance	of	the	enzyme	from	the	bloodstream	limits	its	effect30,31.
HSC	transplantation	can	ameliorate	the	symptoms	of	some	LSDs.	For	example,	beneficial	
effects	of	HSC	transplantation	are	observed	in	Hurler’s	disease	due	to	the	transplanted	cells	
secreting	the	missing	enzyme30–32.	However,	the	levels	are	insufficient	to	halt	progression	of	
the	symptoms.	
Several	studies	in	mice	have	demonstrated	that	HSC	transplantation	could	be	more	effective	
when	 the	 secretion	 of	 the	 missing	 enzyme	 from	 bone	marrow	 HSCs	 is	 increased	 using	
gene	therapy33–35.	Nevertheless,	the	use	of	HSCs	for	gene	therapy	approaches	retains	the	
hurdles	related	to	HSC	transplantations	such	as	shortage	of	suitable	donors	and	graft-vs-
host	disease,	early	morbidity	and	mortality.	Moreover,	as	HSCs	cannot	be	ex vivo	cultured	
and	monitored,	the	oncogenic	potential	of	genome-modifying	viruses,	and	silencing	of	the	
transgenes,	frequently	observed	with	lentivirus,	remain	major	concerns36.	This	underscores	
the	 importance	 of	 organoid	 technology	 by	 which	 genetically	 stable	 stem	 cells	 can	 be	
cultured	over	long-periods	of	time,	clonally	expanded,	genetically	modified,	analyzed	for	any	
dangerous	oncogenic	genetic	changes	and	transplanted	into	recipients2.	Therefore,	a	gene	
therapy	approach	directed	to	organoids	might	provide	high	levels	of	the	necessary	enzyme	
safely	and	for	the	life	of	the	patient,	circumventing	the	drawbacks	of	current	approaches	to	
treatment	of	LSDs.		
The	intrinsic	properties	of	the	liver	such	as	its	well-vascularized	structure	and	ability	to	secrete	
into	the	bloodstream37	prompted	us	to	choose	liver	organoids	for	testing	the	feasibility	of	
an	organ	stem	cell	mediated	gene	therapy	approach	towards	LSDs.	As	a	model	for	LSDs,	we	
picked	Hurler	syndrome,	which	is	one	of	the	most	frequent	LSDs	and	is	due	to	an	inherited	
deficiency	of	the	enzyme	α-L-iduronidase	(IDUA)38.	In	chapter	5	of	this	thesis,	we	showed	
that	liver	organoids	lacking	the	Idua	gene	were	successfully	derived	from	a	mouse	model	
of	Hurler’s	disease	and	cultured	over	many	passages.	Efficient	 transduction	of	 the	 IDUA-
deficient	liver	organoids	with	lentiviral	vectors	expressing	IDUA	generated	organoids,	which	
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not	only	produced	but	also	secreted	high	levels	of	IDUA	enzyme	over	long	periods	of	time.	
This	establishes	the	first	step	of	liver	stem	cell-mediated	gene	therapy	of	Hurler’s	disease.	
In	the	future,	liver	organoid	clones	should	also	be	monitored	to	ensure	the	absence	of	any	
undesired	genetic	changes.		
A	second	step	for	a	liver	organoid	mediated	gene	therapy	approach	relies	on	the	ability	of	
liver	organoid	 cells	 to	 repopulate	 the	 liver.	Huch	and	 colleagues	demonstrated	 that	 liver	
organoid	 differentiate	 into	mature	 hepatocytes	 in vitro	 and	 then	 engraft	 into	 the	 livers	
of	 mice	 upon	 transplantation10,13.	 For	 successful	 engraftment	 of	 liver	 organoid	 derived	
cells	 into	 liver	parenchyma,	 it	 is	necessary	 to	open	up	 stem	cell	niches.	 In	our	 study	we	
adapted	the	acute	damage	model,	which	was	previously	shown	to	generate	a	permissive	
environment	allowing	normal	and	liver	organoid-derived	hepatocytes	engraftment.	For	this,	
recipient	mice	were	pre-treated	with	the	hepatotoxic	reagent	CCl4,	inducing	partial	ablation	
of	hepatocytes39,40	and	with	the	alkaloid,	monocrotaline,	which	inhibit	the	proliferation	of	
the	remaining	hepatocytes39,41.		Indeed,	increased	serum	transaminase	levels	and	damaged	
liver	morphology	verified	the	hepatotoxicity	of	these	reagents.	Nevertheless,	in	chapter	5	
we	showed	that	although	liver	organoid	derived	cells	reached	to	the	livers	of	the	recipient	
mice	 via	 intrasplenic	 injection	 technique,	 these	 cells	 did	not	 engraft	 into	 recipient	mice.	
Since	 achieving	 successful	 engraftment	 of	 liver	 organoids	 is	 essential	 for	 our	 strategy	 of	
liver	 organoid	 mediated	 gene	 therapy	 of	 Hurler	 disease,	 the	 investigation	 of	 probable	
reasons	 behind	 inefficient	 transplantations	 is	 necessary.	 Therefore,	 further	 experiments	
are	 required	 to	assess	whether	 the	damage	model	we	used	 in	 this	 study	 indeed	 formed	
a	regenerative	environment	that	allows	the	engraftment	of	liver	cells.	Transplantations	of	
freshly	 isolated,	 genetically	marked	 hepatocytes	 into	 pre-treated	 recipients	might	 aid	 in	
testing	the	efficiency	of	the	indicated	conditioning	regimens	and	might	serve	as	a	positive	
control.	 Accordingly,	 the	 doses	 of	 the	 toxic	 agents	 can	 be	 adjusted.	Guo	 and	 colleagues	
report	that	CCl4	treatment	following	transplantation	increase	the	efficiency	of	hepatocyte	
engraftment39.	This	 strategy	was	based	on	 the	 fact	 that	 the	 intrasplenically	 injected	cells	
deposit	 in	periportal	 locations	while	CCl4	would	only	affect	the	perivenous	hepatocytes
42.	
The	CCl4	treatment	after	transplantations	would	thus	induce	a	further	proliferation	stimulus	
for	the	transplanted	cells	in	non-ablated	regions42.	Therefore,	in	future	studies	this	regimen	
might	be	 tested	 to	 see	whether	 it	 increases	 the	efficiency	of	 liver	organoid	derived	cells	
engraftment	into	the	liver.	
Exploring	 the	 probable	 reasons,	 we	 observed	 that	 the	 differentiation	 protocol	 we	 used	
did	not	lead	to	efficient	specification	of	liver	organoid	cells	into	mature	hepatocytes.	Thus,	
further	 investigations	 of	 pathways	 known	 to	 influence	 differentiation	 of	 liver	 organoids	
towards	 hepatocytes,	 including	Wnt,	 TGFb,	 BMP,	 cAMP	 and	Notch	 signaling	 pathways13,	
might	 enhance	 the	 engraftment	 potential	 of	 liver	 organoids.	 The	 low	 differentiation	
efficiency	might	also	stem	from	the	presence	of	low	numbers	of	Lgr5+	stem	and	progenitor	
cells	 in	 liver	organoids,	which	are	 routinely	 cultured	with	R-spondin	but	not	with	Wnt3a	
proteins.	Our	data	showed	that	by	activation	of	Wnt	signaling	via	liposome-stabilized	Wnt	
proteins,	the	population	of	Lgr5+	GFP	expressing	organoid	cells	was	drastically	increased.	
This	 increase	 in	 the	number	of	bi-potent	Lgr5+	stem	and	progenitor	cells	might	 increase	
the	yields	of	mature	hepatocytes.	A	further	optimization	step	that	can	be	explored	in	case	
of	 insufficient	 engraftment	 is	 the	additional	 use	of	mesenchymal	 stromal	 cells	 shown	 to	
support	regeneration,	by	blood	vessel	formation43	or	by	suppressing	the	immune	system44.
To	 sum	up,	 in	 this	 chapter	we	demonstrated	 the	utility	 of	 liver	 organoids	 as	 a	 stem	cell	
source	for	production	of	the	enzymes	necessary	for	treatment	of	LSDs,	in	particular	Hurler	
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disease.	A	major	obstacle	is	now	to	obtain	sufficient	numbers	of	mature	hepatocytes	with	
robust	engraftment	potential	from	the	organoids.	Once	this	obstacle	is	overcome,	the	liver	
organoid	based	therapies	will	offer	a	safe	source	of	liver	cells	for	treatment	of	a	variety	of	
diseases.
Concluding remarks
Adult	 stem	 cells	 cells	 are	 capable	 of	 regenerating	 and	 repairing	 damaged	 tissues,	 and	
therefore	 offer	 scientists	 the	 possibility	 of	 creating	 new	 therapies	 and	 cures	 for	 a	 wide	
variety	of	diseases.	In	this	thesis,	we	conducted	studies	aiming	at	investigating	the	use	of	
Wnt	 proteins	 for	 in vitro	 culture	 of	 adult	 stem	 cells.	 Our	 innovative	 liposome-stabilized	
Wnt	 technology	 now	enables	 defined	 culture	 of	 adult	 organ	 stem	 cells,	 allowing	 clinical	
applications	mediated	by	these	stem	cells.	
Our	studies	establishing	a	negative	effect	of	Wnt	proteins	in	the	expansion	of	adult	HSPC	in 
vitro	also	underscores	differential	regulation	of	different	stem	cell	types	by	Wnt	signaling.	
Future	 studies	might	 be	 necessary	 to	 answer	whether	 the	 origin	 of	 the	 stem	 cells	 is	 an	
important	determinant	for	the	effect	of	Wnt	signals.	
Applying	the	organ	stem	cell	technology	for	treatment	of	LSDs,	we	expect	to	overcome	the	
major	obstacle	holding	back	their	gene	therapy:	the	delivery	of	genes	to	the	appropriate	
cells	 without	 unwanted	 side	 effects	 like	 genotoxicity,	 or	 targeting	 the	 wrong	 cells,	 or	
provoking	the	immune	system	with	viruses.	Establishing	such	a	novel	and	safe	application	of	
gene	therapy	in	mouse	models,	would	open	up	new	avenues	for	treatments	of	many	other	
diseases.	
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Summary
The	maintenance	 of	 homeostasis	 and	 repair	 in	 tissues	 and	 organs	 throughout	 adult	 life	
relies	on	stem	cells	of	the	respective	tissues,	such	as	blood,	intestine	or	liver.	These	stem	
cells	could	be	of	great	value	for	clinical	purposes	because	of	their	capability	to	regenerate	
lost	or	damaged	tissues.	For	reasons	such	as	low	availability	of	stem	cells,	lack	of	competent	
donors	and	difficulties	in	expanding	the	cells,	the	development	and	application	of	stem	cell-
based	therapies	has	so	far	been	limited.	Recent	progress	in	the	identification,	isolation	and	
expansion	of	adult	stem	cells	promises	to	advance	their	clinical	use.	The	identification	of	
the	factors	necessary	for	propagation	of	the	stem	cells	is	an	essential	element	in	furthering	
this	 strategy.	 Among	 the	many	 cell	 signaling	 pathways	 indicated	 in	 control	 of	 stem	 cell	
self-renewal	and	differentiation,	the	Wnt	signaling	pathway	stands	out	due	to	 its	roles	 in	
maintenance	of	stem	cells	from	a	variety	of	tissues.	In	this	thesis	we	investigate	the	effects	
and	applicability	of	Wnt	signaling	proteins	in	propagation	of	adult	stem	cells	from	intestine,	
liver	and	blood,	with	the	goal	of	improving	their	use	for	clinical	purposes.	
The	 establishment	 of	 human	 organ	 stem	 cell	 cultures	 as	 organoids	 has	 opened	 new	
avenues	 for	 stem	 cell-based	 assays	 and	 therapies.	 The	 human	 organoids	 are	 dependent	
on	Wnt	signals	provided	in	the	form	of	a	Wnt3a-conditioned	medium.	While	effective,	this	
medium	contains	serum	and	other	undefined	factors	undesirable	for	clinical	and	diagnostic	
applications.	 In	Chapter 2,	we	 investigate	 the	use	of	purified	Wnt3a	protein	 instead	of	a	
Wnt3a-conditioned	medium.	We	find	however	that	purified	Wnt3a	protein	fails	to	support	
human	intestinal	stem	cells.	We	show	that	this	is	because	the	Wnt3a	rapidly	loses	its	activity	
upon	 dilution	 in	 serum-free	medium.	 In	 addition,	 purified	Wnt3a	 contains	 a	 detergent,	
CHAPS,	 that	 is	 required	 to	maintain	 the	 stability	of	Wnt3a	but	 is	 toxic	 to	 the	 stem	cells.	
Searching	for	an	alternative	way	to	stabilize	Wnt3a	protein,	we	explored	the	finding	that	
Wnt3a	protein	can	associate	with	liposomes,	small	aggregates	of	fatty	molecules.	We	show	
that	 these	 liposomes	 can	 replace	 CHAPS	 and	maintain	Wnt3a	 activity	 in	 the	 absence	 of	
serum	 or	 detergent.	 Importantly,	 the	 lipid-stabilized	 Wnt3a	 supports	 both	 serum-free	
establishment	 and	 expansion	 of	 organoids	 from	 healthy	 and	 diseased	 human	 organs,	
including	 intestine	 and	 liver.	 These	findings	 remove	 a	major	 impediment	 for	 clinical	 and	
diagnostic	applications	of	adult	stem	cells,	and	offers	advantages	for	all	cell	culture	uses	of	
WNT3A	protein.	Chapters 3 and 4	of	this	thesis	describe	the	effect	of	Wnt3a	protein	in	ex 
vivo	culture	of	hematopoietic	stem	and	progenitor	cells	(HSPC).	In	Chapter 3, we	show	that	
Wnt3a	protein	leads	to	a	reduction	in	the	number	of	mouse	HSPC	in	our	stroma-free,	serum-
free	culture	system.	Our	data	demonstrate	that	increased	stability	of	Wnt	activity	by	lipid-
associated	Wnt3a	proteins	also	negatively	affects	the	number	of	mouse	HSPC.	Investigating	
a	possible	reason	for	Wnt-induced	loss	of	these	HSPC,	we	found	no	evidence	for	apoptosis,	
but	a	tendency	for	increased	differentiation	of	HSPC.	In	agreement	with	the	mouse	study,	
in Chapter 4,	we	show	that	Wnt3a	protein	decreases	the	number	of	human	umbilical	cord	
blood-derived	 HSPC	 in	 serum-free	 expansion	 cultures	 due	 to	 increased	 differentiation.	
Taken	 together,	 our	 data	 show	 that	ex vivo	 propagation	of	HSPC	may	 require	 additional	
differentiation-inhibiting	factors.	
In Chapter 5,	we	address	the	use	of	liver	stem	cells	cultured	in	organoids	for	gene	therapy	
of	 lysosomal	 storage	 disorders,	 with	 initial	 application	 towards	 Hurler	 disease.	 Hurler	
disease	is	caused	by	a	deficiency	of	the	lysosomal	enzyme	α-L-Iduronidase,	which	leads	to	
accumulation	of	its	undegraded	substrates	and	a	variety	of	subsequent	clinical	symptoms	
in	 a	 diversity	 of	 tissue	 systems.	 The	 treatment	 of	Hurler	 disease	 is	 based	 on	 exogenous	
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administration	of	the	missing	enzyme	to	patients.	In	this	regard,	stem	cells,	which	can	self-
renew,	differentiate	and	reconstitute	target	organs,	might	function	as	the	permanent	donors	
of	the	normal	enzyme.	Moreover,	for	providing	a	high	level	functional	enzyme	to	the	patients,	
stem	cells	should	be	genetically	modified	to	overexpress	the	missing	protein.	Therefore,	ex 
vivo	gene	therapy	of	stem	cells	to	provide	high	levels	of	the	missing	enzyme	for	a	lifetime	
to	the	patients	of	Hurler	disease,	or	most	other	LSDs,	is	an	attractive	therapeutic	modality.	
Here,	we	show	that	liver	organoids	can	be	derived	from	the	mouse	model	of	Hurler	disease	
and	cultured	over	long	periods	of	time.	Moreover,	we	demonstrate	that	genetically	modified	
liver	organoids	efficiently	produce	and	 secrete	 the	missing	enzyme	over	many	passages.	
Nevertheless,	sufficient	engraftment	of	the	modified	 liver	organoids	for	correction	of	the	
disease	phenotype	is	yet	to	be	established	and	might	necessitate	increased	differentiation	
efficiency	towards	hepatocytes.	Setting	up	such	successful	 liver	organoid	transplantations	
might	enable	liver	organoid-based	therapies	for	treatment	of	a	variety	of	genetic	and	liver-
related	diseases.
Finally,	the	significance	and	implications	of	the	findings	described	in	this	thesis	are	integrated	
in Chapter 6,	 where	 also	 perspectives	 for	 further	 studies	 are	 provided.	With	 respect	 to	
improving	 adult	 stem	 cell-based	 therapies,	 defining	 how	 or	 if	 we	 could	 use	 signaling	
molecules	 in vitro	for	expansion	of	stem	cells	are	of	great	importance.	In	this	regard,	this 
thesis	 provides	novel	 insights	 into	 the	effects	 and	applicability	 of	Wnt	 signaling	proteins	
in	serum-free	culture	of	adult	 stem	cells.	Further	studies	will	address	how	to	exploit	 the	
potential	of	adult	stem	cells	and	translate	the	basic	knowledge	into	clinical	applications.
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Nederlandse samenvatting
Het	handhaven	van	homeostase	en	herstel	van	de	weefsels	en	organen	in	ons	lichaam	is	de	
taak	van	stamcellen	die	in	weefsels	zoals	bloed,	darmen	en	de	lever	aanwezig	zijn.	Deze	stam-
cellen	kunnen	van	grote	waarde	zijn	voor	klinische	doeleinden	vanwege	hun	vermogen	om	
verloren	of	beschadigde	weefsels	te	regenereren.	De	ontwikkeling	van	stamcel-gebaseerde	
therapieën	is	echter	beperkt	vanwege	redenen	zoals	het	ontbreken	van	voldoende	dono-
ren,	de	beperkte	beschikbaarheid	van	stamcellen	en	problemen	met	het	vermeerderen	van	
de	cellen	in	celkweek.	Recente	vooruitgang	in	het	identificeren,	isoleren	en	vermeerderen	
van	adulte	stamcellen	biedt	nieuwe	beloften	voor	klinische	toepassingen	van	deze	cellen.	
Een	 belangrijk	 element	 om	dit	mogelijk	 te	maken	 is	 de	 identificatie	 van	 de	 factoren	 die	
vermeerdering	van	stamcellen	in	celkweek	mogelijk	maken.	Onder	de	vele	cellulaire	signaal	
paden	die	de	zelfvernieuwing	en	differentiatie	van	stamcellen	reguleren,	onderscheidt	de	
Wnt-signaleringsroute	zich	door	de	regulering	van	stamcellen	in	een	veelvoud	aan	weefsels.	
In	dit	proefschrift	onderzoeken	we	de	effecten	en	toepassingen	van	Wnt	signaal	eiwitten	bij	
het	manipuleren	van	adulte	stamcellen	van	darm,	lever	en	bloed,	met	als	doel	het	gebruik	
van	deze	stamcellen	voor	klinische	doeleinden	te	verbeteren.
Het	ontwikkelen	van	kweeksystemen	voor	humane	stamcellen	in	de	vorm	van	zogenaamde	
organoiden	heeft	nieuwe	perspectieven	geopend	voor	de	ontwikkeling	van	stamcel-gebas-
eerde	testen	en	therapieën.	Humane	organoiden	zijn	afhankelijk	van	Wnt	signalen	en	deze	
worden	toegevoegd	in	de	vorm	van	een	Wnt3a-geconditioneerd	medium.	Dit	medium	bevat	
echter	ook	serum	en	andere	ongedefinieerde	factoren	die	ongewenst	zijn	 in	klinische	en	
diagnostische	toepassingen.	Derhalve	hebben	we	in	hoofdstuk 2	het	gebruik	van	gezuiverd	
Wnt3a	eiwit	in	plaats	van	Wnt3a-geconditioneerd	medium	bestudeerd.	We	vinden	echter	
dat	 gezuiverd	Wnt3a	eiwit	de	kweek	van	humane	darmstamcellen	niet	ondersteunt.	We	
laten	zien	dat	dit	komt	doordat	het	Wnt3a	snel	zijn	activiteit	verliest	wanneer	het	verdund	
wordt	in	serumvrij	medium.	Bovendien	bevat	het	een	detergens,	CHAPS,	dat	nodig	is	voor	
de	stabiliteit	van	het	Wnt3a	maar	wat	toxisch	is	voor	de	stamcellen.	In	dit	hoofdstuk	laten	
we	vervolgens	zien	dat	Wnt3a	eiwit	bindt	met	liposomen,	kleine	aggregaties	van	vetachtige	
moleculen.	Deze	liposomen	nemen	de	plaats	in	van	het	CHAPS	en	zorgen	voor	het	behoud	
van	Wnt3a	activiteit	in	de	afwezigheid	van	serum	en	CHAPS.	Tenslotte	laten	we	zien	dat	het	
liposoom-gestabiliseerde	Wnt3a	het	serumvrij	kweken	en	expanderen	van	organoiden	van	
gezonde	en	zieke	humane	organen	als	de	darm	en	lever	mogelijk	maakt.	Deze	bevindingen	
ruimen	een	belangrijk	obstakel	uit	de	weg	dat	klinische	toepassingen	van	stamcellen	be-
moeilijkt.	
Hoofdstuk 3 en 4	van	dit	proefschrift	beschrijven	het	effect	van	Wnt3a	eiwit	bij	het	kweken	
van	 stamcellen	 van	 het	 bloedsysteem	 (HSPC:	 hematopoietic	 stem	 and	 progenitor	 cells).	
In hoofdstuk 3	 laten	we	zien	dat	Wnt3a	eiwit	de	vermeerdering	van	muizen	HSPC	in	een	
stroma-vrij,	serumvrij	kweeksysteem	tegenwerkt.	Ook	wanneer	de	stabiliteit	van	het	Wnt3a	
eiwit	verhoogd	wordt	door	associatie	met	liposomen	leidt	het	tot	verlies	van	HSPC	in	plaats	
van	vermeerdering.	We	vonden	geen	aanwijzingen	dat	Wnt3a	celdood	induceert	in	HSPC,	
maar	juist	differentiatie	van	de	cellen	bevordert.	In	overeenstemming	met	de	muizenstudie	
laten	we	in	hoofdstuk 4 zien	dat	Wnt3a	ook	de	differentiatie	en	verlies	van	HSPC	uit	hu-
maan	navelstrengbloed	veroorzaakt.	Deze	observaties	suggereren	dat	voor	vermeerdering	
van	HSPC	in	celkweek	het	nodig	zal	zijn	om	aanvullende	differentiatieblokkerende	signalen	
te	identificeren.	
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In hoofdstuk 5	onderzoeken	we	of	lever	stamcellen,	gekweekt	als	organoiden,	kunnen	wor-
den	ingezet	voor	een	vorm	van	gentherapie,	in	eerste	instantie	toegepast	voor	de	ziekte	van	
Hurler,	een	voorbeeld	van	een	lysosomale	stapelingsziekte.	Deze	ziekte	wordt	veroorzaakt	
door	een	gebrek	aan	het	lysosomale	enzym	α-L-Iduronidase,	wat	leidt	tot	accumulatie	van	
cellulaire	 afbraakproducten	en	ernstige	 klinische	 symptomen.	 Toediening	 van	het	 enzym	
kan	de	symptomen	verminderen.	We	onderzoeken	daarom	of	genetische	modificatie	van	le-
ver	stamcellen,	zodat	deze	het	enzym	uitscheiden,	een	oplossing	kan	bieden.	We	laten	zien	
dat	we	lever	organoiden	kunnen	verkrijgen	van	een	muizenmodel	van	de	ziekte	van	Hurler	
en	deze	voor	langere	tijd	in	kweek	kunnen	houden.	Na	genetische	modificatie	zijn	de	lever	
organoiden	effectief	in	het	produceren	en	uitscheiden	van	het	ontbrekende	α-L-Iduronidase 
enzym,	 zelfs	 na	 vele	 passages.	De	 volgende	uitdaging	 is	 het	 effectief	 transplanteren	 van	
de	gemodificeerde	cellen	 in	de	patient	om	voldoende	enzym	 in	de	bloedbaan	 te	krijgen	
voor	een	succesvolle	behandeling	van	de	symptomen.	Hiervoor	zal	het	wellicht	nodig	zijn	
om	verbeterde	differentiatie	protocollen	te	ontwikkelen	om	uitgerijpte	levercellen	van	de	
organoiden	te	verkrijgen.	Dit	zou	lever	organoide-gebaseerde	therapieën	mogelijk	maken	
voor	verschillende	genetische	en	lever-gerelateerde	ziekten.
Het	belang	en	mogelijke	implicaties	van	de	bevindingen	beschreven	in	dit	proefschrift	wor-
den	tot	slot	beschreven	in	hoofdstuk 6.	Daarnaast	worden	in	dit	hoofdstuk	ook	adviezen	
voor	verdere	studies	gedaan.	Met	betrekking	tot	het	verbeteren	van	adulte	stamcel-gebas-
eerde	therapieën,	is	het	van	groot	belang	te	bepalen	hoe	en	of	we	signalerings	moleculen	in 
vitro	kunnen	gebruiken	voor	de	expansie	van	stamcellen.	In	dit	opzicht	biedt	dit	proefschrift	
nieuwe	inzichten	in	de	effecten	en	toepasbaarheid	van	Wnt	signaal	eiwitten	in	het	serumvrij	
kweken	van	adulte	stamcellen.	Verdere	studies	zullen	nader	 ingaan	op	het	benutten	van	
de	potentie	van	adulte	stamcellen,	en	hoe	fundamentele	kennis	vertaald	kan	worden	naar	
klinische	toepassingen.			
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